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It is known that γδT cells provide immune-surveillance and host defense against infection 
and cancer. Our understanding of γδT cell functionality and antimicrobial immunity, 
however, remains poor. Limited data suggests that γδT cells can phagocytose particles and 
act as professional antigen-presenting cells (pAPCs). In order to examine γδT cell bacterial 
interactions, an ex vivo co-culture model of human peripheral blood mononuclear cell 
(PBMC) responses to Escherichia coli was employed. Following PBMC stimulation with 
E.coli, Vγ9Vδ2 cells underwent rapid T cell receptor (TCR)-dependent proliferation and 
functional transition from cytotoxic, inflammatory cytokine immunity, to cell expansion 
with diminished cytokine but increased costimulatory molecule expression, and capacity 
for professional phagocytosis. Phagocytosis was augmented by IgG opsonization, and 
inhibited by TCR-blockade, suggesting a licensing interaction involving the TCR and 
FcγR. Vγ9Vδ2 cells displayed potent cytotoxicity through TCR-dependent and 
independent mechanisms. Vγ9Vδ2 cell cytokine responses and cytotoxicity further 
presented with variable sensitivity to blocking of host butyrophilin 3A (BTN3A), in 
response to both, self and non-self, stimuli. We conclude that i) Vγ9Vδ2 T cells transition 
from early inflammatory cytotoxic killers to myeloid-like pAPCs in response to infectious 
stimuli, and that ii) Vγ9Vδ2 T cell recognition of targets is predominantly governed by 
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APC – antigen presenting cell 
APC (in the context of FACS staining only, in the Materials and Methods sections) – 
Allophycocyanin 
pAPC – professional antigen presenting cell 
α- - anti 
αβT cell – alpha beta T cell 
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D1-D14 – day 1 to day 14 
E.coli – Eschericia coli  
FITC - Fluorescein isothiocyanate 
FcR – Fc receptor 
FcγR – Fc gamma receptor 
GFP – Green Fluorescent Protein 
GM-CSF – granulocyte macrophage colony stimulating factor 
γδT cell – gamma delta T cell 
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HMBPP - (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate 
HCMV – human cytomegalovirus 
HLA – human leukocyte antigen 
IEL – intraepithelial lymphocyte 
IFN – Interferon 
Ig - immunoglobulin 
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ITAM - Immunoreceptor tyrosine-based activation motif 
LCK – lymphocyte-specific protein tyrosine kinase 
L. monocytogenes – Lysteria monocytogenes 
MFI – median fluorescence intensity 
MHC – major histocompatibility complex 
MICA - MHC class I chain-related A 
M. morganii - Morganella morganii  
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neg – negative 
NK – natural killer cell 
NKG2D - Natural Killer Group 2D receptor 
NKT – natural killer T cell 
Ops. – opsonized (usually IgG-opsonized) 
O/N – overnight 
OD – optical density 
pAg – phosphoantigen 
PBMC – peripheral blood mononuclear cells 
PE – Phycoerythrin 
PMN – polymorphonuclear cells 
pos – positive 
PRR – pattern recognition receptor 
P. falciparum – Plasmodium falciparum 
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S. typhimurium - Salmonella typhimurium 
S. aureus – Staphylococcus aureus 
TB – Trypan Blue 
TCR – T cell receptor  
Th1- Th1 T helper cell 
Th2 – Th2 T helper cell 
Th17 – Th17 T helper cell 
TLR – toll-like receptor 
TM – transmembrane region 
TNF – tumour necrosis factor 
Treg – regulatory T cell 
T. gondii – Toxoplasma gondii 
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w/ - with 




Gamma delta T (γδT) cells are an atypical subset of CD3pos lymphocytes with 
heterogeneous phenotypic patterns, effector functions and anatomical distribution that 
differ significantly from canonical alpha beta T (αβT) cells. Recent immunotherapeutic 
insights have highlighted γδT cells as an attractive putative tool against malignancy and 
infectious disease. Particular attention in this context has been given to the unusual 
capacity of γδT cells to act as both cytotoxic effectors against target cells and professional 
antigen presenting cells (pAPCs) to αβT cells. The following thesis presents an ex vivo 
experimental investigation of peripheral human γδT cell cytokine, cytotoxic and pAPC 
effector phenotype in response to various antigenic challenges, and the molecular factors 
that regulate it, therein.  
A significant portion of the data contained within this thesis has been published in a June 
2017 issue of Scientific Reports journal. The article, titled “E. coli promotes human 
Vγ9Vδ2 T cell transition from cytokine producing bactericidal effectors to professional 
phagocytic killers in a TCR-dependent manner”, can be viewed in the Appendix section.  
1.1. Introduction to γδT cells 
Expressing a T cell receptor (TCR) composed of γ and δ chains, γδT cells comprise 
between 1% and 20% of the human peripheral T cell compartment, and up to 50% of 
epithelial lymphocytes. Often referred to in the literature as “innately-adaptive” 
lymphocytes (1), γδT cells are characterized by potent and rapid pro-inflammatory 
cytokine release and cytotoxicity upon stimulation, which is nonetheless paired with a 
lymphoid-like capacity for extensive clonal expansion (2–4). Some 70% of γδT cells are 
CD4negCD8neg; the remainder are largely CD4negCD8pos, with a CD4posCD8neg phenotype 
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a rarity. Whilst their baseline clonality remains controversial, it is thought that γδT cells 
have a predominantly oligoclonal rather than polyclonal TCR repertoire, which may 
underlie their swift and potent responses to primary antigenic stimulation (5,6).  
γδT cells undergo a distinct developmental process. Unlike their classic, well-
characterized counterparts – peripheral αβT cells - γδT cells appear to develop in several 
waves, the first of which is already evident in the prenatal thymus (reviewed by 
Vantourout and Hayday(7)). “Innate-like” CD27pos and CD27neg γδ T cells, possibly 
derived from foetal liver progenitors and characterized by secretion of interferon-γ (IFN-
γ) and interleukin 17 (IL-17), respectively, have been detected in the prenatal thymus of 
both, mouse and man (7). A second wave of bone marrow-derived “lymphoid-like” γδT 
cells appears to emerge postnatally with a proposed default potential for the production of 
IFN-γ. In a significant deviation from αβ T cell development, some γδ T cells then migrate 
to distinct anatomical locations, rather than entering lymphatic re-circulation; human and 
mouse “innate-like” γδT cells have a particular propensity for epithelial sites, such as the 
gastrointestinal mucosa and skin, whilst “lymphoid-like” γδ T cells reside mostly within 
systemic circulation (7). 
A summary of the basic features, shared and divergent, between the main human adaptive 
lymphocyte cell types - γδT cells, αβT cells and B cells – can be viewed in Table 1.1. 
Anatomical distribution, surface marker expression, cytokine secretion and proliferative 
behaviour have been used as a basis for differential γδT cell investigation and discussion 
in the literature. Perhaps the most basic and frequently used of these divisions relies on 
anatomical localization, with relatively scarce “lymphoid-like” γδT cells residing in 
suspension within the circulatory system, and highly abundant “innate-like” γδT cells 






1-Table 1.1  |  Features of human γδT, αβT and B  cells 
Table 1.1  |  Features of human γδT, αβT and B  cells  
Characteristic αβT cells γδT cells B cells 
Antigen-receptor 
configuration 
CD3 complex + 
αβTCR 





~1015 ~1020 ~1011 
Antigen recognition Peptide + MHC Protein and non-protein 
Protein and non-
protein 
Antigen restriction Yes Rare No 
Phenotype CD4pos or CD8pos 
Mostly CD4negCD8neg; 
some IEL are CD8(αα)pos 
CD19posCD20pos 
























Adapted from Carding and Egan (2002) (8))  
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Human γδT cells are further often denoted based on their respective use of Vδ TCR chains. 
In most healthy human adults the peripheral γδT cell compartment is dominated by Vδ2 
cells, whereas the predominant γδTCRpos IEL population are Vδ1 cells. There are a 
number of further Vδ chains employed by both peripheral and tissue-resident, γδT cells, 
but these rare populations are poorly understood and are often referred to simply as Vδ1-
Vδ2- γδT cells (for a basic subset summary refer to Table 1.2). Meaningful discussion of 
γδT cell physiological functions and therapeutic potential must note that the subdivision 
of γδT cells into “innate-like” and “lymphoid-like” subsets has been disputed. Significant 
further investigation is required for the establishment of well-defined, reproducible 
physiological differences between the multiple γδT cell compartments, regardless of 
subset definition.  
 
A majority of our insight into human γδT cell physiology derives from the study of the 
peripheral blood mononuclear cell (PBMC) compartment. The peripherally dominant Vδ2 
γδT cells – with a Vγ9Vδ2 TCR - are the most-studied and best understood of the many, 
apparently heterogeneous γδT cell subsets. While data from peripheral Vδ2 γδT cell 
investigations in the context of immunotherapy remain promising (reviewed recently by 
Casetti, Martino and others (10,11)), it is crucial to achieve a broader understanding of all 
γδT cell subsets, and to establish whether inferences of γδT cell physiology from the 
human peripheral circulation are relevant to the more enigmatic tissue-resident 
lymphocyte compartments. It is, moreover, crucial to note that it remains, as of yet, unclear 
2-Table 1.2  |  Features of human γδT cell subsets 




Tissue distribution Key cytokines Cytotoxicity 
Vδ1pos Not defined  
Epithelia, dermis, 
spleen and liver  
IFN-γ and TNF; can 
produce IL-17 
Potent 
Vδ2pos  Vγ9Vδ2  Blood  





Not defined  
Liver and gut 
epithelium  
Not defined Not defined 
Adapted from Silva-Santos, et al. (2015) (9) 
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to what extent human and murine γδT cell physiology is related. A significant portion of 
γδT cell literature examines murine γδT cells, which lack a homologous population to the 
human Vγ9Vδ2 cells, and possess oligoclonal, highly tissue-specific γδT cell populations 
such as dendritic epidermal T cells. While the overall differences between mouse and 
human γδT cell functionality and significance remain inconveniently obscure (reviewed 
recently by Pang, Pennington, et al. (12)), I make an effort in this thesis to focus my 
attention on human γδT cells and clinical scenarios.  
1.2. γδT cells in health and disease 
Current thought prevails that the predominant Vγ9Vδ2 human peripheral γδT cell subset  
mediates immuno-surveillance of stress signals emanating from endogenous and 
microbial pyrophosphates, sourced from e.g. tumour cells and infected cells, respectively 
(13).  A significant increase in systemic and mucosal γδT cell numbers is seen in acute 
systemic bacterial and parasitic (as well as viral) infections. These include Brucella, 
Streptococci, Coxiella, Listeria, Francisella, Escherichia, Campylobacter, Shigella, 
Leptospira, Plasmodium and Mycobacterium, among others (14–24) . While further 
exploration into the functionality of these expanded γδT cells is necessary, data indicate 
an activated phenotype, as measured by high cell surface CD69, and significantly 
increased expression of MHC class II (e.g. HLA-DR) and CD86 (21,22,24–26). The 
presence of such CD69posHLA-DRpos γδT cells during sepsis and systemic inflammatory 
response syndrome appears to correlate negatively with mortality (25,27). The natural or 
experimental elevation of functional, activated γδT cell numbers has, moreover, been 
shown to correlate with improved prognosis and even protection from such chronic 
infections as M. tuberculosis, human cytomegalovirus (HCMV), Toxoplasma gondii, 
Listeria monocytogenes and a number of intestinal infections, among others, in murine, 
non-human primate and human models (28–36). Particularly important in a clinical setting 
– and when considering γδT cells as an immunotherapeutic tool - γδT cells are routinely 
shown to infiltrate and play a role in such common human tumour types as breast, colon, 
ovarian and lung cancers, as well as melanoma (37–41). Strikingly, the presence of γδT 
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cells was recently identified as the single most favourable lymphocytic predictive factor 
in human malignancy in a meta-analysis of 18,000 human tumours of 25 different types; 
γδT cells were shown to correlate with positive outcomes in both pan-cancer analysis, 
which included multiple myeloma and various leukaemias, as well as solid tumour 
analysis (42).  
Explanations of the protective properties of γδT cells are extremely varied, and illustrate 
the expansive immune arsenal of these “innately-adaptive” lymphocytes in limiting or 
preventing the onset of disease. The most commonly discussed mechanisms of γδT cell 
effector function include potent, en-masse release of Interferon-γ (IFN-γ) and other Th1 
cytokines for the resolution of intracellular infections, secretion of IL-17 for rapid 
mobilization of innate immunity at epithelial sites during bacterial invasion, upregulation 
of tumor necrosis factor-α (TNF-α) during systemic infection, effective cytotoxicity 
against transformed or infected self-cells and pathogens, mobilization and maturation of 
dendritic cells (DCs) as well as the antibody response in systemic and intestinal disease, 
priming and regulation of the αβT cell response in infectious or malignant scenarios 
through professional antigen presentation, maintenance of the integrity of epithelial 
barriers and even direct suppression of αβT cell-mediated inflammation in 
immunopathological settings (30,37,40,41,43–54). A simplified summary of the six main 
ways in which γδT cells contribute to the human immune response can be viewed in Figure 
1.1, adapted from Vantourout and Hayday (7). 
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1.3. γδT cells as professional antigen presenting cells 
While a T cell pAPC is by no means an accepted concept in mainstream immunology, 
there are multiple lines of evidence suggesting that γδT cells may indeed act as pAPCs to 
classic αβT cells, which range from functional studies to expression of antigen presenting 
and co-stimulatory molecules, to apparent phagocytic capacity - aspects of which have 
been explored in humans, mice and other mammals (49,50,55–59). While the seminal 
publication on the pAPC capacity of human γδT cells may be attributed to Brandes and 
Moser, et al. (60), our own laboratory has previously published work documenting the 
phagocytic capacity of human γδT cells and their ability to act as pAPC even in the context 
of cross-presentation to cytotoxic CD8 αβT cells (49,50). 
Fig. 1.1. γδT cell contribution to the human immune response. Literature documents that 
γδT cells have a central role in defending the host against a range of infectious and sterile 
stresses through six main mechanisms: I) Production of a diverse set of cytokines and 
chemokines to regulate other immune and non-immune cells. II) Direct lysis and, consequently, 
elimination of infected or stressed cells through the production of, e.g. granzymes. III) Help for 
B cells and promotion of IgE production. IV) Regulation stromal cell function through the 
production of growth factors. V) Triggering of dendritic cell maturation. VI) Antigen presentation 




Further to their documented oncolytic properties, γδT cells also have recorded pro-
tumorigenic roles. It appears that the very effector functions which confer them with the 
ability to recruit and shape myeloid, as well as lymphoid immunity, and affect the growth 
and development of epithelial/stromal tissue, enable γδT cells to aid and even protect 
tumour development and survival (37,39–41). IL-17-producing γδT cells have, for 
example, been shown to aid development of breast cancer metastases (61). If we consider, 
howerver, the central aetiological role of epithelial site integrity in infectious and 
malignant disease, the restoration or, more artificially, boosting of appropriate γδT cell 
function emerges as a key tool in the maintenance and restoration of human health. As 
outlined above, overall solid and non-solid tumour meta-analysis identifies γδT cells as a 
factor strongly favorable to tumour clearance and recovery (42). The plethora of functional 
outcomes upon γδT cell stimulation illuminates the potential of their use in therapy, and 
highlights our lack of understanding regarding their functionality. Basic investigation of 
factors determining the development of γδT cell phenotypes is crucial if we hope to 
harvest and manipulate their vast array of effector functions in a reproducible and 
clinically viable manner.  
Vδ2 γδT cell in vitro responses to different bacterial stimuli have been explored by various 
groups and laboratories. IFN-γ production and expansion in response to exposure have 
been described for M. tuberculosis, L. monocytogenes, S. aureus and E.coli, as well as 
products from Morganella morganii and Salmonella typhimurium, among others (35,62–
66). Potent Vδ2 γδT cell responses have, thus, been described to Gram-negative, Gram-
positive bacteria as well as intracellular bacteria. The significance of γδT cells for in vivo 
resolution of infectious disease has remained ambiguous, largely due to the highly 
complex nature of events that occur during bacterial infection at epithelial surfaces. This 
complexity emanates from the multitude of intricate relationships between the highly 
populous, poorly understood and often intra-redundant mucosal immune compartment, 
epithelia and commensal as well as invading microorganisms.  
Recent studies have finally provided unambiguous experimental evidence for the 
protective antibacterial properties of human γδT cells in vivo. Wang et al. were able to 
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provide effective infectious control and resolution of both Gram-positive (S. aureus) and 
Gram-negative (M. morganii) infections in severe combined immuno-deficiency mice by 
adoptive transfer of human Vδ2 cells (14). Curiously, however, these were not Vγ9Vδ2 
cells, but rather Vγ2Vδ2 cells. Successful in vivo experimental control of intracellular 
infection, such as M.tuberculosis, has meanwhile been achieved by adoptive transfer of 
Vγ9Vδ2 cells in non-human primate models (35). IFN-γ is of central importance in these 
anti-microbial responses. It does, however, remain unclear whether IFN-γ production is 
the only significant effector response of bacteria-exposed γδT cells, and whether the anti-
microbial effects observed are the result of direct Vδ2 cell killing of free bacteria or 
infected cells, or an indirect activation of other immune components / bystander effects.  
An area of ongoing debate in the fields of basic γδT cell biology and immunotherapy 
concerns the capacity of γδT cells – often Vδ2 cells, specifically – to act as pAPCs to αβT 
cells. As described, the controversy stems largely from the significant unorthodoxy of a T 
cell pAPC, and the well-founded concern of myeloid contamination of the experimental 
setups. Evidence for the role and significance of in vivo human Vγ9Vδ2 cell pAPC 
function is, as of yet, lacking. Compelling, if not direct, evidence can be sourced from 
numerous studies on mouse TCRδ-/- knockout models. The observations on the immune 
outcome in the absence of γδT cells in these models vary with disease model and 
experimental question being asked. A common thread emerges, however, of increased 
sensitivity to infection and dysregulated, aberrant lymphoid responses – including αβT 
cell responses - particularly at epithelial sites (45–48,67). Significantly, induction of oral 
tolerance could not be achieved in TCRδ-/- knockout mice (46). Re-introduction of γδT 
cells restored suppression of both CD4+ and CD8+ αβT cell responses. Further models 
examining αβT cell knockout mice and γδT cell knockout mice in parallel found that 
TCRα-/- mice present with defects in protective immunity, while TCRδ-/- mice present with 
exaggerated intestinal damage as an apparent consequence of a lack of immune regulation 
at the site of infection (45). γδT cell-deficient mice have further been found to present with 
substantially increased sensitivity to chemically-induced malignancy (68).  
Any discussion of the in vivo pAPC role of γδT cells would be incomplete sans mention 
of mouse dendritic epidermal T cells (DETC). Described for the first time decades ago, 
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DETC were, in fact, found to express a distinctly oligoclonal, tissue-specific γδTCR (69). 
Multiple lines of compelling evidence highlight the antigen presenting and tissue 
homoeostatic roles of DETC (56,70–72). It is important to note, however, that a human 
homologue to mouse DETC has not thus far been identified, nor one for Skint1 -the ligand 
that the DETC TCR appears to recognize (69). Nor, as mentioned earlier - a human pAg-
activated Vγ9Vδ2 cell homologue in mice. I, therefore, refrain from in-depth discussion 
of the plethora of available γδT cell APC data generated in mouse models. The differences 
between mouse and human immune responses are a fascinating field of study and warrant 
significantly more attention from medical researchers, given how reliant we have grown 
on the extrapolation of mouse-generated data to human physiology and pathophysiology. 
A recent Nature editorial, based on work by Moss and group, outlines various reasons as 
to why murine models don’t always translate easily to relevant human settings, and how 
these issues may be addressed, including the use of humanized mouse models (73). 
Reviews on the specific physiological differences between the mouse and human immune 
response, including γδT cells, have been compiled by Zschaler et al. and Mestas, et al. 
(74,75). 
 
1.4. Phagocytosis  
An important aspect of antigen presentation that necessitates consideration in the context 
of a γδT cell pAPC is the uptake of antigenic material destined for presentation. Cell 
internalization of material can take many forms and serves multiple physiologically 
important roles. Recent reviews by Flannagan et al. (76) and Underhill et al. (77) 
summarize what is known about the complex networks of information processing that 
occur during cell uptake of extracellular particles. While some forms of uptake serve a 
crucial immunological function, others are a part of routine cell homeostasis – and others 
still can be both, depending on the physiological context and cell type.  
Endocytosis, the process by which cells internalize small molecules of e.g. nutritional 
value, is actin dependent, and occurs via multiple mechanisms. These include 
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internalization via clathrin-coated pits or cholesterol-rich caveolae. Macropinocytosis - 
sometimes referred to as “cell drinking” - involves extensive utilization of the actin 
cytoskeleton. It occurs via an eruption of membrane ruffles at the cell surface, which 
collapse back and fuse back with the cell membrane engulfing extracellular liquid in the 
process. The resulting vacuole, or macropinosome, is then shuttled down the normal 
endocytic pathway (78). Macropinocytosis is a normal part of all cell physiology. Via 
autophagy a cell may engulf organelles, soluble factors or microorganisms within its own 
cytosol. Trogocytosis describes the intracellular transfer of membrane patches from an 
APC to a lymphocyte (79). Cells can further engage in ‘cannibalism’, consuming whole, 
healthy self-cells, which are then degraded; such cannibalism has been seen with, for 
example, tumour cell ‘eating’ of lymphocytes (80). The unusual phenomenon of cell 
‘burrowing’ is called entosis; the cell burrowing into another cell can die or re-emerge 
from its temporary host (80).    
Phagocytosis – perhaps the most studied mode of material internalization – is actin and 
receptor-dependent uptake of specifically particulate targets >0.5μm in size (81). Potential 
targets range from dead or dying cells to microorganisms, to environmental debris. The 
ability to phagocytose material is restricted to specialized cells, which are predominantly 
immune effectors. There are multiple known mechanisms of phagocytosis, and these 
include i) reaching phagocytosis, mediated by e.g. Fc receptors or dectin 1, ii) triggered 
phagocytosis, which may occur if large particulate antigens are taken up during 
macropinocytosis, iii) sinking phagocytosis that is mediated by complement, and iv) 
macroautophagy, which involves cell ‘eating’ of large cytosolic material. All of these 
uptake routes result in the formation of a mature phagosome, and consequential killing 
and degradation of phagocytosed particles (77).  
A wide range of receptors has been implicated in mediating phagocytosis, categorized 
broadly into opsonic, non-opsonic and triggered (non-specific) receptors and 
phagocytosis, therein.  A brief summary, adapted from Underhill and Goodridge (77) can 




Phagocytosis proceeds through a number of stages, all of which involve tight control and 
multiple possible signaling events. Initial contact of cell and target is known as tasting, 
and involves receptor-mediated identification of target chemical identity by the cell. 
Feeling, the next step, occurs through dynamic membrane interactions between particle 
and cell; this permits the cell to identify the physical shape of the target. The specifics of 
subsequent swallowing are determined by signaling through the particular phagocytic 
receptor that was engaged. The phagocytic receptor(s) engaged further form a part of the 
phagosome membrane and inform phagosome handling and maturation, which result in 
digesting of the phagocytosed particle. The phagocytic process concludes with triggering 
of the inflammatory response within the cell. The inflammatory response involves 
secretion of specific inflammatory mediators from the cell, recruitment and activation of 
other cells, as well as professional antigen presentation of digested target peptides on 
MHC to αβT cells if the phagocyte is a pAPC. 
Definitions of what exactly constitutes a professional APC may vary, but there is general 
agreement that these cells are efficient phagocytes (or in the case of B cells – efficient at 
3-Table 5  |  Types of phagocytic receptors 
Table 1.3  |  Types of phagocytic receptors 
Type of receptor Receptor Ligand Refs 
Opsonic 
Fc gamma family (FcγRI, 
FcγRIIA and FcγRIIA) 
Antibody-opsonized targets (85) 
Complement receptors 
(C1, C3, C4) 
Complement-opsonized targets (86) 
α5β1 integrin Fibronectin (87) 
Non-opsonic 
Dectin 1 β-glucan (88) 
Macrophage receptor 
MARCO 
Bacteria (undefined) (89) 
Scavenger receptor A 
Bacteria (diverse charged 
molecules) 
(90) 
αVβ5 integrin Apoptotic cells (87) 






B cell receptor-mediated endocytosis), efficient at processing internalized material for 
presentation on MHC and express both, MHC class II and co-stimulatory molecules such 
as CD80 and CD86 (89). Occasionally, the ability to cross-present exogenous antigen on 
MHC class I is also included as a pre-requisite for a cell to be deemed a pAPC. In brief, 
pAPCs are cells which specialize in presenting antigen to T cells.  
Some distinction as to ‘professional’ and ‘non-professional’ has also been made in 
reference to phagocytosis. Fibroblasts and epithelial cells have been shown to take up, for 
example, latex beads >0.5μm in size or red blood cells in a receptor-mediated manner, in 
a process which was enhanced by opsonization of the target. What prevents their 
categorization as professional phagocytes by those who venture to define the difference 
(90) is the limited range of particles that fibroblasts and epithelial cells appear to be 
capable of phagocytosing. The limited range of targets is attributable to the limited range 
of phagocytic receptors on the cell surface. Compared to professional phagocytes, non-
professional phagocytes further lack the ability to produce a range of microbicidal 
molecules or mount a diverse cytokine response.  
 
 
1.5. γδT cell recall and memory 
An important aspect of γδT cell physiology in the context of their use as 
immunotherapeutics that has remained impervious to conclusive debate is “memory”. In 
order to avoid semantic misunderstanding, the intended meaning of “memory” further in 
the text implies the phenomenon described by Janeway, et al. as: “… the ability of the 
immune system to respond more rapidly and effectively to pathogens that have been 
encountered previously, and reflects the preexistence of a clonally expanded population 
of antigen-specific lymphocytes”, adding that “a long-standing debate about whether 
specific memory is maintained by distinct populations of long-lived memory cells that can 
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persist without residual antigen, or by lymphocytes that are under perpetual stimulation 
by residual antigen, appears to have been settled in favour of the former hypothesis.” (91) 
While a number of publications, disease models and research groups have suggested that 
γδT cells can confer residual protection from recurring disease, whether this protection is 
antigen-specific has been heavily contested. Publications have reported antigen-specific 
γδT cell memory responses to M.tuberculosis in humans, macaques, mice and cattle, as 
well as murine intestinal L. monocytogenes or imiquimod-induced inflammation-specific 
skin-resident γδT cells with indications of the hallmarks of canonical αβT cell memory: i) 
trafficking to draining lymph nodes, ii) migration through blood to distant tissue sites and 
peripheral lymph nodes, iii) persistence in these locations and iv) increased proliferative, 
and cytokine-producing capacity upon re-challenge (31,62,63,92). These findings are, 
however, inconsistent across various labs and have, importantly, struggled to find support 
in the patchy γδTCR sequencing data available in the literature. The number of known 
γδTCR antigen specificities is limited, and traditional T cell vaccination approaches have 
largely failed to induce reproducible, meaningful γδT cell memory to infectious re-
challenge. It is, moreover, unclear to what extent the γδTCR plays a role in γδT cell 
activation, how it is modulated by a range of agonistic and antagonistic co-receptors, how 
this may differ between various γδT cell subsets or across species, such as mouse and 
human, and what resemblance exactly this bears to the central, tightly-regulated and non-
redundant role of the TCR in canonical αβT cells.  
A detailed understanding of the mode of γδTCR-antigen interaction remains elusive. As 
alluded to earlier in the text, it is known that γδT cells are capable of responding to antigen 
in the absence of major histocompatibility complex (MHC) and classic APC antigen 
processing and presentation. Instead, in what has been described as an “antibody-like 
breadth in antigen recognition” (7), γδT cells are capable of recognizing antigen presented 
on atypical MHC-like molecules (e.g. the CD1 family), altered or absent antigen 
presenting molecules themselves, and even free antigen (54,93–95). The notion that the 
γδTCR may be capable of binding free antigen is supported by the exceedingly high  
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γδTCR CDR3 diversity – found largely in the TCRD locus - which suggests a lack of 
restriction by the γδTCR for any particular antigen delivery structure (reviewed by Chien 
and Konigshofer (96)). The classes of antigen engaged by the γδTCR are consequently 
varied, and range from phosphoantigens (pAg) to peptide and lipid antigens. Some have 
suggested that γδT cells are further capable of responding to antigen in the absence of 
direct TCR stimulation, depending instead on the aforementioned pattern recognition 
receptors (PRRs) (3,44,97–99). A number of studies argue that γδT cells may be capable 
of engaging a single antigen through several different receptors, as is the case - in a 
foreign-antigen context - with bacterial lipopolysaccharide (LPS)-derived Lipid A, which 
triggers both the γδTCR and TLR-4 or, in a self-antigen context, with MHC class I-
homologue MICA that is recognized by the γδTCR and NK-like receptor, NKG2D 
(93,95).  
The question of γδT cell memory is hugely complicated by the popular hypothesis that 
γδT cells may, in fact, be largely auto-reactive, whence their responses are triggered 
primarily by recognition of self-stress markers, such as self-phospholipid cargos or 
aberrantly expressed antigen presenting molecules themselves, rather than foreign 
antigens (for a limited list of known γδT cell activating ligands refer to Table 1.4). These 
self-stress markers can be specific and induced by infection, transformation or other injury 
to tissue; γδT cells may thus mount a potent pro-inflammatory response to, for example, 
E.coli invasion, and yet remain entirely self-reactive. Such an explanation to the 
divergence between the rapid, potent, en-masse γδT cell responses and the delayed, highly 
antigen-specific, canonical αβT cell responses is intriguing. It may shed light on the ability 
of γδT cells to react so effectively to seemingly heterogeneous stimuli with what has been 
stipulated to be a relatively oligoclonal TCR repertoire.  
Table 1.4  |  Activating ligands for human γδT cells  
Subset Antigen 
Vδ1pos 
MICA, CD1c, CD1d tetramers loaded with sulphatide, lipohexapeptides, 
phycoerythrin 
Vδ2pos  
ULBP4, phosphoantigens, F1-ATPase, histidyl-tRNA synthetase, phycoerythrin, 
HMBPP 
Vδ1negVδ2neg Endothelial protein C receptor, phycoerythrin 
Adapted from Hayday, et al. (2013) (7)) 
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Here again, however, γδT cells elude simplicity and categorization; some of the most 
potent documented γδT cell stimuli, such as (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate (or HMBPP), are of microbial origin (31). Some have proposed that the 
mechanism of HMBPP-induced activation of Vδ2 γδT cells may, in fact, be mediated via 
HMBPP induction of self-stress responses through dysregulation of the host mevalonate 
pathway, manifested as conformational changes in host cell surface butyrophilin (BTN) -  
BTN3A specifically - molecules (100). BTN changes through a similar mechanism have 
further been implicated as activatory to γδT cells, upon exposure to E.coli and other 
bacterial pathogens (101,102). Curiously, BTN3A conformational alterations further 
appear to be the mode of Vδ2 γδT cell activation in the context of stimulation with 
zoledronate. Zoledronate, a clinically-relevant bisphosphonate drug, which efficiently 
expands Vδ2 γδT cells in vitro, disrupts the host mevalonate pathway and causes the 
accumulation of endogenous pyrophosphates (IPP), which consequently induce 
conformational changes in BTN3A molecules on “stressed” self-cells (103). It is, perhaps, 
unsurprising that IPP and HMBPP appear to exert similar effects on Vδ2 γδT cells, given 
their high structural homology (Fig.1.2). The striking structural similarity between IPP 
and HMBPP does, however, present a hurdle in discerning the differential mechanisms by 
which these compounds may lead to γδT cell activation, and complicates our 
understanding of how γδT cells may distinguish between self and non-self danger signals. 
It is known, for example, that HMBPP, in the absence of any further immunogenic signals, 
is a far more potent activator of Vδ2  cells than IPP (104).  
Fig. 1.2. Chemical structure of IPP and HMBPP phosphoantigens. Sourced from entirely 
different organisms, isopentenyl pyrophosphate (IPP), of vertebrate origin, and (E)-4-hydroxy-
3-methyl-but-2-enyl pyrophosphate (HMBPP), of microbial origin, present with highly 
homologous chemical structures.  
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A simplified diagram listing the various ways in which γδT cells may recognize pAg can 
be viewed in figure 1.3. There are four potential modes by which γδT cells detect self and 
non-self pAg danger signals: i) detection of the accumulation of self pAgs within self cells, 
induced by self-stress, e.g. transformation or the application of drugs such as zoledronate 
(Fig.1.3A), ii) detection of non-self pAgs directly, sourced from invading pAg-expressing 
microorganisms, e.g. E.coli (Fig.1.3B), iii) detection of non-self pAgs directly, but in a 
manner that is dependent on self cells manifesting these non-self pAgs, e.g. via HMBPP-
induced butyrophilin changes (Fig.1.3C), or iv) detection of non-self pAgs indirectly, 
wherein non-self stressors such as E.coli induce self-stress and consequent accumulation 
of self pAgs that are then detected by γδT cells on self cells (Fig.1.3D). It is possible that 
all four mechanisms play a role in γδT cell detection of immune stress signals. γδT cell 





Fig. 1.3. γδT cell recognition of self and non-self phosphoantigen danger signals. It is known 
that γδT cells can recognise efficiently both endogenous cellular stress and invading 
microorganisms. While this can occur in a phosphoantigen (pAg)-dependent manner,  exact 
mechanisms of recognition are lacking. Four different mechanisms of pAg detection in a self 
and non-self context are possible: (A) Direct detection of self pAgs, induced by self-stress, e.g. 
transformation or drugs such as zoledronate, (B) Direct detection of non-self pAgs, sourced 
from invading pAg-expressing microorganisms, e.g. E.coli (C) Direct detection of non-self pAgs, 
but in a manner that is dependent on self cells manifesting these non-self pAgs, e.g. via 
HMBPP-induced butyrophilin changes, or (D) Indirect detection of non-self pAgs, wherein non-
self stressors such as E.coli induce self-stress and consequent accumulation of self pAgs that 
are then detected by γδT cells on self cells.  
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It remains important to consider in this context the extreme complexity of the immune 
environments that γδT cells predominantly operate in. It is conceivable that the 
gastrointestinal mucosa, an epithelial landscape densely populated by various immune 
cells and trillions of commensal microorganisms, requires effector cells sensitive to 
signals of self-stress as well as foreign pathogens. It is likely, thus, that γδT cells employ 
avenues in addition to the TCR and its machinery to fine-tune antigen recognition and 
determine appropriate effector function. Work to clarify the role in antigen specificity of 
the γδTCR versus the wide variety of other classically lymphoid and myeloid-associated 
pathogen recognition receptors (PRRs) that have been found on γδT cells, including NK-
like receptors, Fc receptors (FcRs) and Toll-like receptors (TLRs) (reviewed by Hayday 
and Vantrout (7)), is crucial if we hope to manipulate antigen-specific γδT cell responses 
in a clinical setting. 
The concept of a predominating γδT cell autoreactivity complicates their categorisation 
into traditional αβT cell memory phenotypes, such as “effector memory” or “naïve”, given 
that these are traditionally prescribed as resulting from various degrees of antigen 
exposure. As memory phenotype remains a traditionally important parameter in predicting 
T cell behaviour in response to antigen, numerous cell surface markers, including CD27, 
CD45RA, CD45RO, CD62L, CCR7, and combinations thereof, have been used to attempt 
γδT cell classification into memory phenotypes with homologues in the αβT cell 
compartment. General consensus is lacking, and, importantly, the relevance of these 
markers in the context of classical αβT cell memory subsets for γδT cells is unclear at best. 
Similar lack of clarity persists with other classic and important parameters of T cell 
physiology. Markers, such as CD69 for early activation or PD-1 for exhaustion, for 
example, are thought to represent γδT cell parallels to αβT cell behaviour, but whether 
these are the definitive readouts of γδT cell activation or exhaustion states remains to be 
established. I proceed, nonetheless, with their use in investigation for want of obviously 
better current alternatives.  
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1.6. Categorisation of γδT cell subsets 
Significant efforts have been poured into establishing reproducible and clear human γδT 
cell functional subsets, providing more detail than merely a reference to the expression of 
a Vδ1 or Vδ2 TCR chain. Particularly important in the pursuit of γδT cells as 
immunotherapeutic tools is the classification of their effector subsets prior to and post 
stimulation. Expansion ex vivo has been a significant component of the γδT cell field since 
its inception. The relative scarcity of γδT cells in human peripheral blood has necessitated 
expansion as a means of amplifying cell number for use in functional assays, protein 
analyses and other experimental probes. Additionally, the promise that γδT cells have 
demonstrated in the clinic has created a new urgency in establishing effective, 
reproducible γδT cell expansion protocols, with a detailed understanding of the effector 
subsets of expanded cells therein. Novel approaches for γδT cell amplification are being 
developed as technological advances permit deepening examination of the poorly 
understood epithelial immune compartment, where γδT cells can constitute up to 60% of 
total intraepithelial lymphocytes (IEL) (7). While expansion with stimuli such as IPP, 
zoledronate and concanavalin A (ConA) have become a routine in basic science as well 
as clinical γδT cell manipulation, our understanding of specific stimuli that drive and 
regulate γδT cell expansion remains limited (4,103,105). Moreover, most established 
protocols appear only effective in expanding the peripherally dominant Vγ9Vδ2 γδT cell 
subset. Significant donor variation in terms of rate-expansion remains an issue in 
optimizing γδT cell use in the clinic; the factors, which impact Vγ9Vδ2 cell expansion 
rate, remain uncertain.  
Fascinating insight into the functional subgroups of human Vδ2 cells has been provided 
by a recent publication from the group of Pennington et. al. (106), which describes the 
surprisingly stable yet heterogeneous populations of peripheral Vδ2 cells in 63 healthy 
individuals, which were found to be independent of donor age, sex, ethnicity or, 
apparently, previous pAg exposure. They were able to identify two predominant Vδ2 cell 
populations, which were deemed γδ(28+) and γδ(16+) based on their respective expression of 
either CD28 or CD16. It was observed that γδ(28+) cells exhibited a CCR6pos phenotype, 
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which futher correlated with increased expression of cytokine receptors (e.g. IL-18R) and 
chemokine receptors (e.g. CCR2 and CCR5), as well as granzyme K. γδ(16+) cells, 
meanwhile, favoured expression of CXCR1, and presented with an increased 
perforin/granzyme B cytotoxic potential, paired with lowered proliferative capacity. Such 
observations are likely to carry significant implications for the design of personalized, 
cell-based anti-tumour therapies, whence a match between tumour cell type (which may 
be e.g. granzyme B inhibitor, PI-9, positive) and immune effector cell killing mechanism 
is important.  
Meanwhile, in my characterization of unstimulated or differentially-expanded Vδ2 cells, 
I placed a particular emphasis on their expression patterns of APC molecules, MHC class 
II (HLA-DR, specifically) and co-stimulatory CD86, as well as homing receptors, 
chemokine receptor 7 (CCR7) and CD62L (also known as L-selectin). HLA-DR and 
CD86 expression has been documented on human γδT cells in various contexts, ranging 
from in vitro stimulation to in vivo infectious disease. Both endogenous pAgs and Gram-
negative bacteria-stimulated γδT cells have been reported to upregulate expression of 
HLA-DR and CD86 (102,105). The dynamics, time scale and stability of this upregulation 
has, however, not been reported in detail.  
CCR7, a homing receptor expressed on naïve T cells and activated APC, plays a central 
role in cell migration to lymphoid tissue. Its corresponding ligands, CCL19 and CCL21, 
are expressed strongly in the thymus and lymph nodes. Naïve CCR7pos T cells continue 
re-circulation through blood and the lymphatic system until encountering an activating 
APC, at which point CCR7 is downregulated and chemokine receptors for tissue-specific 
migration are upregulated. Central memory T cells (Tcm) engage in a similar blood-to-
secondary lymphoid organ re-circulation and, as naïve T cells, downregulate CCR7 and 
upregulate tissue-specific homing receptors upon activation (107). CD62L is a lymphoid 
homing receptor functionally closely related to CCR7, and mediates blood-borne T cell 
rolling on high endothelial venules, allowing their extravasation into lymphatic 
circulation. CCR7 and CD62L are both used as classic markers of T cell migration to 
secondary lymphoid tissue. 
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CCR7 upregulation on APC, such as dendritic cells (DC), is, meanwhile, a marker of cell 
activation. Upon encounter with appropriate stimulation (e.g. invading bacteria) tissue-
resident DC are activated, upregulate CCR7 and migrate to secondary lymphoid tissue. 
Once there, DC engage in presentation of phagocytosed and processed antigen to re-
circulating T cells (108,109). A similar role, although less well understood, has been 
ascribed to CD62L. The two main sources of DCs to lymph nodes are thought to be 
peripheral DCs entering via afferent lymph and monocyte-derived DCs entering via high 
endothelial venules. Luster et al. (110) have produced a comprehensive review on the 
plethora of chemokines and chemokine receptors involved in shaping lymphoid as well as 
myeloid migration during the immune response.  
While CCR7 and CD62L represent but a fraction of potentially significant γδT cell homing 
receptors, I chose to focus on them set against the curious background that these receptors 
appear to follow different patterns post-activation, depending on whether expression is 
examined in T cells or myeloid APC. If peripheral γδT cells do indeed perform an APC 
function during systemic infection - such as modeled in my experimental setup - does this 
APC function occur in blood or in secondary lymphoid tissue? Are APC and homing 
marker expression patterns on γδT cells reminiscent of those on classic αβT cells or 
myeloid APC? Moreover, does PBMC stimulation with the highly differential stimuli of 
zoledronate (representing ‘self’) or E.coli (representing ‘non-self’) induce similar 
upregulation of APC molecules, MHC class II and CD86, and lymphoid homing markers, 
CCR7 and CD62L? Finally, are these similarities or differences in differentially-expanded 
γδT cell APC and homing phenotype reflected in the TCR repertoire?  
 
1.7. Role of the TCR in γδT cell physiology 
Meaningful discussion of the nature and manipulation of γδT cell effector phenotypes 
would be incomplete without examination of the factors that influence the development 
of said phenotypes. Stimulation via the TCR is central to thymocyte development and 
effector T cell function. It determines the deletion or maintenance of a nascent T cell, its 
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activation status and subsequently regulates its ‘fate decisions’. It is striking that decades 
after its discovery and establishment of its importance in the functioning of a healthy 
immune system, the exact mode of TCR engagement – even in canonical αβT cells – 
remains unclear. A number of models have been proposed, and their popularity in the field 
ebbs and flows with the income of new experimental evidence. Van der Merwe and 
Dushek have recently compiled a comprehensive review of various models of TCR 
triggering (111), accompanied by helpful diagrammatic material. In the interest of 
accuracy and clarity, they have defined ‘TCR triggering’ as: “[t]he process by which TCR 
binding to peptide-MHC molecules leads to biochemical changes in the cytoplasmic 
regions of the CD3 complex […]”. These models are based on the central dogma that all 
TCR CD3 complex subunits contain immunoreceptor tyrosine-based activation motifs 
(ITAMs) in their cytoplasmic domains, which – via biochemical modification - are the 
central mediators of T cell activation resulting from TCR triggering. Phosphorylation by 
the Src family kinases, Lck and FYN, has been proposed as one of these essential 
biochemical ITAM changes. The models described have been organized into three main 
groups, depending on the primary mechanism proposed: i) aggregation, ii) conformational 
change and iii) segregation or re-distrubtion.  
Models within the ‘aggregation’ group include: a) co-receptor heterodimerization and b) 
pseudodimerisation. Briefly, the co-receptor heterodimerisation model (arguably, the most 
popular and widely accepted model) proposes that co-receptors bind to the same peptide-
MHC complex as the TCR, which then brings co-receptor-associated Lck into proximity 
with CD3 complex ITAMs, resulting in phosphorylation. A basic illustration of the 
heterodimerization model can be viewed in Figure 1.4. The pseudodimer model postulates 
that two TCRs are brought together by one of the two binding low-affinity self, and the 
other – binding high affinity self or non-self peptide-MHC complexes. The co-receptor 
associated with the low affinity TCR then engages the agonist (high affinity) peptide-
MHC complex that has been bound by the high affinity TCR, thereby forming a dimer 
between the two TCRs. This then permits co-receptor-associated Lck phosphorylation of 





Fig. 1.4. Co-receptor heterodimerisation aggregation model of TCR triggering. The model 
proposes that co-receptor binding to the same peptide-MHC complex as the TCR brings 
co-receptor-associated Lck into proximity with TCR-CD3 ITAMs, thereby enhancing 
phosphorylation. Elements of this diagram have been adapted from van der Merwe and 
Dushek. 
1-Fig. 7.1. Co-receptor heterodimerisation aggregation model of TCR triggering. 
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Models of the ‘conformational change’ group include: a) piston-like movement and b) 
induced clustering. The piston-like movement model describes mechanical ‘pulling’ of 
the TCR by cognate peptide-MHC complex, which then drives phosphorylation of the 
CD3 ITAMs. The induced clustering model argues that TCR clustering is induced by a 
conformational change in the peptide-MHC-engaged TCR-CD3 complex, which then 
enhances kinase activity and leads to the phosphorylation of CD3 ITAMS.  
‘Segregation or re-distribution’ models include: a) kinetic segregation and b) lipid rafts. 
Briefly, the kinetic segregation model proposes that TCR binding to peptide-MHC ligand 
traps the TCR-CD3 complex in close-contact zones, thereby segregating it from inhibitory 
signals (e.g. inhibitory tyrosine phosphatase CD45) leading to stable phosphorylation of 
ITAMs by LCK. Lipid raft models postulate that peptide-MHC engagement results in 
partitioning of the TCR-CD3 complex into regions of membrane enriched in Lck and 
deficient in CD45.  
It is conceivable that elements of all of the above-described models play a role in TCR 
triggering; each model applicable in a particular context, depending on, for example, the 
type of co-receptors a T cell expresses or the type of antigen presenting cell that is 
engaging the T cell at hand. It is important to note that the mechanistic aspects of TCR 
engagement by target do not end with triggering. Questions regarding subsequent events, 
such as “How is productive TCR signaling different from non-productive signaling? “ and 
“How is productive signaling achieved?” are yet to be answered definitively. A multitude 
of further models that consider the mechanisms of post-triggering TCR signaling, 
including kinetic ‘proofreading’, segregation, sequestration of ITAMs, allosteric 
malleability and serial triggering, are evaluated by Chakraborty and Weiss (112). As with 
models of TCR triggering, their discussion of various proposed mechanisms makes 
several assumptions about the processes that occur. They too place importance on Lck, as 
well as a tyrosine kinase, Zap70. An emphasis is placed on the interactions between Lck, 
Zap70 and subunits of the invariant signaling protein CD3 complex, [αβTCR] co-receptors 
CD4 and CD8, and modulatory molecules, therein. Specifically, Chakraborty and Weiss 
describe a new model of TCR signaling, whereupon TCR engagement by peptide-MHC 
invokes basal phosphorylation of CD3, which then poises Zap70 for activation by Lck 
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largely via stabilization of ‘active’ Lck. A significant role is ascribed to the formation of 
TCR microclusters in permitting signal amplification by a triggered TCR.  
Navarro and Cantrell have compiled current thought on what takes place after a TCR has 
been triggered and engaged productively (113). Once again, several different models 
persist, but most include signal transduction by serine threonine kinases. Membrane-
proximal signals from TCR activation are transduced to elicit cytosolic and nuclear 
responses. TCR signaling triggers increased levels of second messengers (Ca2+, 
diacylglycerol, PI3K, etc.), which facilitates activation of downstream kinases (protein 
kinase C, PDK1, Akt, etc.), each of which play a role in the unfolding signaling cascades. 
The signaling outcome of productive TCR engagement is the influencing of transcription 
factor activity, and, ultimately, altered gene expression and metabolic activity. Malissen 
et al. have described that Zap70 activation, downstream of productive TCR engagement, 
exerts an influence even on such T cell functions as rearrangements of the actin 
cytoskeleton and integrin affinity (114). 
Canonical αβT cell TCR signaling, thus, remains an expanding, but, as of yet, contested 
intellectual landscape. Controversy persists regarding even basic conceptual models. A 
whole further level of complexity and controversy is introduced when contemplating 
signaling of the atypical, poorly understood γδT cell population. Rudimental 
understanding on γδTCR engagement of targets is lacking. It is unclear, for example, if 
γδTCR engagement is even necessary for the cells to exert many of their effector 
functions. It is unclear whether a TCR-MHC-peptide triad homologue exists for the 
γδTCR; some have even suggested that γδT cells are capable of recognizing free antigen, 
in the same way that B cells do (7). Data published by various groups, in various in vitro 
scenarios, of various donor species is frequently contradictory. As outlined in previous 
chapters, there are indeed significant species differences, as have been described for 
mouse versus human γδT cells. Subset and anatomical localization differences are likely 
additional factors explaining the heterogeneity of data generated. The recognition of 
‘stressed self’ – if that is indeed what some (or all) γδT cells recognize – is particularly 
difficult to study. This is especially so, when considering that most γδT cells in the human 
body reside at epithelial surfaces, which are, as of yet, nearly impossible to replicate fully 
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in vitro. γδT cells are, moreover, known to express a plethora of non-TCR receptors 
implicated in the recognition of stressed or transformed self (e.g. NK cell receptors, such 
as NKG2D), making dissection of the unique role of the TCR exacting.  
A list of documented human γδT cell clones can be viewed in Table 1.5, elements of which 
have been adapted from a review by Carding and Egan (8). While representing a mixture 
of suspected self and non-self TCR specificities, definitive evidence as to the exact mode 
of antigen engagement (e.g. crystllized TCR-antigen-antigen presenting molecule 
complex) is limited. It is possible that most (if not all) documented non-self ligand 
triggering of γδT cells in a TCR-dependent manner is merely a reflection of non-self 
induction of self-stress molecules, which are then ultimately what is recognized by the 
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The recognition of ‘self’ by the TCR has been discussed by Hogquist and Jameson (131). 
Their focus, in particular, was the functional consequences of TCR signaling in 
CD4+CD8+ double-positive thymocytes and mature T cells. They argue that all T cells 
(canonical αβT cells in this instance) are at least partially self-reactive, as they recognize 
a diverse repertoire of peptides, but only in combination with self MHC molecules. They 
further highlight the classic model of thymic T cell selection, whereupon thymocytes 
undergoing positive versus negative selection present with significantly different Ca2+ flux 
patterns. Strong TCR signaling in the thymus generally leads to negative selection, 
whereas a weaker or ‘intermediate’ signal leads to positive selection. Importantly, 
however, they note that multiple T cell subsets, including IELs (which constitute the 
majority of human γδT cells), invariant NKT cells and regulatory T cells, require strong 
TCR signaling for selection. It is, therefore, clear that factors other than TCR signal 
strength alone are involved in shaping of the TCR repertoire. What these factors may be 
remains poorly understood, although anatomical location of the selection process or origin 
of the T cell may play a role.  
The sensitivity of a TCR to high- or low-affinity peptide interactions evolves as cells 
develop from CD4+CD8+ double positive thymocytes to mature T cells (131). Over the 
developmental process, T cells appear to dampen their sensitivity to self peptide-MHC 
complexes. This process of ‘tuning’ is parallel to alternations in the gene expression 
profile of the cell, as well as changes to basal intracellular Ca2+ concentration. 
Nonetheless, basal TCR signaling in response to self peptide-MHC takes place throughout 
the lifetime of a naïve T cell, and is likely necessary for homeostasis.  
Fascinating insight into the possible TCR dependency of human γδT cells has been 
provided by recent investigations of the mouse γδT cell compartment. Sutton et al. (132) 
found that γδT cells rapidly produce the potent pro-inflammatory cytokine IL-17 in 
response solely to stimulation with IL-1 and IL-23. This stands in stark contrast to the 
dogma that governs our understanding of canonical T cells, which are thought to engage 
potent effector function only after receiving a stimulus via the TCR. The cells producing 
IL-17 in response to cytokine stimulation alone were negative for the co-stimulatory 
receptor CD27, and were subsequently deemed ‘innate-like’ γδT cells (133). Such ‘innate-
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like’ IL17pos γδT cells are particularly abundant in murine and human neonates; their role 
has, thus, been postulated as one of rapid anti-microbial (anti-fungal and anti-bacterial, 
specifically) responders in vulnerable young animals. The same cells have further been 
implicated in a number of immunopathologies of both the young and adults in human and 
animal models, including psoriasis, rheumatoid arthritis and experimental allergic 
encephalomyelitis (134–139).  
Mouse IL-17A-producing CD27neg ‘innate’ γδT cells were considered to emerge by 
default from thymic progenitor cells that receive only weak TCR signals during 
development, in contrast to the strong signals received by CD27pos ‘lymphoid’ γδT cells, 
delineating clearly the TCR as less important for the development and functioning of 
‘innate’ γδT cells (133,140,141). It is known, however, that CD27neg mouse γδT cells 
constitutively display markers associated with TCR activation (133,139,142). A recent 
investigation by Wencker et al. (143) showed that, in total contrast to previous assumption, 
CD27neg mouse γδT cells selectively depend on strong TCR signaling, which thereafter 
alters and significantly mutes their TCR responsiveness. The group, thus, proposes that 
‘innate-like’ lymphocytes reconcile their lymphoid and rapidly-responsive myeloid-like 
nature as follows: “During the development of innate-like T cells, a requisite activation of 
TCR signaling components markedly alters the antigen receptor response mode, removing 
it as the primary checkpoint for peripheral responsiveness. Thus freed, the cells can 
respond rapidly to innate signals.” Wencker et al. further propose that this novel, atypical 
relationship to the TCR may permit innate T cells to utilize their TCR in novel ways. 
These include steady-state TCR-mediated engagement of epithelial cells by IELs or 
particular responses to large amounts of antigen in the context of particular cytokines 
(139,144). As such, TCR-expressing, ‘innate’ cells offer a vast expansion of the innate 
immune response repertoire. Indeed, γδT cells are known to express TCR repertoires that 
range from oligoclonal to polyclonal, depending on the subset and species of origin at 
hand (7). An ‘innate’ cell with a TCR may, moreover, provide an additional layer of 
quality control for lymphocytes entering the innate compartment.  
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While providing a fascinating insight into the workings of ‘innate’ mouse γδT cells, I 
emphasize that it is unclear what bearing this may have on human γδT cell counterparts. I 
stipulate that similar dependence on TCR may be found with human γδT IELs (largely of 
the Vδ1 subset). Importantly, not all mouse γδT cell subsets display TCR independence 
for the engagement of effector function, nor are all subsets stimulated by exposure to 
cytokines alone. It is possible that human γδT cells display a similar subset-specific 
dependence on the TCR.  
 
1.8. Role of the BTN3A in γδT cell physiology 
Detailed examination of human γδT cells function, particularly that of the peripherally 
dominant Vγ9Vδ2 subset, would be amiss without consideration of the role of the B7-like 
butyrophilins (BTN). Study of the B7 co-stimulatory immunoglobulin superfamily has 
expanded our understanding of the factors that regulate and fine-tune T cell activation. 
Classic examples of well-studied B7 member interactions include: I) activatory pairing of 
B7.1 (CD80) and B7.2 (CD86) on APCs to CD28 on T cells, and II) inhibitory pairing of 
B7.1 and B7.2 on APCs to CTLA4 on T cells. Further well-known and important members 
of the B7 family include PD1, PDL1 and B7RP1 (also known as ICOSL). Recent 
discoveries reveal that another immunoglobulin superfamily, closely related to the B7 
family, may play a significant role in regulating the immune response.  
The BTN immunoglobulin superfamily was first described in the 1980’s with the 
discovery of BTN1 (145). BTN1 (BTN1A1, specifically) was found to play a role in milk 
fat globule secretion and stabilization. The immune significance of the BTN family took 
decades to establish and is being unraveled still. With the number of known human BTN 
family members currently at 13, their roles appear almost entirely geared toward immune 
regulation. Even BTN1A1 has been ascribed a role in thymic stromal and B cell 
interactions with activated T cells and macrophages (146). While the exact 
immunomodulatory roles of BTN family members remain unclear, two main lines of 
evidence speak to their putative importance: i) the high phylogenetic homology of BTN 
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and B7 proteins, and ii) the extremely broad BTN expression on immune cells or cells that 
interact closely with immune cells (e.g. thymic stromal cells and intestinal epithelial cells). 
The multiple similarities between the BTN and B7 immunoglobulin superfamilies was 
explored recently by Arnett and Viney (147). Perhaps most obviously, the two protein 
families share high structural homology. Membership of the B7 family is largely defined 
by the presence of a small intracellular cytoplasmic tail and a transmembrane region linked 
to extracellular IgV and IgC domains, which then confer receptor binding specificity that 
is mainly for other immunoglobulin superfamily members (148). Similarly, BTNs have 
two extracellular IgV and IgC domains, as well as a transmembrane region. In a 
divergence from the B7 family, most members of the BTN family further contain an 
intracellular B30.2 signaling domain (illustrated in Fig 1.5).   
Fig. 1.5. Structural comparison of the B7 and BTN superfamilies. Both families share 
hallmark extracellular immunoglobulin domains, typically of IgV and IgC type. While the 
B30.2 domain is a common feature of BTNs, no known B7 members contain intracellular 
signaling domains. (TM, transmembrane domain) 
2-Fig. 8.1. Structural comparison of the B7 and BTN superfamilies. 
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Not a great deal is known about the specific cell surface binding partners of the BTN 
family, although it does not appear that these include the classic B7 targets of CD28, 
CTLA4, ICOS or PD1 (149,150). The intracellular binding interactions of BTNs are, 
meanwhile, governed by the B30.2 protein-binding domain. B30.2 binding partners can 
range from the enzyme xanthine oxidoreductase for BTN1A1 (151) to prenylated pAgs 
for BTN3A.1 (152). Interestingly, the B30.2 domains of these different BTNs do not 
appear cross-reactive in terms of binding partners.  The B30.2 domain is defined by the 
presence of a PRY/SPRY element, which is composed of three specific sequence motifs, 
LDP, WEVE and LDYE. It derives its name from the inclusion of a SPRY domain, which 
is preceded by an amino-terminal PRY motif (153). The B30.2 domain is not exclusive to 
the BTN family, and has been identified in a total of 51 genes in the human genome, where 
it appears to play a role in mediating protein-protein interactions (154). Few specific 
binding partners are known.   
The BTN3A (also known as CD277) subfamily of BTNs (BTNA.1, BTNA.2, BTNA.3) 
is expressed by most human immune cells, myeloid and lymphocytic in origin. These 
include T cells, B cells, NK cells, DCs and monocytes (149). A number of antibodies 
have been generated against all BTN3A subsets. Most of what we know about the 
importance of BTN3A in the functioning of γδT cells has been derived from these 
antibody studies, to which a significant contribution has been made by Dr. Daniel 
Olive’s research group (Marseille, France). A summary of published anti-BTN3A 
antibodies can be viewed in Table 1.6.
5-Table 8  |  Characteristics of published anti-BTN3A mAbs 









Binds to BTN3A directly on T cells, NK cells, 
monocytes and DCs, delivering an activatory signal. 
Results in enhanced proliferation, survival and 










Sterically blocks association of proteins engaged by 
BTN3A.1 during activation. Known to block Vγ9Vδ2 T 





Phosphorylates BTN3A.3 and initiates inhibitory 
signalling. Inhibits T cell function.  
(203) 
 45 
Observations from the various anti-BTN3A antibody clones indicate that these can be 
both, agonistic and antagonistic. The specific binding site and mode of engagement are 
what appear to govern the functional outcome of mAb engagement of BTN3A, ranging 
from phosphorylation to steric blocking (Table 8 and associated references). It is 
interesting to note that, due to the wide lymphocytic expression of BTN3A, anti-BTN3A 
mAb can exert dual effects on T cell activation: i) indirect effects, such as altering BTN 
conformation on target cells (e.g. monocytes) or affecting bystander cell activation with 
consequent pro- or anti-inflammatory effects, and ii) direct effects, such as activatory 
cross-linking of BTN on T cells themselves.  
Comparing the different BTN3A isoforms, it is known that each contains an extracellular 
N-terminal IgV and a membrane-proximal IgC domain, connected to a single-pass 
transmembrane domain. BTN3A.1 and BTN3A.3 further contain an intracellular B30.2 
domain, which is absent in BTN3A.2 (159). Importantly, while all three isoforms mediate 
Vγ9Vδ2 cell activation if treated with the agonistic mAb 20.1, only BTN3A.1 mediates 
pAg-induced activation (100,157).  This alludes to i) high extracellular homology of the 
BTN3A isoforms, and ii) the recognition by Vγ9Vδ2 cells of extracellular BTN3A 
conformational changes. A basic summary of BTN3A isoform differences can be viewed 
in figure 1.6. Curiously, BTN3A.3 was not able to induce Vγ9Vδ2 cell activation in a 
pAg-dependent manner, despite containing a B30.2 domain. Sandstrom et al. recently 
demonstrated that this is due to a single amino acid difference between BTN3A.1 and 
BTN3A.3-associated B30.2 domains, which, in the case of BTN3A.3, impedes effective 
pAg binding (152).  
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Upon co-crystallization of pAg and BTN3A.1-associated B30.2, Sandstrom et al. 
provided definitive evidence for the importance of the B30.2 domain in acting as an 
intracellular pAg ‘sensor’ that communicates stress to Vγ9Vδ2 cells via its extracellular 
BTN3A portion (152).  
  
Fig. 1.6. Different isoforms of BTN3A. All isoforms share the same structure of the extracellular 
domain. Both BTN3A.1 and BTN3A.3 contain further intracellular B30.2 domains. Due to a 
single amino acid change, however, only BTN3A.1. B30.2 is capable of effectively binding pAg 
and, thus, transmitting the presence of intracellular pAg to Vγ9Vδ2 cells. (TM, 
transmembrane domain) 
3-Fig. 8.2. Different isoforms of BTN3A. 
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In contrast to the clarity of pAg-B30.2-BTN3A interactions, little is understood about how 
exactly the binding of pAg to BTN3A.1 B30.2 is recognized by Vγ9Vδ2 cells. Rhodes et 
al., who were crucial in the discovery and characterization of human BTN3A, have 
recently described three different scenarios by which BTN3A.1 may mediate Vγ9Vδ2 cell 
activation (160). These are summarized in figure 1.7.  
 
Fig. 1.7. Models of γδT cell activation by BTN3A. (A) The Direct Interaction model proposes 
that BTN3A.1 and its conformational changes are the ligand for the Vγ9Vδ2 TCR. (B) The 
Co-receptor model proposes that the Vγ9Vδ2 TCR interacts with an MHC-like molecule, 
while BTN3A interacts with a B7-like (e.g. CTLA-4-like or CD28-like) molecule. (C) The Cell-
Adhesion model proposes that BTN3A engages in homotypic interactions, which promote 
cell contact between the Vγ9Vδ2 and potential APC.  
4-Fig. 8.3. Models of γδT cell activation by BTN3A. 
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While all of the models described by Rhodes et al. are based on the finding that it is 
specifically BTN3A.1 that is critical for activatory signal transmission to Vγ9Vδ2 cells, 
they highlight that data indicates there is a role for the BTN3A.2 and BTN3A.3 isoforms 
and the recruitment of periplakin to stabilize the complex in the cell membrane (161). The 
three models they describe are, briefly: I) the Direct Interaction model, in which BTN3A.1 
(or specific conformation, therein) is a ligand for the γδTCR (Fig.1.7A), II) the Co-
receptor model, which assumes that γδT cell activation occurs much more along the lines 
of canonical T cell – APC interactions; in this model, the γδTCR recognizes an MHC-like 
molecule, while BTN3A acts as a co-receptor, likely binding to CD28-like or CTLA-4-
like molecules; importantly, no such target molecules for the γδTCR or BTN3A have (yet) 
been identified (Fig.1.7B), III) the Cell Adhesion model, whereupon BTN3A molecules, 
in given conformation, simply act as adhesion factors promoting cell-cell interation in a 
pAg-dependent manner (Fig.1.7C). Whether the γδTCR is engaged directly by BTN3A, 
thus, remains unclear.  
In fact, so little is understood about the direct nature of BTN3A-Vγ9Vδ2 contact, that one 
is forced to expand the intracellular pAg-B30.2-BTN3A model. Acknowledging that pAg 
binding to B30.2 of BTN3A.1 is indeed activatory to Vγ9Vδ2 cells in vitro, Harly et al. 
hypothesize that the reality may be more complicated than that (162). One hypothesis put 
forth argues that extracellular pAgs are imported into target cells by unidentified 
transporter(s), or are produced intracellularly. Potentially, both are the case. These pAgs 
then bind the intracellular B30.2 domain of BTN3A.1, which induces non-exclusive key 
modifications in the receptor protein, which may include conformational changes, 
modifications of its membrane topology, recruitment or exclusion of molecular patterns, 
etc. Any or all of these changes can then be sensed by Vγ9Vδ2 cells. This is, perhaps, the 
current most popular model among researchers interested in Vγ9Vδ2 cell activation. 
Alternatively, Harly et al. argue, pAg binding could occur intracellularly as well as the 
extracellularly. Accepting that the B30.2-pAg interaction (and BTN3A.1 conformational 
changes, therein) are important does not exclude the possibility that also a kind of ‘antigen 
presentation’ occurs, whereupon the conformationally-changed BTN3A.1 can therefore 
present pAg to the Vγ9Vδ2 TCR. In contrast to Rhodes et al. and their proposed 
hypothetical mechanisms of activation, Harly and group appear to place significantly more 
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emphasis on the specific involvement of the TCR in BTN3A.1-triggered activation of 
Vγ9Vδ2 cells. A basic summary of Harly’s different hypotheses can be viewed in figure 
1.8. The idea that prenyl pyrophosphates may be presented to γδT cells on extracellular 
portions of BTN3A.1 has garnered experimental and intellectual support from a number 
of groups and researchers, including Vavassori et al., Kabelitz et al., De Libero et al. and 
Esser et al. (163–165).  
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Fig. 1.8. Alternate models of pAg sourcing for Vγ9Vδ2 cell activation via BTN3A.1. Several 
competing and, possibly, complementary hypotheses exist of Vγ9Vδ2 cell activation by pAg 
via BTN3A.1 as put forth by Harley et al. (A) One hypothesis argues that intracellular pAg 
are exported from the cell by unidentified transporter(s), or are found in the extracellular 
environment, or both. These pAgs then bind BTN3A.1 on its extracellular portion (e.g. via 
the IgV). It is then the combination of pAg + BTN3A.1 ‘carrier’ that is recognized by the 
Vγ9Vδ2 TCR. (B) Another hypothesis stipulates that pAgs are produced intracellularly and 
sourced from therein or imported from the extracellular space via unknown transporters, 
or both. Intracellular pAg then binds the BTN3A.1 B30.2 domain, inducing key 
modifications to the to the receptor protein, such as changes to the membrane topology, 
recruitment/exclusion of molecular patterns or conformational changes to the receptor. 
Possibly, extracellular pAg then further binds BTN3A.1 extracellularly. These changes are 
then recognized by the Vγ9Vδ2 TCR.  
5-Fig. 8.4. Alternate models of pAg sourcing for Vγ9Vδ2 cell activation via BTN3A.1. 
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Experimental clarification is necessary to establish whether BTN3A extracellular domains 
are engaged by the Vγ9Vδ2 TCR directly. Even if this is achieved, reconciliation of the 
various BTN3A-TCR engagement theories and the observation that cross-linking of all 
BTN3A isoforms with agonistic mAb (e.g. clone 20.1) mimics Vγ9Vδ2 cell pAg 
stimulation is necessary. It is possible that all proposed scenarios are true in particular 
settings and that significant mechanistic redundancy is in place for the activation of γδT 
cells by pAg. It is not inconceivable that γδT cells may be capable of sensing pAg-related 
cellular stress via receptors other than the TCR. As described in earlier sections, it is 
known that human Vδ2 cells express a range of non-TCR receptors that sense stressed or 
transformed self, e.g. NKG2D.  
An important aspect of placing a pivotal role on BTNs in Vγ9Vδ2 cell activation is the 
consequent apparent divergence of γδT cells from other innate-like human T cels. Like 
invariant NKT (iNKT) cells or MAIT cells, human γδT cells appear to originate 
preferentially prior to birth and express semi-invariant TCRs: Vγ9Vδ2 for γδT cells, 
Vα24-Jα14-Vβ11 for iNKT cells and Vα7.2-Jα22-oligoclonal Vβ for MAIT cells (166). 
iNKT and MAIT cells do, however, both recognize antigen presented on MHC class I-like 
molecules, CD1d and  MR1, respectively. Thus, unlike nearly all other T cell types, 
including innate-like αβT cells, Vγ9Vδ2 cell activation appears indepdendent of MHC 
class-like molecules. As outlined earlier, γδT cells do not appear to share the αβT cell 
dependence on the presence of professional antigen presentation or specific antigen 
presenting molecules. And when and if a dependence on a cell surface molecule for 





1.9. γδT cells as a tool in immunotherapy 
As outlined above, elevated counts of activated, functional γδT cells correlate with 
improved health outcomes in human infection and malignancy, both solid and non-solid 
in nature. The physiological rationale for the apparently beneficial presence of γδT cells 
may derive from their production of inflammatory cytokines, direct target lysis, 
recruitment and activation of innate immune components, maintenance of epithelial 
barrier integrity and tissue healing, regulation of B cell immunity and even priming and 
modulation of the αβT cell response.  
Such an expansive array of effector phenotypes for any one cell type carries complications 
in its use and manipulation in the clinic. It remains unclear whether these functions can be 
carried out by all human γδT cell subsets and are stimulation-dependent. Is it crucial we 
focus on Vδ1, Vδ2 or Vδ1-Vδ2- γδT cells? Does sourcing γδT cells from peripheral blood 
bear consequences on their putative eventual clinical effects at epithelial surfaces? Can 
the same γδT cells act as pAPCs and killers simultaneously? Questions such as these, 
among others, need to be resolved prior to the safe and effective introduction of γδT cells 
into the clinic. If, however, we are able to gain a firm grasp of understanding on this 
complex and potentially heterogeneous set of γδTCRpos cells, their clinical expediency 
would be significant. Perhaps the most useful property of γδT cells as an 
immunotherapeutic tool is the range of effector functions they may offer, uniting current 
clinical efforts with αβT cells, DCs and other myeloid cells under one cell type. A 
significant advantage of using γδT cells is their lymphoid capacity for rapid, extensive and 
sustained expansion in vivo and in vitro, in contrast to other pAPCs in immunotherapy 
development, such as DCs. We know, furthermore, that zoledronate – perhaps the most 
routinely used expansion stimulus for peripheral Vδ2 γδT cells – is safe to use in humans 
systemically. Zoledronic acid (zoledronate) is already used in the clinic as a treatment for 
osteoarthritis. It’s proposed mechanism of action involves the reduction of osteoclast 
activity (167).  
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1.10. Aims of the project 
The observations of in vivo γδT cell expansion upon clinical infectious disease, and the ex 
vivo work by Brandes, et.al. and our own laboratory on the pAPC function of human γδT 
cells prompted us to investigate how Gram-negative bacteria may impact the effector 
phenotype of this atypical T cell subset. I modeled the events that may occur during 
systemic infection by exposing whole, freshly-isolated PBMC to UV-irradiated E.coli. 
E.coli is a common cause of sepsis and bacteremia in humans, and resides as a commensal 
in the gastrointestinal mucosa highly populated by γδT cells. As mentioned above, E.coli 
further expresses known γδT cell targets such as HMBPP. 
I ventured to document freshly-isolated γδT cell effector responses to acute E.coli 
exposure and subsequent responses to re-exposure of expanded cells. I further set out to 
compare γδT cell effector phenotype in response to two radically different stimuli: i) 
E.coli, representing a target-rich, complex, highly pro-inflammatory non-self stimulus, 
and ii) zoledronic acid, a small molecule pyrophosphate accumulation-inducing 
bisphosphonate drug, representing a stressed self stimulus.   
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2. MATERIALS AND METHODS 
2.1. Study Design 
This study was designed to investigate how Gram-negative bacteria may impact 
development of γδT cell effector phenotype. The experimental setup was modeled to 
reflect events that may occur during systemic infection via stimulating whole, freshly-
isolated PBMC with UV-irradiated E.coli. γδT cell responses were recorded upon 
primary stimulation of fresh PBMC and subsequent re-stimulation of expanded cells. I 
further addressed which γδT cell effector functions are dependent on the γδT cell receptor 
and butyrophilin 3A. 
The sample number for most expansions and experiments was five different donors; 
donor number is listed for all data in the corresponding figure legend. All donors used 
were healthy adults, between the ages of 21 and 55 years old, representing a roughly 
equal mixture of male and female participants. I note that recent research by Pennington 
and colleagues (106) indicates that gender and age of peripheral Vδ2 cell donors are 
unlikely to exert significant effects on observed cell behaviour. The number of five 
donors was chosen from previous experience in the study of known phenotypic variations 
between donors, in order to accurately reflect these variations. All experiments were 
repeated at least once, with the exception of DNA sequencing. DNA sequencing was, 
however, done as a separate experiment and eachclonotype sequencing included in the 
analysis was represented by multiple individual reads. In addition, spectratyping was 
carried out on two donors, both of whom yielded similar results.  
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All experiments using peripheral blood-derived cells were performed in accordance with 
relevant guidelines and regulations, and were approved by UCL Research Ethics 
Committee. Informed consent was obtained from all volunteer blood donors.  
2.2. Statistical analysis 
Where relevant, acquired data was evaluated statistically with paired or unpaired t tests 
without assumed consistent standard deviation. Statistical significance was assessed 
through the Holm-Sidak method of correcting for multiple comparisons. The results 
referred to as “significant” further in the text entail a P value of 0.05 or lower. The 
statistical and graphic analysis software employed was Prism 6.0. All bar graps indicate 
the mean and respective error bars indicate standard deviation of the data sets. Individual 
significant P values are indicated in each figure as appropriate. The individual donor 
number used to generate the data in each figure is indicated in accompanying figure 
legends. All figures are indicative of at least two experiments.  
2.3. Sample acquisition and preparation 
 PBMCs from healthy adult donor peripheral blood were routinely extracted via Ficoll 
density gradient separation. Briefly, peripheral blood was obtained by venipuncture and 
collected in EDTA-treated containers to prevent coagulation. It was then layered onto 
Lymphoprep solution and centrifuged at 800g for 35min at room temperature, leading to 
a layer separation, according to constituent density. Plasma and red blood cell layers were 
discarded, while the PBMC buffy coat was processed by washing twice in phosphate-
buffered saline (PBS; Invitrogen) with centrifugation at 800g for 10min. The PBMCs were 
then counted, suspended in complete RPMI 1640 at the desired concentration, and either 
stained immediately or cultured overnight for subsequent investigation. 
Cells were cultured in supplemented RPMI 1640 medium at a density of 1.5x106 cells/mL 
at 37oC and 5% CO2. Supplemented culture medium contained RPMI 1640-GlutaMax 
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(Life Technologies), 10% foetal calf serum, 1% Penicillin/Streptomycin (Life 
Technologies), 10mM HEPES buffer (Life Technologies), 1mM Sodium Pyruvate (Life 
Technologies) and 1x MEM non-essential amino acids (Life Technologies) (Table 2.1). 
All stimulation studies, unless explicitly specified, further included 100 IU/mL 
recombinant human IL-2 (MACS Miltenyi); medium was supplemented every two to three 
days. 
  
6-Table 4  |  Recipe for complete γδT cell culture media 
Table 2.1  |  Recipe for complete γδT cell culture medium  
Reagent Concentration 
RPMI 1640 GlutaMax  1x 
Foetal Calf Serum 10% 
Penicillin / Streptomycin 100IU/mL 
HEPES buffer 10mM 
Sodium Pyruvate 1mM 
MEM Non-Essential Amino Acids 1x 
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2.4. Growth and preparation of E.coli DH5α 
E.coli (Thermo Fisher) were grown overnight at 37oC shaking culture in 1mL ampicillin 
(Life Technologies)-supplemented LB medium (Sigma) from cryogenically preserved 
aliquots. Once grown, E.coli culture was washed thoroughly and assessed for colony 
forming unit (CFU) count via duplicate measurement of suspension optical density (OD), 
which typically equalled OD ~0.5 after overnight growth. With the exception of killing 
assays, all bacteria employed in co-culture experiments were irradiated in a trans-
illuminator chamber (UVITEC), equipped with eight UV-C (250-280nm) lamps, for a 
period of at least 7min. Irradiation times were decided based on the minial irradiation 
period necessary to prevent growth of irradiated E.coli in subsequent overnight liquid 
culture. With the exception of E.coli-pHrodo acidification assays, all assays employed 
freshly-grown E.coli DH5α. 
2.5. E.coli opsonisation  
E.coli were opsonized with commercially available highly purified anti-E.coli rabbit 
serum IgG (Escherichia coli BioParticles Opsonizing Reagent from Thermo Fisher) 
according to commercial protocol. Briefly, irradiated E.coli were re-suspended in PBS to 
OD ~0.5, mixed with the recommended saturating dose of purified anti-E.coli rabbit serum 
IgG and incubated for 30min at room temperature. E.coli were then washed twice in 30mL 
of sterile PBS.  
2.6. PBMC stimulation with UV-irradiated E.coli 
Freshly isolated or expanded 1.5x106 cells/mL PBMC were co-cultured with E.coli (MOI 
10) in supplemented RPMI 1640 medium, and cultured overnight (16-18h) or left to 
expand for 14 days. Re-stimulation of expanded PBMC with E.coli was carried out by 
mixing 14-day E.coli-expanded PBMC with irradiated E.coli at MOI 10. Re-stimulation 
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of expanded PBMC with E.coli in the presence of freshly-isolated autologous PBMC was 
carried out by mixing fluorescence-assicted cell sorting (FACS)-stained 14 day E.coli-
expanded PBMC with freshly-isolated unstained autologous PBMC at a ratio of 1:10 prior 
to the addition of irradiated E.coli at MOI 10. 
2.7. PBMC stimulation with zoledronate 
Freshly isolated 1.5x106 cells/mL PBMC were cultured in 5μM zoledronic acid 
monohydrate (zoledronate; Sigma-Aldrich) in supplemented RPMI 1640 medium, and 
cultured for 14 days. Re-stimulation of expanded PBMC with E.coli was carried out by 
mixing 14 day E.coli-expanded PBMC with irradiated E.coli at MOI 10. 
2.8. FACS staining and processing 
PBMC were stained for cell viability, surface markers, intracellular cytokines and cell 
surface CD107a throughout stimulation and expansion as indicated in supplied 
commercial protocols. Intracellular cytokine and CD107a staining was carried out on 
overnight stimulated PBMC that were cultured for a further 4h in the presence of monensin 
(BioLegend). Colour compensation was carried out using OneComp eBeads 
(eBioscience). FACS analysis was performed on the Becton Dickinson (BD) LSR II and 
data processing - on FlowJo vX.07 software.  
The following antibody conjugates were used in PBMC staining: CD3-PE/Dazzle594 
(BioLegend; clone: UCHT1), αβTCR-PE (BioLegend; clone: IP26), αβTCR-PE/Vio770 
(MACS Miltenyi; clone: BW242/412), γδTCR-PE/Vio770 (MACS Miltenyi; clone: 
11F2), Vδ1-FITC (Thermo Fisher; clone: TS8.2), Vδ1-APC (MACS Miltenyi; clone: 
REA173), Vδ2-PerCP (Biolegend; clone: B6), Vδ2-PE (Biolegend; clone: B6), IFN-γ-PE 
(BioLegend; clone: B27), TNF-α-APC (BioLegend; clone: MAb11), IL-17-Brilliant 
Violet 605 (BioLegend; clone: BL168), CD69-PerCP (BioLegend; clone: FN50), IL-10-
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FITC (Affymetrix eBiosciences; clone: BT-10), granulysin-PE (BioLegend; clone DH2), 
CD107a-FITC (BioLegend; clone: H4A3), CCR7-PE (R&D Systems; clone: 150503), 
CD62L-Brilliant Violet 605 (Biolegend; DREG-56), CD4-FITC (Miltenyi Biotec; clone: 
M-T466), CD8-APC (Miltenyi Biotec; clone: BW135/80), CD56-PE (Biolegend; clone: 
MEM-188), CD14-FITC (Miltenyi Biotec; clone: TÜK4), CD16-Brilliant Violet 605 
(Biolegend; clone: 3G8), CD19-PE/Cy7 (Biolegend; clone: HIB19), CD33-APC 
(Biolegend; WM53), CD1c-PerCP/Cy5.5 (Biolegend; clone: L161), CD27-APC/Vio770 
(Miltenyi Biotec; clone: M-T271), CD45RA-FITC (BioLegend; clone: HI100), HLA-DR 
(MHC II)-APC/Cy7 (BioLegend; clone: L243), CD86-APC (MACS Miltenyi; clone: 
FM95), CD277-PE (clone: BT3.1; Biolegend), Vγ9–APC/Vio770 (clone: REA470; 
MACS Miltenyi). Mouse IgG1κ of known, irrelevant, non-human specificity served as 
isotype control (BioLegend; clone: MG1-45). All FACS data presented subsequently is 
on singlet, live lymphocytes. All further references to ‘MFI’ denote median fluorescence 
intensity. The gating strategy employed in analysis is shown below in Fig.2.1. The use of 








 cells is 
justified and examined in Fig.2.2. No significant difference in γδT cell content was found 




 cells were used to identify γδT cells due to the much 
brighter expression of αβTCR versus γδTCR, thus permitting clearer delineation of the 














 cells, respectively. 
6-Fig. 3.1. Gating strategy. 
 
Fig. 2.2. Gating on γδT cells according to γδTCR versus αβTCR. Two methods of gating on γδT 
cells within whole, live PBMC, were compared. Two donor data is shown on freshly-isolated 
PBMC; one donor is representative of relatively high resting γδT cell content (~10% of total 
PBMC), and the other – of relatively low resting γδT cell content (~0.5% of total PBMC). The 
same anti-CD3 fluorochrome-antibody conjugate  is used for both stains. Both anti-γδTCR and 
anti-αβTCR fluorochrome-antibody conjugates were purchased from the same vendor and are 




 cells; (B) γδT 








 cell expression of Vδ1 
and Vδ2.  
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2.9. Confocal imaging of γδT cell uptake of E.coli 
Acknowledgement: This preliminary work was carried out by Dr. Anne Marijn Kramer, 
another PhD student in the laboratory, in collaboration with Dr. Dale Moulding of GOS 
ICH Imaging Facility. It is included in the present thesis, with her consent, to illustrate the 
evolution of thought that produced the experimental narrative.  
Imaging was performed on a Zeiss AxioObserver LSM 710 confocal microscope. FACS-
purified 14 day zoledronate-expanded γδT cells were incubated with IgG-opsonized, 
IPTG-inducible green fluorescent (GFP)-expressing E.coli (Thermo Fisher) for 60min, 
placed on ice and fixed. Cells were then fluorescently labeled, deposited on cleaned 
coverslips and mounted on glass slides using ProLong Gold antifade mountant (Thermo 
Fisher) and cured in the dark at room temperature for 24 hours. Images of cell conjugates 
were acquired with a 63× Plan-Apochromat oil objective, numerical aperture 1.4. 
Acquisition was optimized for subsequent deconvolution with Huygens software, using 
appropriate voxel sizes according to the Huygens Nyquist calculator. 
2.10. Confocal imaging of γδT cell uptake of E.coli 
Acknowledgement: This preliminary work was carried out by Dr. Anne Marijn Kramer. It 
is included in the present thesis, with her consent, to illustrate the evolution of thought that 
produced the experimental narrative.  
Imaging was performed on an Image StreamMark II flow cytometer (Amnis). Prior to 
analysis, 14 day zoledronate-expanded γδT cells were incubated with protease-sensitive 
DQ-Green (Thermo Fisher), BSA-labelled opsonized or non-opsonized polystyrene beads 
0.5μm or 1.0μm in size (Polysciences) for 60min, fixed and stained for cell surface 
markers. The opsonin used was Rituximab, a monoclonal, chimeric human-mouse IgG 
(Hoffman La Roche). The mode of opsonisation was passive adsorption of a saturating 
concentration of antibody to the bead, according to commercial protocol as supplied by 
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Thermo Fisher. Post- acquisition data analysis was performed using IDEAS software 
(Amnis). ImageStream internalisation scores (IS) were generated by IDEAS software as 
described in commercially supplied protocol. Briefly, IS is defined as the ratio of 
fluorescence intensity inside the cell to the intensity of the entire cell. The inside versus 
outside of the cell is judged by application of an internal mask based on the brightfield 
image that covers the inside of the cell, the thickness of the cell membrane in pixels and 
the fluorescence channel of interest, while the external region is determined by dilating 
the internal mask by the membrane thickness and combining this with the object mask of 
the channel of interest.  
2.11. E.coli FITC uptake assay 
A FITC-Trypan blue quenching assay was employed to assess PBMC uptake of E.coli. 
Briefly, UV-irradiated E.coli DH5α were FITC labeled by a gentle shaking in a saturated 
FITC isomer I (Sigma)-PBS solution for 1h at 37oC, followed by washing prior to co- 
culture with fresh or expanded PBMC at MOI 10. PBMC were co-cultured in triplicate 
60min at 37oC in a 5% CO2 incubator. Cells were then fixed in cold fixation buffer 
(Biolegend) before quenching with 0.4% Trypan blue solution (Sigma-Aldrich) to remove 
extracellular FITC signal. After quenching, PBMC were washed three times in a large 
volume of PBS and analyzed using flow cytometry. Each sample of quenched PBMC-
E.coli mixture was treated in parallel to a non-quenched sample of the same origin to 
ensure that quenching had taken place. A quenched PBMC sample incubated with non-
FITCylated E.coli was used as a control for background FITC fluorescence. In order to 
determine the involvement of actin polymerization in E.coli uptake, PBMC were pre-
incubated in 0.2mM CyD (Sigma), vessel control, DMSO (Sigma), or normal medium.  
Trypan blue quenching as a method to study phagocytosis has been described previously 
by Busetto et al. (168). Figure 3.1. illustrates the effect that Trypan blue quenching exerts 
on green fluorescent dyes, such as FITC (ex/em at 495/519) or close homologue, 5(6)-
FAM-SE (ex/em at 494/519), which Busetto et al. employed in the development of this 
 63 
uptake assay. The principles that the assay is based upon, briefly, are that Trypan blue i) 
absorbs light emitted by green dyes and emits it at a far red frequency, and ii) does not 
penetrate into the interior of live cells. Fig.2.3A and B show a Trypan blue quenched 
polymorphonuclear cell (PMN)-green Candida albicans co-culture analyzed via confocal 
microscopy and flow cytometry, respectively.  
2.12. E.coli pHrodo acidification assay 
A commercial E.coli-pHrodo assay was employed to assess PBMC acidification of 
internalized bacteria according to supplied protocol (available from “pHrodoTM Red and 
Green BioParticles® Conjugates for Phagocytosis” by Thermo Fisher Scientific). Briefly, 
Fig. 2.3. Trypan blue (TB)-quenching as a method to study uptake of green fluorescent 
material. This figure is an adaptation from Busetto et al. (97)  who describe a quantifiable 
assay to study uptake of fluorescently-labeled target particles, which employs Trypan blue 
quenching and flow cytometry. Polymorphonuclear (PMN) cells were incubated with 5(6)-
FAM-SE-labeled Candida albicans, washed thoroughly, fixed, quenched with Trypan blue and 
analayzed via confocal microscopy or flow cytometry. 5(6)-FAM-SE is a FITC homologous 
fluorescent dye with an absorbance peak at 494nm and an excitation peak at 519nm. (A) PMN 
were examined via confocal microscopy, following Trypan blue quenching. Extracelular 
C.albicans particles can be seen in far red, while intracellular particles – in green. A magnified 
single PMN is shown, with both extracellularly adherent and internalized C.albicans. (B) The 
same sample was analyzed via flow cytometry. Gated on PMN, one can observe: i) negative, 
ii) Green single positive, iii) Far Red single positive or iv) double positive cells, corresponding 
to i) no C.albicans, ii) internalized C.albicans only, iii) extracellularly-adherent C.albicans only, 
or iv) PMN, which have both adhered and internalized C.albicans.  
7-Fig. 4.1. Trypan blue (TB)-quenching as a method to study uptake of green fluorescent material. 
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supplied PFA-fixed, pHrodo-dyed E.coli (strain: K-12; product code: P35366) was re- 
suspended via sonication in a pH neutral isotonic buffer, HBSS (Life Technologies), and 
co-cultured with PBMC in triplicate in a 96-well plate for 60min at 37oC and 5% CO2. 
The medium used in this assay was pre-warmed, pH neutral HBSS, sans IL-2. After co- 
culture, the sample was removed into cold commercial fixation buffer (Biolegend). After 
fixation, PBMC were washed thoroughly and FACS stained for cell surface markers. 
Fixed and stained PBMC were then analyzed using flow cytometry. pHrodo dyes do not 
fluoresce at basic or neutral pH, but fluoresce strongly in proportion to pH drop below pH 
of 7. E.coli-pHrodo alone served as control for background pHrodo fluorescence. In order 
to determine the involvement of actin polymerization in bacterial acidification, PBMC 
were pre-incubated in 0.2mM CyD, DMSO or normal medium. 
2.13. Meso Scale Discovery electrochemiluminescence assay 
The following work was carried out in collaboration with and guidance by Dr. James 
Bonner and Dr. Intan Yeop, of ICH GOS Infection, Immunity and Rheumatology section. 
Levels of various cytokines in the medium of freshly-isolated, overnight-stimulated 
PBMC were measured and analyzed using a multiplex assay, the Meso Scale Discovery 
electrochemiluminescence assay (MSD). MSD analysis is a highly reproducible and 
accurate analysis platform, described by some as a more precise and reliable multiplex 
cytokine measurement system compared to the Cytometric Bead Array (169). Freshly-
isolated PBMC were co-cultured overnight with irradiated E.coli (MOI 10) or zoledronate 
(5μM) and pelleted. Culture supernatant was removed and analyzed as described in 
commercial protocol. Samples were analyzed in duplicate using two MSD® Multi-Spot 
Assay System kits: i) V-PlexTM Cytokine Panel 1 (human) kit, which included the 
cytokines GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, 
VEGF, and ii) V-PlexTM Proinflammatory Panel 1 (human) kit, which included the 
cytokines / inflammatory mediators IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, 
IL-13 and TNF-α. 
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2.14. Sequencing of γδTCR CDR3 
The following work was carried out in collaboration with Dr. Yvonne Majani, of ICH 
GOS Developmental Biology and Cancer section. RNA was extracted from 1x106 freshly 
isolated, 14 day E.coli or zoledronate-expanded PBMC. cDNA synthesis and PCR 
amplification of the gamma and delta chain sequences was performed using a commercial 
kit (Irepertoire Illumina human gamma delta kit; Cat. No. HTDGI-01-P). Amplified, 
barcoded fragments were sequenced on an Illumina MiSEq to a depth of 250 paired ends. 
Analysis was performed using a commercial platform provided by Irepertoire®. 
2.15. Spectratyping of γδTCR CDR3 
The following work was carried out in collaboration with Dr. Stuart Adams, of GOSH 
Department of Bone Marrow Transplantation. Spectratyping was used to determine 
CDR3 lengths for functional V-gamma 9 and V-delta 2 genes. RNA was extracted from 
14 day E.coli-expanded or zoledronate-expanded PBMC. Following this, cDNA was 
synthesized using High Capacity RNA to cDNA (Thermo Fisher Scientific). With cDNA 
as the template, TCR V-delta 2 specific forward primer 
(TGAAAGGAGAAGCGATCGGT) or TCR V-gamma 9 specific forward primer 
(TGGAATGTGTGGTGTCTGGA), and a fluorescently labeled TCR C-delta 
(GACAAAACGGATGGTTTGG) or TCR C-gamma 
(GGGGAAACATCTGCATCAAG) reverse primer were used to amplify fragments of 
interest by PCR. Fragments were separated by size using capillary electrophoresis and 
analyzed by GeneMapper v3.7 software (Applied Biosystems). 
2.16. Confocal imaging of E.coli-expanded γδT cell morphology 
γδT cells were expanded from PBMC with E.coli for 14 days. Expanded PBMC were not 
purified, but were checked via FACS staining for 90+ % CD3pos cell content. PBMC were 
 66 
then stained with Vδ2-PE mAb (clone: B6), washed, re-suspended at 1x106 cells/mL in 
Live Cell Imaging Solution (Thermo Fisher Scientific) and plated in a 96-well glass-
bottom plate (Thermo Fisher Scientific). After live imaging, cells were stained with DAPI 
and Hoechst dyes to visualize the cell nucleus and outer cell membrane. Imaging was 
performed on a Zeiss AxioObserver LSM 710 confocal microscope. Images of live cells 
were acquired with a 63× Plan-Apochromat oil objective, numerical aperture 1.4. 
2.17. γδT cell sorting by flow cytometry 
Day 14 expanded PBMC, with a predominantly γδT cell content, were purified further 
using flow sorting on the LSR II to >98% purity. Prior to the sort, PBMC were stained for 
expression of CD3 with CD3-PE/Dazzle594 (BioLegend; clone: UCHT1) and αβTCR 
with αβTCR-PE/Vio770 (MACS Miltenyi; clone: BW242/412). γδT cells were sorted for 
as CD3posαβTCRneg PBMC, gated as shown in Fig.2.1 in the general Materials and 
Methods chapter (Chapter II). Bright fluorophores were used to maximize the clear 
separation of expanded αβT and γδT cells. Samples of purified γδT cells were stained 
post-sort for further γδT cell markers including Vδ2 and γδTCR to establish purity. γδT 
cells were sorted into 50% foetal calf serum and cultured overnight in complete RPMI 
1640 prior to use in functional assays. 
2.18. γδT cell antigen presentation assay 
γδT cells were purified from 14 day zoledronate-expanded PBMC using FACS sorting to 
>98% purity; >90% of zoledronate-expanded γδT cells express a Vδ2 TCR, as described 
earlier in Chapter III. To mitigate the stress and potential TCR internalization in response 
to purification, purified γδT cells were rested overnight in supplemented, antibiotic-free 
RPMI 1640 medium. Zoledronate-expanded PBMC were used instead of E.coli-expanded 
PBMC to avoid the possibility that E.coli or debris thereof may still be present in culture 
medium or even intracellularly, if taken up by PBMC. Overnight rested, purified γδT cells 
were then incubated overnight with irradiated, IgG-opsonized E.coli DH5α at MIO 10 to 
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allow time for phagocytosis, antigen processing and presentation at the cell surface.  γδT 
cells were then washed thoroughly. In parallel, αβT cells were purified via positive 
magnetic selection (Anti-αβTCR MicroBead selection kit, Miltenyi Biotec) from 
autologous, freshly-isolated PBMC and rested overnight. Purified, opsonized E.coli-
stimulated, expanded γδT cells were then co-cultured for 2 days with purified, autologous 
fresh αβT cells at αβT:γδT cell ratios of 5:1, 10:1 and 20:1. After 2 day co-culture, αβT 
cells were blocked with monensin, permeabilized and stained via FACS for intracellular 








2.19. Expanded γδT cell re-stimulation with E.coli in the presence of autologous 
‘helper’ cells 
Freshly-isolated or expanded 1.5x106 PBMC/mL were co-cultured with E.coli (MOI 10) 
or zoledronate (5μM) in supplemented RPMI 1640 medium, and left to expand for 14 
days. Re-stimulation of expanded PBMC with E.coli in the presence of freshly-isolated 
autologous PBMC was carried out by mixing FACS-stained 14 day E.coli-expanded 
PBMC with freshly-isolated, unstained autologous PBMC at a ratio of expanded PBMC : 
freshly-isolated PBMC of 1:10 prior to the addition of irradiated E.coli at MOI 10. The 
experimental setup is illustrated below in Figure 2.5. 
Fig. 2.4. Assay to assess expanded γδT cell antigen presentation to freshly-isolated, autologous 
αβT cells. γδT cells were expanded for 14 days from freshly-isolated PBMC using zoledronate 
(5μM). On day 14, γδT cells were purified from expanded PBMC using FACS. FACS purified γδT 
cells were then incubated overnight IgG-opsonized, irradiated E.coli at MOI 10 and washed 
thoroughly. In parallel, αβT cells were purified via positive magnetic selection from autologous, 
freshly-isolated PBMC and rested overnight. Purified, E.coli-stimulated, expanded γδT cells 
were then co-cultured for 2 days with purified, autologous fresh αβT cells. After 2 day co-
culture, αβT cells were blocked with monensin, permeabilized and stained via FACS for 
intracellular IFN-γ.  
8-Fig. 6.1. Assay to assess expanded γδT cell antigen presentation to freshly-isolated, autologous αβT cells. 
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2.20. γδT cell bactericidal activity against E.coli 
γδT cells were purified from 14 day E.coli or zoledronate-expanded PBMC using FACS 
sorting to >98% purity. To mitigate the stress and potential TCR internalization in 
response to purification, purified γδT cells were rested overnight in supplemented, 
antibiotic-free RPMI 1640 medium. 1.5x106 cells/mL γδT cells were then co-cultured with 
live, non-irradiated E.coli DH5α at MOI 10 for 15, 30, 60 or 90 minutes. At designated 
time points, PBMC-bacterial suspension was removed in duplicate into sterile-filtered, 
room temperature distilled H20, allowed to hypotonically lyse for 10 minutes (to account 
for possible uptake of bacteria by γδT cells) and then serially diluted in H20 to 10-6 of the 
original concentration. The dilution series was plated in duplicate onto LB agar plates and 
grown overnight. The number of colony forming units (CFU) was as a measure of 
bactericidal activity.  
Fig. 2.5. Assay to assess expanded γδT cell responses to E.coli in the presence of 
autologous, freshly-isolated PBMC. γδT cells were expanded for 14 days from freshly-
isolated PBMC using zoledronate (5μM) or E.coli (at MOI 10). On day 14, expanded PBMC 
were FACS-stained for γδT cell surface markers. In parallel, PBMC were isolated from 
autologous donors. Freshly-isolated, unstained PBMC were then mixed with stained, 
autologous 14 day-expanded PBMC (1 expanded cell per 10 freshly-isolated cells), prior 
to the addition of irradiated, IgG-opsonized E.coli at MOI 10. After overnight co-culture, 
PBMC were blocked with monensin, permeabilized and stained via FACS for CD107a, 
CD69, as well as intracellular IFN-γ and TNF- α.  
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2.21. γδT cell bead phagocytosis assay 
A green fluorescent bead-Trypan Blue quenching assay was employed to assess PBMC 
uptake of opsonized beads. Briefly, streptavidinylated (SA) ‘Dragon Green’ beads (Bangs 
Laboratories) were incubated with anti-SA rabbit mAb (GeneScript), washed and co-
cultured in triplicate with PBMC for 60min at 37oC in a 5% CO2 incubator. Cells were 
then fixed in cold fixation buffer (Biolegend) before quenching with 0.4% Trypan Blue 
solution (Sigma-Aldrich) to reduce extracellular Dragon Green signal. After quenching, 
PBMC were washed three times in a large volume of PBS and analyzed using flow 
cytometry. Each sample of quenched PBMC-bead mixture was treated in parallel to a non-
quenched sample of the same origin to ensure that quenching had taken place.  
2.22. γδTCR blocking 
PBMC were co-incubated for 2h with 10μg/mL LEAF-purified anti-γδTCR mouse IgG1κ 
mAb (Biolegend; clone: B1), the blocking properties of which have been described by 
Correia, et al.(170) or isotype-matched LEAF purified mouse IgG1κ mAb of known 
nonhuman specificity (BioLegend; clone: MG1-45). PBMC were than washed in PBS and 
utilized in the functional assay of interest.  
2.23. BTN3A staining and blocking 
BTN3A.1 (CD277) was stained for analysis via flow cytometry with CD277-PE 
(Biolegend; clone: BT3.1). BTN3A functionality was blocked using anti-BTN3A mAb 
(clone: 103.2), which was kindly supplied by Dr. Daniel Olive (Marseille, France). To 
achieve blocking, PBMC stimulator cells were co-incubated for 2h with 1.5μg/mL anti-
BTN3A mouse IgG2a mAb or LEAF purified mouse mAb of known nonhuman specificity 
(BioLegend; clone: MG1-45). PBMC were than washed in PBS and utilized in the 
functional assay of interest.  
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2.24. PBMC responder stimulation with autologous cells in the presence of 
BTN3A and γδTCR blocking 
Freshly-isolated PBMC were depleted of γδT cells using a positive magnetic selection kit 
for γδTCR (MACS Miltenyi). Labeled PBMC were run through two magnetic columns in 
sequence to ensure total γδT cell removal from PBMC. PBMC were then stimulated 
overnight in complete RPMI 1640 medium with one of the following stimuli: irradiated 
E.coli at MOI 10, HMBPP at 10μM (highly purified (E)-1-Hydroxy-2-methyl-2-butenyl 
4-pyrophosphate lithium salt, dissolved for storage in ddH20; Sigma), IPP at 10μM (highly 
purified isopentenyl pyrophosphate lithium salt, dissolved for storage in ddH20; Sigma), 
zoledronate at 5μM (zoledronic acid; Sigma) or mock stimulated with medium only. After 
overnight stimulation PBMC were washed thoroughly in a large volume of PBS and 
blocked with either anti-BTN3A mAb (clone: 103.2) or isotype-matched control (clone: 
MG1-45). These PBMC served as BTN3A blocked or non-blocked stimulator cells. 
Stimulator cells were then pre-incubated with autologous, non-depleted PBMC responder 
cells. Responder cells were either pre-blocked for 2h with anti-γδTCR mAb (clone: B1) 
or isotype-matched control (clone: MG1-45). Responder cells and stimulator cells were 
then co-cultured at a ratio of 2:1. Responder γδT cell intracellular IFN-γ and cell surface 
CD107a were measured via FACS after overnight co-culture. The experimental setup is 
illustrated in figure 2.6.  
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Fig. 2.6. Assay to assess γδT cell effector responses in the presence of autologous stimulator 
cell pre-incubation with anti-BTN3A mAb and responder cell pre-incubation with anti-γδTCR 
mAb. Freshly-isolated PBMC were split into “stimulator” and “responder” cells. Stimulator 
PBMC were depleted of γδT cells using a magnetic positive γδT cell selection kit. Stimulator 
cells were then co-cultured overnight with E.coli, HMBPP, IPP, zoledronate or mock-
stimulated with media only, washed thoroughly and cultured for 2h with anti-BTN3A mAb 
or isotype-matched control. Responder cells were rested overnight during stimulator cell 
preparation, and then cultured for 2h with anti-γδTCR mAb or isotype-matched control. 
Stimulator and responder cells were then co-cultured at a ratio of 1 stimulator per 2 
responders. Responder γδT cell intracellular IFN-γ and cell surface CD107a were measured 
via FACS after overnight co-culture.  
9-Fig. 8.5. Assay to assess γδT cell effector responses in the presence of autologous stimulator cell pre-incubation 
with anti-BTN3A mAb and responder cell pre-incubation with anti-γδTCR mAb. 
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2.25. PBMC responder stimulation with THP-1 cells in the presence of BTN3A 
and γδTCR blocking 
THP-1 cells were stimulated overnight in complete RPMI 1640 medium with one of the 
following stimuli: irradiated E.coli at MOI 10, HMBPP at 10μM (highly purified (E)-1-
Hydroxy-2-methyl-2-butenyl 4-pyrophosphate lithium salt, dissolved for storage in 
ddH20; Sigma), IPP at 10μM (highly purified isopentenyl pyrophosphate lithium salt, 
dissolved for storage in ddH20; Sigma), zoledronate at 5μM (zoledronic acid; Sigma) or 
mock stimulated with medium only. After overnight stimulation THP-1 cells were washed 
thoroughly in a large volume of PBS and blocked with either anti-BTN3A mAb (clone: 
103.2) or isotype control (clone: MG1-45). These THP-1 cells served as BTN3A blocked 
or non-blocked “stimulator” cells. Freshly-isolated PBMC served as “responder” cells. 
Responder cells were either pre-blocked anti-γδTCR mAb (clone: B1) or isotype-matched 
control (clone: MG1-45). Stimulator THP-1 cells were incubated with freshly-isolated 
responder PBMC at a ratio of 1:2. Responder γδT cell intracellular IFN-γ and cell surface 
CD107a were measured via FACS after overnight co-culture. The experimental setup is 




Fig. 2.7. Assay to assess γδT cell effector responses in the presence of THP-1 stimulator 
cell pre-incubation with anti-BTN3A mAb and responder cell pre-incubation with anti-
γδTCR mAb. THP-1 stimulator cells were co-cultured overnight with E.coli, HMBPP, IPP, 
zoledronate or mock-stimulated with media only, washed thoroughly and cultured for 2h 
with anti-BTN3A mAb or isotype-matched control. Freshly-isolated PBMC responder cells 
cultured for 2h with anti-γδTCR mAb or isotype-matched control. Stimulator and 
responder cells were then co-cultured at a ratio of 1 stimulator per 2 responders. 
Responder γδT cell intracellular IFN-γ and cell surface CD107a were measured via FACS 
after overnight co-culture.  
10-Fig. 8.6. Assay to assess γδT cell effector responses in the presence of THP-1  stimulator cell pre-
incubation with anti-BTN3A mAb and responder cell pre-incubation with anti-γδTCR mAb. 
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3. γδT CELL ACQUISITION OF PHAGOCYTIC CAPACITY  
3.1. Aims 
My intent in this chapter was to examine whether γδT cells are capable of target uptake in 
a fashion which bears relevance to their putative pAPC function. As described above, 
phagocytosis and receptor-mediated endocytosis can both contribute material to pAPC 
antigen processing and eventual presentation. Both processes are also dependent on actin 
polymerization. I shall not strive further in the text to determine the particular type of 
antigen uptake γδT cells may engage in, but rather to establish whether γδT cells are 
capable of target uptake in a pAPC function-permissive manner, and what cellular 
conditions are necessary for this to take place. 
I set out to determine i) whether human peripheral γδT cells are capable of phagocytosis, 
and ii) what the optimal conditions for this phagocytosis may be. The conditions examined 
included single versus repeated exposure to antigen, cells freshly-isolated from blood 
versus cells expanded in vitro and target opsonisation or non-opsonisation with antibody. 
Various aspects of phagocytosis, such as uptake and acidification of material, were 
examined.  
3.2. Zoledronate-expanded γδT cells take up IgG-opsonized 1.0μm beads and 
E.coli 
We have previously reported limited phagocytosis by freshly-isolated peripheral γδT cells. 
Specifically, Wu et al. were able to induce γδT cell uptake of IgG-opsonized 1.0μm beads, 
which was inhibitable by cell pre-incubation with anti-CD16 (FcγR) mAb and was 
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sensitive to Cytochalasin D (CyD), an inhibitor of actin polymerization (50). Herein, I 
examined the effect of cell expansion on γδT cell phagocytic capacity in greater detail. I 
highlight that the data visible in Fig.3.1 and Fig.3.2 was generated predominantly by 
another PhD student in the Gustafsson laboratory, Anne Marijn Kramer, who has given 
her consent to the inclusion of the relevant data into the present thesis. This data was not 
further utilized by her, and is included in the present thesis to illustrate the evolution of 








14 day zoledronate-expanded γδT cells were co-cultured with protease-activated DQ-
Green fluorescent, bovine serum albumin (BSA)-labeled polystyrene beads (0.5μm or 
1.0μm in size), with or without IgG opsonization. DQ-Green, BSA-labeled beads have 
been employed previously as an indicator of phagosome maturation and antigen 
processing in macrophages (171). Internalization of fluorescing, i.e. protease exposed, 
beads was quantified using an ImageStream internalization score (Fig.3.1A). Expanded 
γδT cell incubation with non-opsonized beads revealed significant uptake of 0.5μm, but 
not 1.0μm beads. Opsonization with Rituximab (monoclonal, chimeric human-mouse IgG 
against CD20) significantly enhanced 1.0μm bead uptake - to a level statistically 
indistinguishable from the uptake of beads 0.5μm in size (Fig.3.1B). Internalization scores 
indicated that ~9% of γδT cells associated with opsonized beads, of which ~86% showed 
internalization.  
  
Fig. 3.1. Zoledronate-expanded γδT cells take up IgG-opsonized 1.0μm beads. 14 day 
zoledronate (5μM)-expanded γδT cells (n=3) were incubated with IgG-opsonized or non-
opsonized protease-sensitive DQ BSA polystyrene beads, and analyzed for internalized 
material. γδT cell uptake of beads was assessed with an internalization score generated via 
ImageStream analysis. (A) Representative data is shown from one donor, with γδTCR in blue 
and beads in green. Bead fluorescence was an indicator of DQ BSA exposure to proteases.  (B) 
Zoledronate-expanded PBMC (n=3) were cultured for 60min with non-opsonized 0.5μm and 
1.0μm beads, as well as IgG (Rituximab; RTX)-opsonized 1.0μm beads. PBMC were then 
stained for ImageStream analysis; internalisation scores, as generated by ImageStream 
software, are shown for γδT cells. Bar graphs indicate the mean ± standard deviation. 
11-Fig. 4.3. Zoledronate-expanded γδT cells take up IgG-opsonized 1.0μm beads. 
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The observation that a significant portion of expanded γδT cells internalize opsonized 
beads into a protease-rich environment (as indicated by fluorescence of the DQ Green dye) 
prompted us to investigate γδT cell uptake of bacteria, such as E.coli. Confocal 
microscopy allowed detection of whole and partially-degraded E.coli in the interior of 
zoledronate-expanded γδT cells incubated with IgG-opsonized, GFP-expressing E.coli 
(Fig.3.2). As exemplified in Fig.3.2, virtually all γδT cells within the field of vision were 
associated with multiple adherent E.coli, whereupon only a minor fraction of the bacteria 
were found to be intracellular. 
 
 
Fig. 3.2. Zoledronate-expanded γδT cells take up IgG-opsonized E.coli. 14 day zoledronate 
(5μM)-expanded, FACS-purified γδT cells were stained with phalloidin (red), DAPI (blue), 
incubated with IgG opsonized, GFP-expressing E.coli, and analyzed via confocal microscopy. 
Representative data is shown of a single cell in 3D-rotation with or without phalloidin. 
Internalised E.coli is indicated with white arrows. 
12-Fig. 4.4. Zoledronate-expanded γδT cells take up IgG-opsonized E.coli. 
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3.3. E. coli-expanded, but not freshly-isolated γδT cells, take up IgG-
opsonized E.coli 
I next quantified the uptake of IgG opsonized versus non-opsonized E.coli by freshly 
isolated versus E.coli-expanded γδT cells. Freshly-isolated PBMC from healthy 
laboratory donors were co-cultured with UV-irradiated E.coli and left to expand for 14 
days. Expansion resulted in a marked increase in CD3pos cells (Fig.3.3A), with a 
preferential (>200-fold) expansion of γδT cells (Fig.3.3B, C). It was interesting to note 




Fig. 3.3. PBMC stimulation with E.coli induces preferential γδT cell expansion. Freshly-
isolated PBMC (n=5) were stimulated with irradiated E.coli at MOI 10 and left to expand in 
IL-2-supplemented media for 14 days. Rates of expansion were compared between γδT 
and αβT cells. (A) The proportion of CD3pos cells of total live PBMC was tracked. (B) Fold-
expansion of γδT and αβT cells, assessed by FACS and Trypan Blue exclusion, was 
compared. (C) PBMC were compared via FACS for γδT and αβT cell content of total live 
lymphocytes. Bar graphs indicate the mean ± standard deviation. 
13-Fig. 4.5. PBMC stimulation with E.coli induces preferential γδT cell expansion. 
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Vδ2 γδT cells displayed the highest rate of expansion (~250-fold), followed by Vδ1-Vδ2- 
cells (~40-fold) and Vδ1 γδT cells, which instead contracted (Fig.3.4A). Donor-matched, 
parallel expansions of PBMC in IL-2 medium with zoledronate or E.coli induced similar 
rates of expansion of subsets (Fig.3.4B). Of note, IL-2 medium alone failed to induce 
expansion of γδT or αβT cells. 
  
Fig. 3.4. PBMC stimulation with E.coli and zoledronate induces preferential Vδ2 γδT cell 
expansion. Freshly-isolated PBMC (n=5) were stimulated with irradiated E.coli at MOI 10 
or zoledronate (5μM) and left to expand in IL-2-supplemented media for 14 days. Rates of 




 γδT cell subsets. (A) Fold-
expansion over 14 day stimulation was compared between γδT cell subsets in E.coli-
expanded PBMC only, or (E) compared between E.coli and zoledronate-stimulated PBMC.  
14-Fig. 4.6. PBMC stimulation with E.coli and zoledronate induces preferential Vδ2 γδT cell expansion. 
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To measure phagocytosis, freshly-isolated or expanded PBMC were incubated with IgG-
opsonized or non-opsonized FITCylated-E.coli for 60min, and analysed via Trypan Blue 
quenching and flow cytometry (Fig.3.5). Freshly-isolated γδT and αβT cells failed to show 
notable bacterial uptake; in contrast ~25% and ~45% of freshly isolated CD3neg PBMC 
(predominantly monocytes) internalized non-opsonized and opsonized E.coli, 
respectively; both processes were found to be sensitive to CyD (Fig.3.6). More than 50% 
of E.coli expanded γδT cells took up opsonized E.coli in a CyD-sensitive manner. 
Interestingly, a subpopulation (mean 35%) of the residual αβT cells following E.coli 
expansion also took up opsonized E.coli, but this uptake was not significantly inhibited 




Fig. 3.5. γδT cell uptake of E.coli was investigated using a FITC-Trypan Blue quenching assay. 
PBMC were incubated for 60min with FITC-labeled E.coli, washed and quenched post-culture 
with Trypan Blue. PBMC were then stained for cell surface markers and analyzed via FACS. 
Shown are representative stains, gated on γδT cells: i) non-quenched co-culture indicating 
total FITC fluorescence (black, solid, unshaded), ii) quenched co-culture indicating 
intracellular FITC fluorescence (black, dotted, unshaded), iii) co- culture with non-FITCylated 
E.coli (gray, shaded).  
15-Fig. 4.7. γδT cell uptake of E.coli was investigated using a FITC-Trypan Blue quenching assay. 
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Fig. 3.6. E.coli-expanded, but not fresh, γδT cells take up IgG-opsonized E.coli. Freshly-
isolated or E.coli-expanded PBMC (n=5) PBMC were incubated for 60min with FITC-labeled 
E.coli at MOI 10, washed and quenched post-culture with Trypan Blue. PBMC were then 
stained for cell surface markers and analyzed via FACS. Remaining post-quench FITC 
fluorescence was interpreted as intracellular in origin. The proportion of FITC
pos
 PBMC was 
tallied, and compared between fresh and E.coli-expanded γδT and αβT cells, as well as fresh 
CD3
neg
 cells. Intracellular FITC fluorescence was evaluated in the presence of PBMC pre-
culture with normal media (control), Cytochalasin D at 0.2mM (CyD) or DMSO at 0.2mM 
(DMSO). E.coli were UV-irradiated prior to co-culture with PBMC and left non-opsonized 
(non-ops.) or opsonized with purified rabbit anti-E.coli IgG (ops.). Bar graphs indicate the 
mean ± standard deviation. 
 
16-Fig. 4.8. E.coli-expanded, but not fresh, γδT cells take up IgG-opsonized E.coli. 
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Phagocytosis promotes fusion of the phagosome with the lysosomal compartment. To 
determine whether E.coli uptake by E.coli-expanded γδT cells resulted in bacterial 
acidification (implying phagolysosome formation), freshly-isolated and 14 day expanded 
PBMC were co-cultured for 60min with IgG-opsonized pH-sensitive pHrodo-E.coli 
(Fig.3.7). E.coli-expanded γδT cells, but not αβT cells or freshly isolated γδT cells, 
showed notable acidification of E.coli, which increased further upon opsonization. As a 
positive control, freshly isolated CD3neg PBMC (largely monocytes) also acidified non-






It remains unclear as to why bacterial uptake but not acidification appeared CyD-sensitive. 
One possible explanation may be the difference in bacterial preparations employed, as 
fresh exponentially-grown E. coli were irradiated just prior to uptake studies whilst 
Fig. 3.7. γδT cell acidification of E.coli was investigated using a pHrodo-E.coli assay. PBMC 
were incubated for 60min with pH sensitive pHrodo-labeled E.coli and washed post-culture. 
PBMC were then stained for cell surface markers and analyzed via FACS. Shown are 
representative stains, gated on γδT cells, of: i) PBMC, gated on γδT cells, co-cultured with 
pHrodo-E.coli (black, solid, unshaded), ii) pHrodo-E.coli only control (gray, shaded).  
17-Fig. 4.9. γδT cell acidification of E.coli was investigated using a pHrodo-E.coli assay. 
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lyophilized, E.coli-pHrodo conjugates were utilized to examine acidification. 
Lyophilisation may lead to bacterial acquisition of a spherical rather than rod shape, with 
consequential changes to the involvement of the actin cytoskeleton in the uptake process 
(172,173). Nonetheless, this series of experiments provides evidence for the first time that, 
upon expansion, γδT cells can phagocytose and direct bacteria to an acid-rich 
environment.  
  
Fig. 3.8. E.coli-expanded, but not fresh, γδT cells acidify IgG-opsonized E.coli. Freshly-isolated 
or E.coli-expanded PBMC (n=5) PBMC were incubated for 60min with pHrodo-labeled E.coli 
and washed. PBMC were then stained for cell surface markers and analyzed via FACS. pHrodo 
positivity was interpreted as labeled E.coli exposure to acidic pH. The proportion of pHrodo
pos
 
PBMC was tallied, and compared between fresh and E.coli-expanded γδT and αβT cells, as 
well as fresh CD3
neg
 cells. pHrodo fluorescence was evaluated in the presence of PBMC pre-
culture with normal media (control), Cytochalasin D at 0.2mM (CyD) or DMSO at 0.2mM 
(DMSO). pHrodo-E.coli were left non-opsonized (non-ops.) or opsonized with purified rabbit 
anti-E.coli IgG (ops.). Bar graphs indicate the mean ± standard deviation. 
 
18-Fig. 4.10. E.coli-expanded, but not fresh, γδT cells acidify IgG-opsonized E.coli. 
 85 
A similar degree of opsonized E.coli uptake and CyD-sensitivity by expanded γδT cells 
was seen regardless of whether PBMC were expanded with E.coli or zoledronate (Fig.3.9). 
The same was true for expanded γδT cell acidification of opsonized E.coli (Fig.3.10). 
Fig. 3.9. E.coli and zoledronate-expanded γδT cells take up IgG-opsonized E.coli with similar 
dynamics. 14 day E.coli or zoledronate-expanded PBMC (n=5) PBMC were incubated for 
60min with FITC-labeled E.coli at MOI 10, washed and quenched post-culture with Trypan 
Blue. PBMC were then stained for cell surface markers and analyzed via FACS. Remaining post-
quench FITC fluorescence was interpreted as intracellular in origin. The proportion of FITC
pos
 
PBMC was tallied, and compared between E.coli or zoledronate-expanded γδT cells. 
Intracellular FITC fluorescence was evaluated in the presence of PBMC pre-culture with 
normal media (control), Cytochalasin D at 0.2mM (CyD) or DMSO at 0.2mM (DMSO). E.coli 
were UV-irradiated prior to co-culture with PBMC and opsonized with purified rabbit anti-
E.coli IgG. Bar graphs indicate the mean ± standard deviation. 
 
20-Fig. 4.11. E.coli and zoledronate-expanded γδT cells take up IgG-opsonized E.coli with similar dynamics. 
Fig.3.10. E.coli and zoledronate-expanded γδT cells acidify IgG-opsonized E.coli with similar 
dynamics. 14 day E.coli or zoledronate-expanded PBMC (n=5) PBMC were incubated for 
60min with pHrodo-labeled E.coli and washed. PBMC were then stained for cell surface 
markers and analyzed via FACS. pHrodo positivity was interpreted as labeled E.coli exposure 
to acidic pH. The proportion of pHrodo
pos
 PBMC was tallied, and compared between E.coli or 
zoledronate-expanded γδT cells. pHrodo fluorescence was evaluated in the presence of PBMC 
pre-culture with normal media (control), Cytochalasin D at 0.2mM (CyD) or DMSO at 0.2mM 
(DMSO). E.coli were opsonized with purified rabbit anti-E.coli IgG. Bar graphs indicate the 
mean ± standard deviation. 
 
19-Fig.4.12. E.coli and zoledronate-expanded γδT cells acidify IgG-opsonized E.coli with similar dynamics. 
 86 
 Interestingly, the magnitude of bacterial acidification varied between expanded γδT cells 
and freshly-isolated CD3neg PBMC (Fig.3.11), suggesting cell-specific pathways may be 





Fig. 3.11. Expanded γδT cells acidify bacteria with different dynamics than CD3
neg  
fresh PBMC.  
Freshly-isolated or E.coli-expanded PBMC (n=5) were incubated with IgG-opsonized pHrodo-
E.coli for 60min, washed and stained for cell surface markers for subsequent analysis via 
FACS. Shown are representative stains of three donors, gated on E.coli-expanded γδT cells 
and freshly-isolated CD3
neg
 PBMC, of: i) PBMC, gated on either cell type, co-cultured with 
pHrodo-E.coli (black, solid, unshaded), ii) pHrodo-E.coli only control (gray, shaded). A 
compilation of donor pHrodo MFI is shown, comparing E.coli-expanded γδT cells and freshly-
isolated CD3
neg
 cells.  
21-Fig. 4.13. Expanded γδT cells acidify bacteria with different dynamics than CD3neg  fresh PBMC. 
 87 
3.4. Discussion 
In this chapter, I sought to address whether human peripheral γδT cells are capable of 
phagocytosis, to quantify this phenomenon and to establish what the conditions permissive 
of this phenotype may be. My findings included: 
i) Zoledronate-expanded γδT cells are capable of phagocytosing 1.0μm 
polystyrene beads, but only if the beads are opsonized with IgG, as indicated 
by ImageStream quantification.  
ii) Intracellular E.coli can be visualized using confocal microscopy after 60min 
zoledronate-expanded γδT cell co-culture with opsonized E.coli.  
iii) Freshly-isolated PBMC stimulation with E.coli and IL-2 leads to a preferential 
expansion of Vδ2 γδT cells, at rates similar to those achieved by PBMC 
stimulation with zoledronate and IL-2. 
iv) A novel application of a FITC-Trypan blue quenching FACS-based assay for 
the quantification of E.coli uptake by γδT cells. Some 50% of expanded, but 
not fresh, γδT cells can take up E.coli at the same rate as freshly-isolated 
CD3neg PBMC (mostly monocytes).  
a. This uptake is significantly enhanced if the E.coli is opsonized with IgG.  
b. The uptake of opsonized E.coli is sensitive to cytochalasin D (CyD), an 
inhibitor of actin polymerization. 
c. Expanded αβT cells appear capable of some uptake of opsonized E.coli, 
but this uptake is not CyD sensitive. 
v) A novel application of a pHrodo Green FACS-based assay for the study and 
quantification of E.coli acidification by γδT cells. Some 50% of expanded, but 
not fresh, γδT cells can acidify E.coli at the same rate as freshly-isolated 
CD3neg PBMC (mostly monocytes).  
a. This acidification is significantly enhanced if the E.coli opsonized with 
IgG.  
b. In γδT cells this acidification is, curiously, not significantly sensitive to 
CyD, an inhibitor of actin polymerisation, but is CyD-sensitive in freshly-
isolated CD3neg PBMC. 
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c. Expanded αβT cells appear capable of some uptake of opsonized E.coli, 
but it is not CyD sensitive. 
vi) E.coli and zoledronate-expanded γδT cells take up and acidify opsonized E.coli 
with similar efficiency.  
vii) γδT cell acidification of opsonized E.coli is different from acidification by 
freshly-isolated CD3neg PBMC. CD3neg PBMC appear to acidify opsonized 
E.coli with greater intensity to a lower pH, as indicated by higher fluorescence 
of the pH-sensitive pHrodo dye. 
 
As mentioned previously, work by our lab and others has reported limited phagocytosis 
by freshly-isolated peripheral γδT cells. Wu et al. were the first to publish an account of 
phagocytosis by peripheral human γδT cells (50). They were able to induce CyD-sensitive 
γδT cell uptake of IgG-opsonized 1μm beads in a process that was inhibitable by cell pre-
incubation with anti-CD16 (phagocytic FcγR) mAb. Their work further documented some 
uptake of opsonized E.coli. Himoudi et al. have since demonstrated that γδT cells are 
seemingly able to cross-present antigen from IgG-opsonized tumour cells (49), implying 
phagocytosis (or an alternative uptake process) of target material. While establishing that 
γδT cells are indeed capable of phagocytosis, these experiments crucially lacked 
quantification of the phenomena observed.  
Important questions such as I) “What proportion of γδT cells are capable of 
phagocytosis?”, II) “How does γδT cell phagocytosis of targets quantifiably differ from 
that carried out by established myeloid phagocyets?”, III) “Are particles uptaken by γδT 
cells shuttled into phagolysozomes for subsequent processing?”, IV) “Does the phagocytic 
capacity of freshly-isolated versus expanded γδT cells differ significantly?” and V) “Is 
γδT cell phagocytosis enhanced by previous encounter with specific antigen?” have not 
been addressed comprehensively in published research. Therein, I carried out the 
experiments described in this chapter.  
Preliminary ImageStream work by Anne Marijn Kramer quantified for the first time γδT 
cell uptake of material; she was able to perform statistical analysis on zoledronate-
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expanded γδT cell uptake of pH-sensitive IgG-opsonized beads. Some 7% of expanded 
γδT cells presented with intracellular, pH<7-exposed beads (Fig.3.1). While this presented 
an advance in the examination of γδT cell phagocytic capacity, it was carried out using a 
highly non-physiological target - plastic beads - and used a single phagocytosis stimulus, 
IgG, neglecting the potential necessity TCR, TLR and other PRR stimulation (or co-
stimulation) that may be necessary to stimulate γδT cell uptake of antigenic material. 
Using confocal microscopy, she was further able to document E.coli in the interior of 
zoledronate-expanded γδT cells. This was not quantified. The desire to quantify and 
explore in detail γδT cell phagocytosis of a physiologically relevant target, I set out to 
characterize and quantify γδT cell uptake of E.coli.  
My initial attempts to quantify γδT cell phagocytosis of E.coli were via gentamicin 
protection assays, considered the ‘gold standard’ in classic phagocytosis literature (174–
177). These assays are based on the principle that gentamicin, a potent bactericidal Gram 
negative antibiotic, does not penetrate the cell membrane of mammalian cells. Cells are 
incubated with live E.coli for a given time period, washed thoroughly, treated with 
gentamicin, washed once more and lysed with hypotonic pressure. The cell lysate is then 
plated and cultured on agar, providing optimal growth conditions for surviving E.coli. If 
any E.coli CFU are seen, one concludes that these E.coli must have been protected from 
the bactericidal effects of gentamicin by the mammalian cell membrane - therein implying 
intracellular location.  
My attempts at γδT cell gentamicin protection assays consisted of FACS-purified E.coli 
or zoledronate-expanded γδT cells co-cultured with E.coli at various MOIs (ranging from 
1-100). None of my attempts yielded viable E.coli CFU post gentamicin treatment. The 
obvious conclusion that γδT cells must, therefore, not engage in phagocytosis of E.coli, 
was overturned when I began examining the capacity of γδT cells to kill live E.coli in 
culture. Data on γδT cell killing of bacterial targets is further discussed in Chapter V. 
Briefly, expanded, FACS-purified γδT cells exhibited a surprisingly rapid and potent 
bactericidal phenotype: within less than an hour γδT cells reduced E.coli CFU by >90%. 
Given that a gentamicin protection assay involves hours-long incubation periods – during 
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which time γδT cells may have effectively killed present E.coli – I decided to pursue 
different phagocytosis quantification methodology. 
As outlined in the ‘Materials and Methods’ chapter, I employed a FITC-Trypan blue 
quenching assay, described by Busetto et al. (168). In addition to permitting quantification 
of phagocytosis, the use of a FACS-based assay further permitted staining for cell surface 
markers, which omitted the need for cell purification. I could, thus, examine E.coli uptake 
by various PBMC populations simultaneously and in parallel (Fig.3.6). The pH-sensitive 
pHrodo dye phagocytosis assay further indicated that, within the 60min of observed 
E.coli-FITC uptake, E.coli-pHrodo is also acidified (Fig.3.7). Using this as an indirect 
readout of phagolysosome formation allowed me to state with added confidence that the 
phenomenon I am observing is indeed phagocytosis.  
It was interesting to note the difference in the intensity of acidification between expanded 
γδT cells and freshly-isolated CD3neg PBMC (Fig.3.11). While this may allude to cell-
specific phagocytic and antigen processing mechanisms, it is important to address the 
possibility that - given the potent cytotoxicity that γδT cells displayed upon exposure to 
E.coli - it cannot be ruled out that E.coli-pHrodo may also be acidified by γδT cells 
extracellularly. The bactericidal mechanisms of γδT cells are poorly understood. It is 
conceivable that one route of killing involves γδT cell release of acidic lysosomal contents 
onto nearby bacteria, which may activate the pH-sensitive pHrodo dyes. Further work, 
involving visualizing techniques such as confocal microscopy, is necessary to determine 
whether pH-sensitive dyes are an adequate means of studying post-phagocytosis 
phagolysosomal formation in γδT cells. I stipulate that a likely scenario is that γδT cells 
acidify E.coli via cytotoxicity extracellularly and via phagolysosome formation 
intracellularly. Cytotoxicity data (Chapter V) indicated potent anti-E.coli CD107a-
mediated degranulation by freshly-isolated γδT cells, which nonetheless failed to show 
acidification of E.coli-pHrodo. This observation lends strength to the idea that expanded 
γδT cells take up and subsequently acidify opsonized E.coli intracellularly. It is 
nonetheless important to clarify this question prior to drawing meaningful conclusions 
from data concerning γδT cell acidification intensity of internalized bacterial targets.  
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Tt is also important to further examine the CyD-insensitivity of γδT cell acidification of 
E.coli. A potential cause of this may be the different preparations of E.coli used. One way 
to address this would be to label freshly-grown E.coli with FITC and a pHrodo dye in 
parallel, ensuring that both types of labeled E.coli have undergone the same treatment. 
Thus, the two preparations could also have more closely controlled MOIs, omitting the 
reliance on commercially-available E.coli-pHrodo protocols that do not specify bacterial 
cell number. It is possible that the difference in CyD sensitivity between uptake of E.coli-
FITC and acidification of E.coli-pHrodo was caused by differences in phagocyte-to-target 
ratio.   
The necessity for IgG opsonisation of targets for γδT cells has been reported previously 
(178). What was surprising and a novel finding herein was the stark difference I found 
between the phagocytic capacity of expanded versus freshly-isolated γδT cells, whereupon 
expanded γδT cells phagocytosed E.coli at a rate statistically similar to that observed in 
freshly-isolated CD3neg PBMC (largely monocytes and B cells). The marked difference in 
phagocytic capacity between freshly-isolated and E.coli-expanded γδT cells implies a 
significant phenotypic shift of γδT cells after initial exposure to E.coli. This prompted us 
to examine whether the acquired extensive phagocytic capacity for E.coli may be antigen 
specific. I enquired whether expansion with a particular antigen followed by a re-challenge 
by that same antigen (E.coli in this case) was responsible for the vast difference in 
phagocytic γδT cells that I observed.  
I quantified the phagocytic capacity for opsonized E.coli of zoledronate-expanded γδT 
cells, and compare it to that of E.coli-expanded γδT cells. To my surprise, no significant 
difference between the two expansion conditions could be found in either uptake of E.coli-
FITC (Fig.3.9) or acidification of E.coli-pHrodo (Fig.3.10). The importance of this finding 
lies in the different mechanisms that have been proposed by which E.coli and zoledronate 
induce γδT cell proliferation. As outlined in the thesis introduction, both stimuli are known 
to activate Vδ2 γδT cells. General consensus argues, however, that E.coli activates Vδ2 
cells via HMBPP, Lipid A and other bacterial antigens via stimulation of the TCR and 
various PRRs (93,179). Zoledronate, meanwhile, is a small molecule 
aminobisphosphonate drug, which does not contain any conceivable targets for γδT cell 
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antigen receptors. Instead, zoledronate is thought to disrupt the mevalonate pathway 
during cholesterol synthesis, and lead to the accumulation of toxic intermediates, such as 
isoprenyl pyrophosphate (IPP). IPP accumulation then leads to cellular stress and 
consequent conformational changes in cell surface butyrophilin 3A (BTN3A) molecules 
(180). IPP itself and its effect on BTN3A conformation have both been proposed as 
mediators of γδTCR activation (100,181). E.coli and zoledronate, thus, represent two 
separate types of antigen: i) non-self and ii) ‘stressed’ self. The observation that these 
differential stimuli induced γδT cell populations with equivalent phagocytic capacity - 
which was nonetheless different from that of freshly-isolated γδT cells - prompted us to 




Analysis of the data laid out in this chapter lead us to the conclusion that E.coli or 
zoledronate-expanded γδT cells are capable of effective phagocytosis of IgG-opsonized 
targets, including E.coli, while freshly-isolated γδT cells are not.  
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4. E.COLI AND ZOLEDRONATE PROMOTE EXPANSION 
OF PHENOTYPICALLY EQUIVALENT γδT CELL 
POPULATIONS 
4.1. Aims 
Surprised to find that E.coli and zoledronate-expanded, but not fresh, γδT cells display 
equivalent efficiency in opsonized E.coli phagocytosis, I set out to compare the phenotype 
of these expanded γδT cells in greater detail. Particular emphasis was placed on antigen 
presenting cell (APC) phenotype expression and T cell receptor (TCR) repertoires. 
In the characterization of E.coli versus zoledronate-expanded Vδ2 cells, I placed a 
particular emphasis on their expression patterns of APC molecules, MHC class II (HLA-
DR, specifically) and co-stimulatory CD86, as well as homing receptors, chemokine 
receptor 7 (CCR7) and CD62L (also known as L-selectin). HLA-DR and CD86 expression 
has been documented on human γδT cells in various contexts, ranging from in vitro 
stimulation to in vivo infectious disease. Both endogenous pAgs and Gram-negative 
bacteria-stimulated γδT cells have been reported to upregulate expression of HLA-DR and 
CD86 (75,106). The dynamics, time scale and stability of this upregulation has, however, 
not been reported in detail.   
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4.2. E.coli and zoledronate stimulation induces sustained γδT cell 
upregulation of HLA-DR and CD86 
In the previous chapter I outlined phagocytosis by zoledronate and E.coli-expanded 
peripheral γδT cells. Consequently, I hypothesized that opsonization-mediated 
phagocytosis is associated with acquisition of APC capabilities by γδT cells. To test this, 
expression of classic APC markers, HLA-DR and CD86, was investigated. E.coli 
mediated a steady increase in both markers, with a majority of expanding γδT cells 
developing an HLA-DRposCD86pos phenotype within days of stimulation (Fig.4.1A and 
B). HLA-DR and CD86 expression on expanded γδT cells was similar to that observed on 
freshly-isolated monocytes (CD3negCD14pos PBMC). αβT cells remained negative for both 
markers throughout expansion (Fig.4.1B).  
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Fig. 4.1. PBMC stimulation with E.coli leads to γδT cell upregulation of cell surface HLA-DR 
and CD86. Freshly-isolated PBMC (n=5) were expanded for 14 days with irradiated E.coli at 
MOI 10, and FACS stained for cell surface HLA-DR and CD86 throughout expansion. (A) 
Representative stains of one donor γδT cells is shown, with specific antibody in black, 
unshaded, and isotype-matched control - in gray, shaded. (B) HLA-DR and CD86 of five 





 PBMC). Points of E.coli stimulation are indicated with black 
arrows. Bar graphs indicate the mean ± standard deviation. 
 
























22-Fig. 5.1. PBMC stimulation with E.coli leads to γδT cell upregulation of cell surface HLA-DR and CD86. 
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Data indicated, moreover, that PBMC stimulation with E.coli or zoledronate produced a 





Fig. 4.2. PBMC stimulation with zoledronate leads to similar levels of γδT cell upregulation of 
cell surface HLA-DR and CD86 as stimulation with E.coli. Freshly-isolated PBMC (n=5) were 
expanded for 14 days with irradiated E.coli, and stained for cell surface HLA-DR and CD86 
throughout expansion. (A) Representative stains of one donor γδT cells is shown, with specific 
antibody in black, unshaded, and isotype-matched control - in gray, shaded. (B) HLA-DR and 





 PBMC). Points of E.coli stimulation are indicated with black arrows. Bar graphs 
indicate the mean ± standard deviation. 
 23-Fig. 5.2. PBMC stimulation with zoledronate leads to similar levels of γδT cell upregulation of cell surface HLA-
DR and CD86 as stimulation with E.coli. 
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4.3. E.coli and zoledronate stimulation induces transient γδT cell upregulation 
of CCR7 and downregulation of CD62L 
In order to further explore the putative pAPC phenotype of expanded, but not fresh 
unstimulated γδT cells, I set out to document whether γδT cell expression of the lymphoid 
tissue homing markers, CCR7 and CD62L, mirror those of classic αβT cells or, rather - 
those of myeloid APCs, such as DC. Brandes, et al. have previously documented γδT cells 
as negative for CCR7 when freshly-isolated, followed by a rapid, potent and transient 
upregulation of CCR7 on short-term (overnight-36h) endogenous pyrophosphate-
stimulated, peripheral human γδT cells, which then returned to baseline negativity during 
short term culture; up to 100% of peripheral γδT cells in their culture displayed a CCR7pos 
phenotype 24h post-stimulation. They specify further that maximal γδT cell upregulation 
of CCR7 took place prior to the initiation of cell proliferation (182). PBMC stimulation 
with E.coli in my model produced a similar result (Fig.4.3).  
While Brandes and others interpreted CCR7 upregulation on freshly-isolated γδT cells as 
an indication of migration to lymph nodes as part of putative pAPC function, my data 
indicate that freshly-isolated γδT cells do not engage in en-masse phagocytosis of targets. 
This is supported by the findings of Wu et al., discussed in the previous chapter, who were 
able to find only a small minority of short term-activated γδT cells engaging in active 
phagocytosis (50). Moreover, as laid out in this chapter, freshly-isolated or short term-
activated γδT cells do not appear positive for the APC markers, HLA-DR and CD86. My 
data indicate that 50+ % of γδT cells, expanded with zoledronate or E.coli, engage in 
phagocytosis only upon expansion. Curiously, expanded, phagocytic γδT cells did not re-
upregulate CCR7 after exposure to E.coli (Fig.4.3). 
In order to establish whether γδT cell expression of CCR7 was similar to that on αβT cells 
during expansion with E.coli, CCR7 levels were compared between the two cell 
populations in parallel. During the transient upregulation by γδT cells, CCR7 levels were 
similar between the two T cell populations (Fig.4.4). Indeed, within 24h of PBMC 
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stimulation with E.coli, a vast majority of γδT cells expressed CCR7 at the same level as 
freshly-isolated αβT cells. However, while αβT cells – which did not expand after PBMC 
stimulation with E.coli – maintained their expression of CCR7, it was lost entirely on the 
rapidly-expanding Vδ2 cells, and was not rescued by E.coli re-stimulation. 
  
Fig. 4.3. PBMC stimulation with E.coli leads to a transient γδT cell upregulation of cell surface 
CCR7. Freshly-isolated PBMC (n=4) were expanded for 14 days with irradiated E.coli, re-
stimulated overnight with E.coli at D14, and stained for cell surface CCR7. Representative 
stains of one donor γδT cells is shown, with anti-CCR7 antibody in black, unshaded, and 
isotype-matched control - in gray, shaded. Points of E.coli stimulation are indicated with 
black arrows.  
24-Fig. 5.3. PBMC stimulation with E.coli leads to a transient γδT cell upregulation of cell surface CCR7. 
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Fig. 4.4. CCR7 expression dynamics after PBMC stimulation with E.coli vary between αβT and 
γδT cells. Freshly-isolated PBMC (n=4) were expanded for 14 days with irradiated E.coli, re-
stimulated overnight with E.coli at day 14, and stained for cell surface CCR7. CCR7 expression 
is shown in three representative donor (D1-D3) CD3
pos
 PBMC, and compared in αβT versus 
γδT cells over 14 days of expansion.  
25-Fig. 5.4. CCR7 expression dynamics after PBMC stimulation with E.coli vary between αβT and γδT cells. 
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I concurrently examined γδT cell expression of CD62L, which mediates αβT cell 
extravasation from blood into the lymphatic circulation – a step necessary for blood borne 
cell migration to sites of classic DC antigen presentation. Brandes et al. too examined γδT 
cell expression of this lymphoid migratory marker (182). Once again, my data relates 
closely to their findings. As discussed in their work, and unlike with CCR7, freshly-




Fig. 4.5. PBMC stimulation with E.coli leads to a transient γδT cell downregulation of cell 
surface CD62L. Freshly-isolated PBMC (n=4) were expanded for 14 days with irradiated 
E.coli, re-stimulated overnight with E.coli at D14, and stained for cell surface CD62L 
throughout. Representative stains of one donor γδT cells is shown, with anti-CD62L 
antibody in black, unshaded, and isotype-matched control - in gray, shaded. Points of E.coli 
stimulation are indicated with black arrows.  
26-Fig. 5.5. PBMC stimulation with E.coli leads to a transient γδT cell downregulation of cell surface CCR7. 
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PBMC stimulation with E.coli produced a transient downregulation of CD62L. Recovered 
CD62L expression was also decreased upon re-stimulation of E.coli-expanded γδT cells. 
In further contrast to CCR7, CD62L levels followed a similar pattern on both cell types, 





Fig. 4.6. PBMC stimulation with E.coli leads to a transient γδT cell upregulation of cell 
surface CCR7 and downregulation of CD62L. Freshly-isolated PBMC (n=4) were 
expanded for 14 days with irradiated E.coli, re-stimulated overnight with E.coli at D14, 
and stained for cell surface CCR7 and CD62L throughout. Donor CCR7 and CD62L 
expression MFI was compiled and compared between γδT and αβT cells throughout 
expansion and re-stimulation. Points of E.coli stimulation are indicated with black 
arrows. Bar graphs indicate the mean ± standard deviation. 
 
27-Fig. 5.6. PBMC stimulation with E.coli leads to a transient γδT cell upregulation of cell surface CCR7 and 
downregulation of CD62L. 
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As with other parameters examined, no significant difference in terms of CCR7 or CD62L 
expression could be seen between zoledronate and E.coli-expanded γδT cells (Fig.4.7).  
  
Fig. 4.7. PBMC stimulation with zoledronate leads to similar levels of CCR7 and CD62L 
on γδT cells and stimulation with E.coli. Freshly-isolated PBMC (n=4) were expanded 
for 14 days with irradiated E.coli, re-stimulated overnight with E.coli at D14, and 
stained for cell surface CCR7 and CD62L throughout. Donor CCR7 and CD62L 
expression MFI was compiled and compared between γδT and αβT cells throughout 
expansion and re-stimulation. Bar graphs indicate the mean ± standard deviation. 
 
28-Fig. 5.7. PBMC stimulation with zoledronate leads to similar levels of CCR7 and CD62L on γδT cells and 
stimulation with E.coli. 
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4.4. E.coli and zoledronate stimulation lead to expansion of similar 
populations of γδT cells, as well as αβT cells and CD3neg cells 
I further endeavored to examine the non-APC effector markers routinely used to 
distinguish different γδT cell populations. As mentioned in the general introduction, 
peripheral as well as epithelia-resident γδT cells display a largely CD4negCD8neg 
phenotype, with small single positive CD8pos subpopulations. A similar phenotype was 
observed upon investigation of both E.coli and zoledronate-expanded γδT cells (Fig. 4.8). 
 
  





 γδT cells. Day 14 E.coli and zoledronate-expanded PBMC (n=4) were examined 
for γδT cell surface marker expression via flow cytometry. Shown are representative 
stains from three donors, gated on total live γδT cells.  
29-Fig. 5.8. PBMC expansion with E.coli or zoledronate leads to proliferation of predominantly CD4-CD8- γδT 
cells. 
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Similarly, E.coli and zoledronate-expanded γδT cells exhibited equivalent positivity for 
the cytotoxic marker CD56 and low affinity phagocytic FcγR, CD16, both of which are 
further classic markers of NK cells and NKT cells (Fig.4.9). Expression of CD16 and 
CD56 on freshly-isolated peripheral γδT cells and Vδ2 cells, in particular, has been 
documented in the literature previously (183,184). In summary, my data indicate that 
freshly-isolated peripheral E.coli and zoledronate-sensitive Vδ2 cells transition from a 
non-phagocytic, largely CD4-CD8- HLA-DRneg CD86neg CCR7neg CD62Lpos CD16pos 
CD56pos phenotype to a phagocytic, largely CD4-CD8- HLA-DRpos CD86pos CCR7neg/pos 
CD62Lpos CD16pos CD56pos phenotype as they expand in response to stimulus.  
 
  





. Day 14 E.coli and zoledronate-expanded PBMC 
(n=4) were examined for γδT cell surface marker expression via flow cytometry. Shown 
are representative stains from three donors, gated on total live γδT cells.  
30-Fig. 5.9. PBMC expansion with E.coli or zoledronate leads to proliferation of γδT cells that are 
predominantly CD56pos and CD16pos. 
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The apparent homogeneity of E.coli and zoledronate-expanded γδT cells brought my 
attention to the phenotype of other cell types that may have been expanded or maintained 
with these expansion protocols. As discussed in the previous results chapter, while both 
conditions resulted in the preferential expansion of Vδ2 cells, αβT cells and a minor 
population of CD3neg cells persisted in culture throughout stimulation. αβT cells remaining 
in culture after two weeks of PBMC expansion with E.coli or zoledronate presented with 
similar proportions of single positive CD4pos, CD8pos or double negative CD4negCD8neg T 
cells – with each phenotype representing roughly a third of all αβT cells (Fig.4.10).  
  









 αβT cells. Day 14 E.coli and zoledronate-expanded PBMC (n=4) were 
examined for αβT cell content via flow cytometry. Shown are representative stains from 
three donors, gated on total live αβT cells.  
31-Fig. 5.10. PBMC stimulation with E.coli or zoledronate sustains CD4pos, CD8pos and CD4negCD8neg αβT 
cells. 
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A minor difference could be observed between E.coli and zoledronate-maintained αβT 
cells in terms of CD56 expression, whence E.coli-expanded αβT cells contained a ~5% 
CD56pos subpopulation, whereas zoledronate-expanded αβT cells did not (Fig.4.11). 
 
  
Fig. 4.11. PBMC stimulation with E.coli or zoledronate sustains CD16neg CD56neg αβT cells. Day 
14 E.coli and zoledronate-expanded PBMC (n=4) were examined for αβT cell content via flow 
cytometry. Shown are representative stains from three donors, gated on total live αβT cells.  
32-Fig. 5.11. PBMC stimulation with E.coli or zoledronate sustains sustains CD16neg CD56neg αβT cells. 
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Perhaps, most crucial to my examination of non-γδT cell populations maintained within 
E.coli or zoledronate-expanded PBMC was to determine whether expanded PBMC 
cultures contain bona fide myeloid, phagocytic APCs. Published data of γδT cell APC 
characteristics have been met with great scepticism from large swaths of the T cell field, 
informed by justified concern for the effects observed being cause by ‘contaminating’ 
classic myeloid APC, rather than γδT cells. Staining whole, expanded PBMC for CD33 – 
a general myeloid marker (185) – suggested that both E.coli and zoledronate-expanded 
PBMC contained 0.1-0.8% CD3neg CD33pos cells (Fig.4.12).  
 
  
Fig. 4.12. PBMC stimulation with E.coli or zoledronate does not expand myeloid cells. Day 
14 E.coli or zoledronate-expanded PBMC (n=4) were examined for CD3neg cell content via 
flow cytometry. Shown are representative stains from three donors, gated on total live 
PBMC.  
33-Fig. 5.12. PBMC stimulation with E.coli or zoledronate does not expand myeloid cells. 
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While such a low proportion of myeloid cells cannot be deemed a significant potential 
contaminant set against my observation that nearly 100% of expanding γδT cells express 
CD86 and HLA-DR, while ~50% display phagocytic activity, it was further found that the 
0.1-0.8% proportion of CD3neg CD33pos cells was not significantly different from that of 
CD3neg isotype controlpos cells. The minor CD33pos population observed is, thus, likely to 
represent non-specific binding of the antibody, rather than a real subset of CD3neg cells 
within expanded PBMC. Further staining revealed that these CD3neg cells are also negative 
for cell surface, CD14 and CD1c, excluding the possibility that expanded PBMC may 
contain B cells, monocytes or DCs, respectively, all of which possess well-documented 




Fig. 4.13. PBMC stimulation with E.coli or zoledronate does not expand B cells, dendritic 
cells or monocytes. Day 14 E.coli or zoledronate-expanded PBMC (n=4) were examined 
for CD3
neg
 cell content via flow cytometry. Shown are representative stains from three 
donors (A) of total live PBMC expression of CD3 versus CD19, or (B) of CD3
neg
 cell CD14 
versus CD16 or CD1c versus CD16 expression.  
34-Fig. 5.13. PBMC stimulation with E.coli or zoledronate does not expand B cells, dendritic cells or 
monocytes. 
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Notably, however, a significant portion of CD3neg PBMC presented with a CD16pos 
phenotype. Closer examination revealed that the vast majority of these CD16pos cells were 
also positive for CD56 (Fig.4.14). I, thus, stipulate that the minor CD3neg population that 
is sustained during γδT cell expansion with E.coli or zoledronate consists largely of natural 
killer (NK) cells.  
 
  
Fig. 4.14. PBMC stimulation with E.coli or zoledronate and IL-2 sustains NK cells. Day 14 
E.coli-expanded PBMC (n=4) were examined for non-γδT cell content via flow cytometry. 
Markers employed in the analysis were: CD3, CD16 and CD56. Shown are representative 
stains from three donors, gated on total live CD3
neg
 PBMC.  
35-Fig. 5.14. PBMC stimulation with E.coli or zoledronate and IL-2 sustains NK cells. 
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4.5. E.coli and zoledronate induce significantly different early cytokine 
environments within stimulated PBMC 
While both E.coli and zoledronate have been linked to pAg-mediated activation of γδT 
cells directly and indirectly, respectively, both stimuli nonetheless represent vastly 
different antigenic challenges to the PBMC compartment (64,103). As covered briefly in 
the general introduction, zoledronate is a small molecule bisphosphonate drug that that 
inhibits farnesyl pyrophosphate synthase of the eukaryotic cell mevalonate cholesterol 
synthesis pathway and, consequently, leads to the accumulation of endogenous 
pyrophosphate metabolic intermediates, such as isopentenyl pyrophosphate (IPP) (180). 
IPP is then thought to induce conformational changes in the MHC-like butyrophilin (BTN) 
molecules at the cell surface, signalling cell ‘stress’. T cell receptor (TCR)-engagement of 
BTN3A.1, specifically, is thought to play a central role in Vγ9Vδ2 T cell recognition of 
transformed or damaged cells (100). Phosphoantigens within E.coli, meanwhile, include 
some of the most potent documented Vγ9Vδ2 T cell stimuli, such as (E)-4-hydroxy-3-
methyl-but-2-enyl pyrophosphate (known as ‘HMBPP’), which is synthesized by some 
bacterial and parasitic species via isoprenoid biosynthesis (64). The potency of HMBPP 
in activating γδT cells, by some estimates, exceeds that of IPP by up to a 1000-fold. The 
structural differences between IPP and HMBPP are briefly addressed in Fig.1.2, while the 
various routes by which IPP and HMBPP may be activating γδT cells – in Fig.1.3. 
 In addition to HMBPP, E.coli expresses a plethora of further immunogenic signals that 
are thought to be recognized by γδT cells via a number of pathogen-sensing mechanisms, 
such as i) Lipid A, thought to engage the γδTCR directly (93), ii) LPS, which triggers γδT 
cell TLR-4 (93) or iii) a series of alkyl amines, including isobutylamine, which too activate 
γδT cells in a TCR-dependent manner (66,124). I note that, while γδT cell use and 
expression of TLRs has been studied and reviewed before (186,187), a comprehensive 
understanding of the role this receptor family plays in the physiology of various γδT cell 
subsets is lacking.  
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In addition to E.coli representing a significantly different stimulus from zoledronate to 
γδT cells directly, the introduction of a bisphosphonate drug versus a bolus of Gram-
negative bacteria induces starkly different responses in other non-γδT cell PBMCs. To 
assess the collective early PBMC response to E.coli, zoledronate or a non-specific T cell 
stimulus, such as IL-2, freshly-isolated PBMC were cultured overnight in IL-2 medium 
(100 IU/mL) with the addition of E.coli (MOI 10) or zoledronate (5μM), or medium only 
(mock). After overnight culture, supernatant was collected and analysed for cytokine 
content via the cytokine multiplex assay, meso scale discovery electrochemiluminescence 
(MSD) (Fig.4.15). An examination of the lymphocyte growth factors, IL-7 and IL-15, 
revealed that neither cytokine was produced by zoledronate or E.coli-stimulated PBMC. 
High levels of IL-2 among all conditions served as an internal technical control for MSD, 
as all cell culture medium in the experiment contained added IL-2 at a pre-specified, equal 
amount. Significant differences in the cytokine response could be observed in terms of 
IFN-γ, TNF-α and TNF-β – cytokines associated with a pro-inflammatory Th1-type 
response. It is, perhaps, unsurprising that PBMC stimulation with E.coli, rather than 
zoledronate, induced a potent Th1 response and production of cytokines linked to 
activated monocytes. Such responses by PBMC to Gram-negative bacteria have been 
documented previously (66,102,188–190). Although Th2-type cytokines (IL-4, IL-5 and 
IL-13) could not be detected at high levels, E.coli nonetheless elicited higher levels than 
zoledronate. Unlike PBMC stimulation with zoledronate, stimulation with E.coli induced 
high levels of pyrogens and systemic inflammatory cytokines, such as IL-6, IL-1α and IL-
1β, as well as IL-8 and GM-CSF. Interestingly, while the mean amount produced was 
higher in E.coli compared to zoledronate-stimulated PBMC, the same vast differences in 
statistical significance between the two stimuli couldn’t be observed when examining 
antigen presentation and priming-associated cytokines, such as IL-12p40, IL-12p70 and 
IL-16. The same was true for the anti-inflammatory, regulatory mediator, IL-10. Freshly-
isolated PBMC stimulation with IL-2 medium alone (mock) failed to induce a response in 




Figure 4.15 is continued on the next page.  
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36-Fig. 5.15. Fresh PBMC stimulation with E.coli or zoledronate leads to significantly different early 
cytokine environments. 
Fig. 4.15. Fresh PBMC stimulation with E.coli or zoledronate leads to significantly different 
early cytokine environments. Freshly-isolated PBMC (n=4) were stimulated overnight 
with irradiated E.coli, zoledronate (5μM) or mock-stimulated with IL-2 media alone. 
Supernatants were collected and analyzed using a meso scale discovery 
electrochemiluminescence assay (MSD). The x-axis on the graphs indicates the stimulus 
applied to each set of PBMC; the y-axis indicates the amount of cytokine detected in 
media (pg/mL). ‘>DR’ denotes that the cytokine amount was above the detection range 
of the MSD assay. Bar graphs indicate the mean ± standard deviation. 
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4.6. E.coli and zoledronate induce similar Vγ9Vδ2 TCR repertoires 
The observation that E.coli and zoledronate stimulation of freshly-isolated PBMC induces 
largely equivalent γδT cell populations in terms of APC marker, homing receptor, CD4 
and CD8, as well as CD16 and CD56 expression prompted us to examine the early 
cytokine environment within stimulated PBMC. Upon noting that the early cytokine 
environment is vastly different between zoledronate and E.coli-stimulated PBMC, I set 
out to characterise the T cell receptor (TCR) repertoire of the differentially expanded γδT 
cells. As described earlier, zoledronate and E.coli are antigenically vastly divergent stimuli 
– each representing one documented self TCR ligand (i.e. BTN3A) and multiple non-self 
TCR ligands (e.g. Lipid A, isobutylamine, HMBPP, etc.), respectively.  
Freshly-isolated PBMC were expanded with E.coli or zoledronate for 14 days, and the 
resulting TCR repertoire was examined, using an Irepertoire Illumina human gamma delta 
CDR3 sequencing platform. The TCR CDR3 regions of (a) freshly-isolated unexpanded, 
(b) E.coli-expanded and (c) zoledronate-expanded γδT cells from one representative donor 
were sequenced. E.coli and zoledronate-expanded γδT cells showed significant overlap of 
their Vγ and Vδ CDR3 sequences; both expansions resulted in a predominantly Vγ9Vδ2 




Fig. 4.16. E.coli and zoledronate induce proliferation of similar γδT cell clones. Freshly-
isolated PBMC were expanded with UV-irradiated E.coli or zoledronate for 14 days. The 
resulting γδT cell CDR3 repertoire was examined. Representative heat maps of one donor 
expanded γδT cell Vγ (VG), Vδ (VD) and Vj (VJ) chain reads are shown.  
37-Fig. 5.16. E.coli and zoledronate induce proliferation of similar γδT cell clones. 
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CDR3 homology and frequency in selected sequences that represented 5000 or more 
CDR3 reads were investigated (Fig.4.17). The most prominent group in Vγ chain CDR3 
sequences was shared between all three expansion conditions, suggesting a largely 
conserved expansion. The other prominent group was shared between E.coli and 
zoledronate-expanded γδT cells, with only low counts exclusive to either group. ~80-90% 
overlap in the Vγ and the Vδ chain CDR3 regions was observed between the two 
expansion protocols. Notably, the single exclusive group of Vδ chains was found in freshly 
isolated γδT cells, indicating a significant shift in Vδ chain CDR3 repertoire post 
expansion. 
  
Fig. 4.17. E.coli and zoledronate focus the γδT cell CDR3 repertoire in a similar manner. 
Freshly-isolated PBMC were expanded with UV-irradiated E.coli or zoledronate for 14 
days. The resulting γδT cell CDR3 repertoire was examined. The number of shared TCR 
CDR3 sequences was tallied and compared in expanded and fresh unexpanded γδT cells. 
A comparison of the number of sequencing reads shared as well as the number of unique 
sequences in each category is shown for both Vγ and Vδ TCR chains. For all samples, total 
depth of sequencing was equivalent. Only sequences with more than 5000 reads were 
tallied to select for the commonest clones.  
38-Fig. 5.17. E.coli and zoledronate focus the γδT cell CDR3 repertoire in a similar manner. 
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To further examine the homology between the TCR repertoires of γδT cells expanded with 
E.coli or zoledronate, CDR3 spectratype analysis was performed for both populations. The 
donor used for spectratype analysis was different to the donor used for sequencing, so as 
to validate repertoire similarities or differences in more than one donor.  Striking 
homology in CDR3 spectratypes was observed in the Vγ9 and Vδ2 chains of E.coli and 
zoledronate-expanded γδT cells, confirming the CDR3 overlap observed in CDR3 




Fig. 4.18. E.coli and zoledronate-expanded γδT cells present with similar spectratypes. 
Freshly-isolated PBMC were expanded with UV-irradiated E.coli or zoledronate for 14 days. 
The resulting γδT cell CDR3 repertoire was examined. TCR CDR3 spectratyping was carried 
out for expanded Vγ9Vδ2 T cells. Representative spectratypes of one donor are shown.  
39-Fig. 5.18. E.coli and zoledronate-expanded γδT cells present with similar spectratypes. 
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4.7. Discussion 
The experiments described in this chapter were designed to provide a detailed phenotypic 
analysis of fresh versus E.coli and zoledronate-expanded γδT cells. Particular focus was 
placed on expression of the APC molecules, CD86 and MHC class II (HLA-DR, 
specifically), and lymphoid tissue homing receptors, CCR7 and CD62L. Further analysis 
was performed on expanded and freshly-isolated Vγ9Vδ2 cell TCR repertoires. Findings 
included:  
i) Freshly-isolated PBMC stimulation with E.coli or zoledronate induces 
sustained γδT cell (including Vδ2 cell) upregulation of HLA-DR and CD86. 
ii) γδT cell upregulation of HLA-DR and CD86 is equivalent to that of freshly-
isolated monocytes in terms fluorescence intensity.  
iii) αβT cells do not significantly upregulate HLA-DR or CD86 in response to 
PBMC stimulation with E.coli or zoledronate.   
iv) Freshly-isolated PBMC stimulation with E.coli or zoledronate induces 
transient γδT cell (including Vδ2 cell) upregulation of CCR7.  
v) Expanding γδT cells return to a CCR7neg phenotype post-transient 
upregulation, which is not rescued by expanded γδT cell re-stimulation with 
E.coli.  
vi) The period of maximal γδT cell surface HLA-DR and CD86 levels does not 
overlap with that of maximal cell surface CCR7 levels.  
vii) Freshly-isolated γδT cells are positive for CD62L.  
viii) Freshly-isolated PBMC stimulation with E.coli or zoledronate induces 
transient γδT cell (including Vδ2 cell) downregulation of CD62L.  
ix) Expanding γδT cells return to a somewhat CD62Lpos phenotype post-transient 
downregulation, although positivity eventually declines as the expansion 
progresses.  
x) Some downregulation of γδT cell CD62L is still seen upon expanded γδT cell 
re-stimulation with E.coli.  
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xi) Of the markers examined, fluctuation levels of γδT cell surface CD86 and 
HLA-DR, pre- and post-stimulation, follow a similar pattern. CCR7 levels do 
not match the pattern of CD86 and HLA-DR positivity. CD62L levels do not 
match the pattern of either CD86 and HLA-DR, nor CCR7.  
xii) Freshly-isolated PBMC stimulation with E.coli or zoledronate leads to the 
expansion of predominantly CD4negCD8neg Vδ2 cells that are CD56pos and 
CD16pos. 
xiii) The same expansions further sustain a mixture of CD4pos, CD8pos and 
CD4negCD8neg αβT cells that are largely CD56neg and CD16neg. 
xiv) Freshly-isolated PBMC stimulation with E.coli or zoledronate does not sustain 
or expand myeloid cells (including DC and monocytes) or B cells. 
xv) The stimulation does, however, sustain a minor population of 
CD3negCD56posCD16pos PBMC. 
xvi) TCR sequencing of expanded γδT cells indicates that both E.coli and 
zoledronate expand Vγ9Vδ2 cells preferentially.  
xvii) Sequencing further indicates that both expansion stimuli expand highly 
homologous TCR repertoires, in terms of CDR3, which are nonetheless 
significantly different from freshly-isolated γδT cell CDR3.  
xviii) Focusing of the CDR3 repertoires in response to both stimuli compared to 
freshly-isolated γδT cells is largely located in the Vδ chain locus and not the 
Vγ chain locus.  
xix) The homology of CDR3 repertoires between E.coli versus zoledronate-
expanded Vγ9δ2 cells is further supported by spectratype analysis.  
xx) Similar populations of γδT cells, αβT cells and CD3neg cells were expanded or 
sustained despite divergent early cytokine milieus present in PBMC stimulated 
with E.coli versus zoledronate.  
The focus of this chapter was two-fold. Firstly, I aimed to characterize the dynamics of 
pAPC markers on γδT cells expanded with E.coli or zoledronate. Secondly, I aimed to 
establish whether the expansion of Vδ2 cells with apparently equivalent phagocytic 
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capacity in response to stimulation with E.coli or zoledronate, as described in the previous 
chapter, correlates to further phenotypic similarities in the two cell populations.  
As outlined in the chapter introduction, the upregulation of MHC class II (HLA-DR, 
specifically) and CD86 on activated Vδ2 cells in response to diverse stimuli, ranging from 
IPP to Gram-negative bacteria as well as mycobacteria, has been described in the literature 
previously (102,105). I was able to reproduce these results and establish, moreover, that 
this upregulation is sustained and consistent among the various donors examined. This is 
strongly indicative of the putative pAPC role of activated, but not resting (i.e. freshly-
isolated, unstimulated) peripheral Vδ2 cells. γδT cell upregulation of the lymphoid-
homing receptor CCR7 in response to stimulation has been previously described by 
Brandes, Moser and colleagues (51,182). This finding was interpreted as an indication that 
γδT cell APC function is likely to resemble that of classic professional APCs, such as DC, 
in terms of localisation.  
Curiously, I was unable to find an obvious correlation between these lymphoid homing 
cell surface markers and cell surface levels of HLA-DR and CD86. While transient 
upregulation of CCR7 could be observed in response to freshly-isolated γδT cell 
stimulation, it did not appear to correlate with maximal γδT cell upregulation of HLA-DR 
nor CD86, nor was I able to detect significant phagocytosis of opsonized E.coli by freshly-
isolated γδT cells. It must be noted that staining for homing receptors on circulating γδT 
cells is significantly complicated by the fact that CCR7 and CD62L are homing markers 
with dual interpretations of function. On canonical, peripheral αβT cells these are markers 
of a naïve, unstimulated state and continued lymphatic re-circulation in search of cognate 
antigen. On classic APC, such as DC, meanwhile, these are markers of exit from tissue 
where an inflammatory target has been encountered, and shuttling to lymph nodes for 
presentation of phagocytosed antigenic material to naïve T cells. It remains unclear as to 
what relationship the ‘innate-like’ γδT cells bear to canonical αβT cell homing markers. 
The interpretation of Brandes et al. regarding γδT cell CCR7 ascribes it to the ‘myeloid-
like’ properties of these ‘innate T cells’. Due to a lack of obvious correlation and in the 
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absence of functional studies, I hesitate to make such a conclusion sans further 
investigation. It remains, moreover, unclear as to whether γδT cell antigen presentation 
occurs in lymph nodes in vivo.  
Comprehensive further experimental investigation is necessary to determine the homing 
patterns of activated, phagocytic APC-like peripheral human Vδ2 cells. It cannot be ruled 
out, for example, that the phagocytic and antigen presenting capacity of these cells peaks 
at seven days post-stimulation and not the 14 days post-stimulation employed in the study. 
At seven days post-stimulation CCR7 positivity on stimulated γδT cells remained higher 
than compared to baseline expression. The phagocytic and antigen presenting capacity 
peak may even occur at any time before the seven-day mark after PBMC stimulation with 
E.coli or zoledronate. Perhaps ‘maturation’ into this phenotype occurs at different rates in 
a donor-dependent manner. The only way to effectively address this question is to carry 
out comparative γδT cell phagocytic assays and chemokine receptor staining at much 
shorter time intervals than the experiments described. A more thorough enquiry would 
warrant investigation of these phenomena every successive day post-stimulation, or even 
at hour intervals to ensure precision of the data generated. The resources required for such 
an undertaking are vast, which was a deciding factor in my not pursuing of this strategy. 
It is curious to note, however, that 14 day expanded γδT cells were capable of E.coli 
phagocytosis, but did not re-upregulate CCR7 in response to re-encounter with E.coli. 
CD62L was, furthermore, downregulated upon γδT cell re-encounter with E.coli. This 
may be indicative that γδT cell phagocytosis does not correlate with γδT cell migration to 
lymphoid tissue – at least in terms of CCR7 and CD62L.  
A point of consideration in the context of examining APC phenotype in short term-
expanded γδT cells concerns my investigative motivation, which is rooted in the potential 
use of γδT cells in the clinic. A requirement in the clinic for a large number of cells 
available for use, in combination with the relative scarcity of γδT cells in the periphery, 
indicates a likely necessity for clinic-destined γδT cells to be expanded in vitro for 14 days 
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or more. The phenotypic characterisation of γδT cells expanded for 14 days and more, 
thus, carries some value in and of itself.  
A crucial step in the meaningful exploration of activated peripheral γδT cell homing 
properties is characterisation of homing receptors beyond CCR7 and CD62L. In addition 
to the above-mentioned CCR7 and CD62L, various groups have addressed γδT cell 
expression of CCR2, CCR5, CCR6, CXCR3 and CXCR4, among others (191,192). There 
persists, however, an overall lack of consensus on the significance of each of these 
receptors on γδT cells compared to canonical αβT cells. It is, moreover, unclear whether 
these investigations have examined both activated and non-activated γδT cells. 
Comprehensive review on γδT cell homing properties is necessary. Such an undertaking 
is significantly complicated by the ambiguous relationship between human and laboratory 
animal (e.g. mouse) γδT cells, making information on in vivo human γδT cells trafficking 
scarce. While some review on the subject is available in the literature, it is nearly 15-years-
old and likely out of date (193). The chemokine receptors I propose ripe for investigation 









7-Table 6  |  Homing receptors of interest to γδT cell APC function 
Table 4.1  |  Homing receptors of interest to γδT cell APC function 
Receptor Immune cell expression Key immune function 
CXCR3 
Th1, CD8pos TCM and TEM, Treg, Tfh, 
NK, NKT, pDC, B cell 
Th1-type adaptive immunity 
CXCR5 Tfh, Tfr, CD8pos TEM, B cells 
T and B cell trafficking in 
lymphoid tissue to B cell 
zones/follicles 
CCR2 
Th1, monocyte, macrophage, iDC, 
basophil, NK 
Th1-type adaptive immunity, 
monocyste trafficking 
CCR4 
Th2, skin- and lung-homing T, Treg, 
Th17, CD8pos T, monocytes, B cells, 
iDC 
Homing of T cells to skin and 
lung, Th2-type immune response 
CCR6 Th17, iDC, γδT, NKT, NK, Treg, Tfh 
iDC trafficking, GALT 
development, Th17 adaptive 
immune responses 
CCR8 
Th2, Treg, skin TRM, γδT, monocyte, 
macrophage 
Immune surveillance in skin, type 
2 adaptive immunity, 
thymopoiesis  
CCR9 
Gut-homing T, thymocytes, B cells, 
DC, pDC 
Homing of T cells to gut, GALT 
development and function, 
thymopoiesis 
CCR10 Skin-homing T, IgA-plasmablasts 
Humoral immunity at mucosal 
sites, immune surveillance in skin 
CXCR1 
Cross-presenting CD8pos DC, thymic 
DC 
Antigen cross-presentation by 
CD8pos DCs 
CX3CR1 
Resident monocytes, macrophages, 
microglia, Th1, CD8pos TEM, NK γδT, 
DCs 
Patrolling monocytes in innate 
immunity, microglial cell and NK 
cell migration, Th1-type adaptive 
immunity 
Elements of this table have been adapted from Luster at. al. (2014) (103). 
Abbreviations: DC, dendritic cell; iDC, immature DC; GALT, gut-associated lymphoid tissue; NK, 
natural killer cell; NKT, natural killer T cell; TCM, central memory T cell; TEM, effectory memory T 
cell; TRM, resident-memory T cell; Tfh, T follicular helper cell; Tfr, follicular regulatory T cell; Th, 
T helper cell; Treg, regulatory T cell.  
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Upon considering non-γδT cell populations that were sustained during expansion post 
PBMC stimulation with E.coli or zoledronate, it is perhaps unremarkable that I found these 
consisted largely of αβT cells and CD3negCD33negCD56posCD16pos cells. While finding 
PBMC in culture that were CD3neg after 14 days of T cell expansion was initially 
surprising, learning that these are CD33neg (i.e. not of myeloid origin) as well as 
CD56posCD16pos leads us to postulate that these cells are likely NK cells. All γδT cell 
expansion media employed in these studies contained high concentrations of IL-2, which 
is a known mitogen of T cells (with γδTCRs or αβTCRs) as well as NK cells (194). As 
indicated by MSD data, PBMC exposure to E.coli or zoledronate further induced high 
levels of potent pro-inflammatory cytokines, such as IFN-γ. An intriguing possibility 
remains that the αβT cells remaining in culture after two weeks of E.coli or zoledronate 
expansion represent antigen-specific outgrowth of αβT cell clones rare at baseline, rather 
than a non-specific bystander effect. Significant further phenotyping and, importantly, 
functional assays are necessary to determine the nature of the αβT cells and likely NK 
cells remaining in γδT cell culture. It cannot be ruled out that these cells play a ‘supportive’ 
role in their engagement of expanding γδT cells. While a skewing of the functional 
phenotype is possible, expansion protocols with purified γδT cells have been published, 
suggesting that the presence of αβT cells or NK cells is not essential for γδT cell expansion 
(195).  
The finding that both expansion conditions induced proliferation of predominantly 
CD4negCD8neg Vδ2 cells that are CD56pos and CD16pos is, perhaps, also unremarkable. The 
expansion of CD56pos and CD16pos Vδ2 cells using pAg stimulation has been described 
previously (184,196). More surprising was the finding that no significant differences could 
be found in terms of these important functional markers whether PBMC had been exposed 
to E.coli versus zoledronate. I postulated initially that, given the highly divergent stimuli 
that E.coli and zoledronate represent, proliferating Vδ2 cells may be skewed to divergent 
phenotypic paths. In terms of the parameters that I examined, this did not appear to be the 
case.  
 126 
Expanded γδT cell TCR sequencing determined that both expansion stimuli induced 
proliferation of specifically Vγ9Vδ2 cells. CDR3 sequencing and spectratyping further 
revealed a striking similarity between E.coli and zoledronate-expanded Vγ9Vδ2 cell 
CDR3, which were nonetheless significantly different from freshly-isolated, unexpanded 
γδT cells. These finding are consistent with the focusing of the γδTCR repertoire on a 
common set of TCR ligands, regardless of stimulation with E.coli versus zoledronate. As 
described earlier, it has been proposed that zoledronate activates γδT cells by causing 
accumulation of endogenous pyrophosphates and, consequently, conformational changes 
in butyrophilin molecules, such as BTN3A. Like zoledronate, E.coli too has been 
documented to cause the accumulation of endogenous pyrophosphates (IPP), which then 
serve to drive activation and proliferation of Vγ9Vδ2 T cells (101,102). It may have to be 
considered, therefore, that Vγ9Vδ2 cell proliferation is regulated foremostly by 
recognition of ‘self-stress’, via e.g. BTN molecules, even if the stimulus is exogenous in 
nature (as addressed briefly in Fig.1.3); even if the stimulus contains a plethora of further 
pro-inflammatory molecules in and of itself, as is the case with E.coli. Related to this is 
the observation that the recognition of pAg signals appears to occur primarily through 
germline-encoded regions of the Vγ9Vδ2 TCR, and involves all CDR loops (181). 
Relative to the αβTCR, there are, moreover, relatively few germline genes available for 
assembly of the γδTCR (197). While some have postulated that the expansion of the 
Vγ9Vδ2 subset in the periphery after birth is driven by exposure to environmental 
microbial ligands, there remains a lack of consensus on the factors that drive Vγ9Vδ2 cell 
expansion in vivo (198). 
Having observed striking similarities between Vγ9Vδ2 cell responses within PBMC 
stimulated with zoledronate or E.coli, I ventured to better characterise the functional 
responses of both freshly-isolated and expanded γδT cells. I set out, moreover, to 
determine whether the functional shift between a non-phagocytic to a phagocytic cell 
population pre- and post-expansion correlates with further effector function changes in 
γδT cells pre- and post-stimulation.  
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4.8. Summary 
Data laid out in this chapter lead us to the conclusion that E.coli and zoledronate-expanded 
γδT cells bear a close resemblance in terms of functional cell surface marker expression, 
with both populations presenting with a predominantly HLA-DRpos CD86pos CCR7neg 
CD62Llow CD4neg CD8neg CD16pos CD56pos phenotype. Striking homology could, 
moreover, be seen in the differentially expanded Vγ9Vδ2 TCR CDR3 sequences, which 
were similar to one another, but not to freshly-isolated TCR CDR3s. This suggests that 
PBMC stimulation with E.coli and zoledronate leads to Vγ9Vδ2 CDR3 focusing on a 
similar set of ligands.  
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5. γδT CELL ACQUISITION OF pAPC PHENOTYPE IS 
CONCURRENT TO A LOSS OF Th1 INFLAMMATORY 
PHENOTYPE 
5.1. Aims 
The previous results chapter documents the observation that expanded Vδ2 γδT cells 
acquire an opsonin-dependent phagocytic phenotype that correlates with upregulation of 
CD86 and MHC class II. This phenotypic shift resulted from PBMC stimulation with 
either E.coli or zoledronate. Surprisingly, in all parameters examined (including TCR 
repertoire) Vδ2 cells expanded with E.coli or zoledronate appeared highly similar. In this 
chapter I set out to document in further detail the impact of expansion on Vδ2 cell effector 
phenotype. Parameters such as antigen presentation, cytokine production and cytotoxic 
capacity were considered.  
A number of publications describe the in vitro pAPC activity of human γδT cells (49–
51,60). This phenotype has, however, not been correlated to corresponding output of 
cytokines, memory phenotype, expansion status or cytotoxic capacity of the γδT cells in 
question. In this chapter I set out to determine whether γδT cells expanded with E.coli or 
zoledronate do indeed act as APCs to naïve peripheral αβT cells. I explored, moreover, 
how this antigen presentation correlates to more accepted and classic γδT cell functions, 
such as production of IFN-γ and cytotoxicity.   
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5.2. γδT cells expanded with E.coli or zoledronate display a pAPC effector 
phenotype 
The previous chapters described my observation that γδT cell expansion with E.coli or 
zoledronate produces a population of efficiently phagocytic HLA-DRposCD86pos Vδ2 
cells. While these observations provide evidence toward pAPC function by γδT cells, 
functional assays are necessary to establish whether expanded Vδ2 cells are indeed 
capable of antigen presentation.  
E.coli-expanded PBMC examination with confocal microscopy revealed that, within 
~30min of plating, Vδ2 cells had re-formed large, ‘grape-like’ clusters, observed typically 
with in vitro activated γδT and αβT cells (Fig.5.1A). These Vδ2 cells further displayed a 
single, regular, rounded nuclear shape, as indicated by DAPI staining (Fig.5.1B), another 
classic T cell morphological feature. Inadvertently, such clustering presents a significant 
technical challenge to imaging. Clear cell images via confocal microscopy require a low 
cell density and separation of single cells, so as to be able to document cell shape and 
movement precisely.  Thus, detailed information about expanded cell morphology was 
acquired by examination of non-clustered Vδ2 cells (Fig.5.2). Low density, unclustered 
expanded Vδ2 cells revealed a shape highly atypical for normally-round and regular T 
cells - with dendritic-like cell shape and irregular membrane ruffles extending in all 




Fig. 5.1. γδT cell activation and expansion leads to Vδ2 cell clustering. Day 14 E.coli-
expanded PBMC were stained with Vδ2-PE mAb, DAPI and examined via confocal 
microscopy. (A) Shown is a representative field of vision with Vδ2-PE seen in red. (B) A 
section of the field of vision, showing a Vδ2 cell cluster, was amplified to provide greater 
detail of cell membrane and nuclear shape.  
40-Fig. 6.3. γδT cell activation and expansion leads to Vδ2 cell clustering. 
 131 
 
Fig. 5.2. Vδ2 cell expansion leads to their acquisition of a phagocyte-like morphology and probing 
behaviour. Day 14 E.coli-expanded PBMC were stained with Vδ2-PE mAb and examined via confocal 
microscopy. (A) Shown is a representative field of vision, with PBMC in light phase contrast, Vδ2-PE or 
a merge of the two, with (B) magnified Vδ2 PBMC from the representative field of vision. (C) Light 
phase contrast images from the same field of vision as shown in panel (A) were collected every 2 
seconds for 5 minutes. Shown is a video sequence of the collected images. Vδ2 PBMC are indicated 
with white arrows. The video material is available for viewing in the CD attached to the thesis as 
supplementary media material.  
41-Fig. 6.4. Vδ2 cell expansion leads to 
their acquisition of a phagocyte-like 
morphology and probing behaviour. 
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Strikingly, the movement of expanded Vδ2 cells was strongly reminiscent of phagocyte 
probing (a screenshot from the video material is visible in Fig.5.2C; the full video is 
provided in a CD attached to the thesis in Supplementary Media Material). Every single 
Vδ2 cell in the field of vision appeared engaged in active, exploratory membrane ruffling. 
Grinstein and Botelho define ‘probing’ as “membrane extensions enriched in phagocytic 
receptors flail[-ing] about in an actin-dependent manner, enhancing the likelihood of 
particle contact and receptor-ligand engagement” (199). Such probing is characteristic of 
phagocytic cells, including dendritic cells, and constitutes the first stage of phagosome 
formation. The stages of phagosome formation, as described by Grinstein and Botelho, 
are i) probing via membrane ruffling followed by receptor-ligand binding, given presence 
of target, ii) early signalling and cup formation, mediated by receptor clustering and 
tyrosine kinase activation, iii) pseudopod extension via actin remodelling and localised 
membrane secretion, and iv) phagosome closure involving phagocytic signal termination.   
To test whether expanded Vδ2 cells are capable of activating naïve αβT cells, zoledronate-
expanded PBMC were FACS-sorted for Vδ2 cells to >98% purity. Zoledronate instead of 
E.coli-expanded PBMC were used to avoid the possibility that E.coli debris may be 
lingering in the cell media or has been internalized by cells. Purified Vδ2 cells were then 
incubated overnight with IgG-opsonized E.coli. In parallel, αβT cells were purified from 
freshly-isolated, unstimulated autologous PBMC. Expanded, opsonized E.coli-stimulated 
Vδ2 cells were then co-cultured for two days with purified αβT cells at γδT:αβT ratios of 
1:20, 1:10 and 1:5. The experimental setup is illustrated in the Materials and Methods 
chapter. Normally, αβT cell antigen presentation assays require the use of a cell line with 
a known TCR specificity or αβT cell transduction with TCR of known specificity, and 
possibly even transduction of the APC with a specific HLA type. I was able to overcome 
the necessity for HLA transduction by employing ‘responder’ αβT cells isolated from the 
same donor as the ‘stimulator’ expanded Vδ2 cells. As for the necessity for TCR 
transduction of responder αβT cells, I stipulated there may be a relatively high baseline 
frequency of E.coli-reactive αβT cells in the peripheral blood of healthy human adults, 
due to the ubiquitous distribution of E.coli as both, a commensal and pathogen. I, 
therefore, speculated that there may be high-enough numbers of E.coli-reactive αβT cells 
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in unstimulated donor PBMC to be detectable using flow cytometry. Indeed, various 
groups have documented the relatively high numbers of E.coli-reactive αβT cells in 
humans at various anatomical sites, ranging from blood to synovial fluid, to lamina propria 
(200–203). The responders in this antigen presentation assay were, thus, non-transduced, 
normal adult PBMC αβT cells.  
αβT cells co-cultured with mock-stimulated Vδ2 cells (Vδ2 cells stimulated with medium 
only) did not produce IFN-γ. Importantly, this indicates that HLA-DRposCD86pos Vδ2 
alone are not sufficient to induce an IFN-γ response from naïve αβT cells (Fig.5.3A, B). 
E.coli-stimulated Vδ2 cells, meanwhile, induced αβT cell IFN-γ production at all the 
γδT:αβT cell ratios examined. γδT:αβT ratios ranging from 1:5 to 1:20 did not produce a 
significant difference in the IFN-γ observed. In terms of subset-specificity of the response, 
IFN-γ production was observable only in CD4+ αβT cells (Fig.5.3C).  
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Fig. 5.3. Expanded γδT cells, co-cultured with opsonized E.coli, induce IFN-γ production in 
fresh autologous αβT cells. γδT cells were expanded for 14 days from freshly-isolated 
PBMC using zoledronate (5μM). On day 14, γδT cells were purified from expanded PBMC 
using FACS-sorting and rested overnight. Purified γδT cells were then incubated overnight 
with IgG-opsonized, irradiated E.coli at MOI 10 and washed thoroughly. In parallel, αβT 
cells were purified via positive magnetic selection from autologous, freshly-isolated PBMC 
and rested overnight. Purified, E.coli-stimulated, expanded γδT cells were then co-
cultured for 2 days with purified, autologous fresh αβT cells. After 2 day co-culture, αβT 
cells were blocked with monensin, permeabilized and stained via FACS for intracellular 
IFN-γ. (A) Representative stains of one donor αβT cells is shown comparing co-culture 
with mock (media only)-stimulated or E.coli-stimulated expanded γδT cells at a γδT:αβT 
ratio of 1:10 (anti-IFN-γ antibody in black, unshaded, and isotype-matched control - in 
gray, shaded). (B) Three donor αβT cell IFN-γ MFI were compiled and compared between 
αβT cells stimulated with i) media only (αβT only), ii) mock-stimulated γδT cells at a 
γδT:αβT ratio of 1:10, iii) E.coli-stimulated γδT cells at a γδT:αβT ratio of 1:5, iv) E.coli-
stimulated γδT cells at a γδT:αβT ratio of 1:10, v) E.coli-stimulated γδT cells at a γδT:αβT 
ratio of 1:20. (C) Representative stains of three donor αβT cells is shown comparing co-
culture with mock (media only)-stimulated or E.coli-stimulated expanded γδT cells. αβT 
cell IFN-γ production is set against expression of CD4. Bar graphs indicate the mean ± 
standard deviation. 
42-Fig. 6.5. Expanded γδT cells, co-cultured with opsonized E.coli, induce IFN-γ production in fresh 
autologous αβT cells. 
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αβT cells within freshly-isolated, E.coli-stimulated whole PBMC did not produce IFN-γ 
(Fig.5.4). Freshly-isolated Vδ2 cells do not, thus, appear capable of professional antigen 
presentation to naïve αβT cells. Significant further experimental investigation is, however, 
necessary to draw this conclusion with certainty. The autologous stimulator-responder 
APC assay setup is experimentally convenient and interesting in some aspects, but is far 
from an all-encompassing experimental design. Of note, γδT cells within freshly-isolated, 
E.coli-stimulated whole PBMC, meanwhile, produced large amounts of IFN-γ (Fig.5.4). 
 
  
Fig. 5.4. αβT cells within whole, freshly-isolated, E.coli-stimulated PBMC do not produce 
IFN-γ. Freshly-isolated PBMC were stimulated overnight with E.coli or mock stimulated 
(media only). PBMC were then blocked with monensin, stained for cell surface markers, 
permeabilized and stained for intracellular IFN-γ. (A) Representative stains of intracellular 
IFN-γ levels from one donor are shown, comparing mock or E.coli-stimulated γδT cells and 
αβT cells (anti-IFN-γ antibody in black, unshaded, and isotype-matched control - in gray, 
shaded). (B) Five donor data were compiled, comparing IFN-γ production by γδT and αβT 
cells within overnight E.coli-stimulated, freshly-isolated PBMC. Bar graphs indicate the 
mean ± standard deviation. 
 43-Fig. 6.6. αβT cells within whole, freshly-isolated, E.coli-stimulated PBMC do not produce IFN-γ. 
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5.3. γδT cell expansion leads to a loss of a Th1 inflammatory phenotype 
Having documented the phagocytic and pAPC capacity of expanded γδT cells, I set out to 
further explore the E.coli response of freshly-isolated γδT cells. Freshly-isolated PBMC 
were co-cultured with irradiated E.coli at MOI 10. After overnight stimulation, responses 
within stimulated PBMC were characterised. E.coli, but not mock, stimulation resulted in 
significant γδT cell upregulation of CD69, production of IFN-γ and TNF-α, as well as 
CD107a-mediated cytotoxic degranulation in a manner that was highly consistent among 
all donors examined (Fig.5.5A). γδT cells presented with high baseline positivity for 
granulysin, which remained largely unchanged after stimulation. A mean ~50% of γδT 
cells within freshly-isolated PBMC responded to E.coli with the upregulation of CD69, 
production of IFN-γ and cytotoxic degranulation (Fig.5.5B). While αβT cells failed to 
upregulate CD69 or produce cytokines, a cytotoxic response could be observed, albeit at 




Fig. 5.5. Freshly-isolated PBMC stimulation with E.coli leads to potent γδT cell activation 
and effector responses. Freshly-isolated PBMC (n=5) were stimulated with irradiated E.coli 
at MOI 10 and analysed after overnight (16-18h) culture. (A) Shown are overlaid five donor 
sample stains of unstimulated, and overnight mock (IL-2 only) or E.coli-stimulated PBMC. 
The parameters examined were γδT cell surface CD69 and CD107a, as well as intracellular 
IFN-γ, TNF-α and granulysin (marker in black, unshaded; isotype control in gray, shaded). 






 cells was examined in γδT cells of 
overnight E.coli-stimulated PBMC.  
45-Fig. 6.7. Freshly-isolated PBMC stimulation with E.coli leads to potent γδT cell activation and effector 
responses. 
Fig. 5.6. Fresh PBMC stimulation with E.coli leads to γδT cell, but not αβT cell, effector 
responses. Freshly-isolated PBMC (n=5) were stimulated with irradiated E.coli at MOI 10 
and analysed after overnight (16-18h) culture. The MFI of cell surface CD69, CD107a, as 
well as intracellular IFN-γ, TNF-α and granulysin were compared in γδT and αβT cells of 
overnight E.coli-stimulated PBMC. Bar graphs indicate the mean ± standard deviation. 
 
44-Fig. 6.8. Fresh PBMC stimulation with E.coli leads to γδT cell, but not αβT cell, effector responses. 
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A majority of γδT cells were IFN-γposCD107apos; a significant fraction, nonetheless, 
exhibited a single-positive IFN-γpos or CD107apos phenotype (Fig.5.7). These were later 
found to be Vδ2 and Vδ1 cells, respectively (Fig.5.7B). While Vδ2 and Vδ1negVδ2neg γδT 
cell populations were major cytokine producers, Vδ1 cells exhibited a significantly more 
potent cytotoxic response as measured by granulysin and CD107a expression. CD69 
expression was markedly higher on Vδ2 cells compared to other γδT cell subsets. No IL-
17 or IL-10 production by γδT cells could be detected via FACS, ELISA or MSD prior to 
or after expansion, as indicated in the previous chapter.  
  
Fig. 5.7. Fresh PBMC stimulation with E.coli leads to predominantly Vδ2 cell activation and 
effector responses. Freshly-isolated PBMC (n=5) were stimulated with irradiated E.coli at 
MOI 10 and analysed after overnight (16-18h) culture. (A) Two representative donor 
stains are shown for E.coli-stimulated γδT cells, comparing cell surface CD107a and 
intracellular IFN-γ. (B) Cell surface CD69, CD107a, as well as intracellular IFN-γ, TNF-α and 




 γδT cells. Bar graphs indicate 
the mean ± standard deviation. 
 
46-Fig. 6.9. Fresh PBMC stimulation with E.coli leads to predominantly Vδ2 cell activation and effector 
responses. 
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I next hypothesized that γδT cell expansion with E.coli may enhance the anti-E.coli 
response upon re-challenge. Unexpectedly, following expansion with E. coli, γδT cells 
exhibited a significantly decreased cytokine (IFN-γ, TNF-α) response to E.coli, and 
decreased CD69 expression compared to that observed in freshly isolated γδT cells 
(Fig.5.8A). E.coli-expanded γδT cells did, however, continue to exhibit CD107a-mediated 
cytotoxic degranulation and presence of granulysin, albeit at lower levels compared to 
freshly isolated γδT cells (Fig.5.8A, B). These observations may partially be attributed to 
the loss of the highly cytotoxic Vδ1 subset after expansion. Further surprising was the 
finding that γδT cell expansion with zoledronate resulted in a similar loss of cytokine 
production capacity post-expansion (Fig.5.9), ruling out the possibility that the loss of Th1 






Fig. 5.9. γδT cell loss of early Th1 and reduction of cytotoxic phenotype occurs in response to 
expansion with zoledronate. Freshly-isolated PBMC (n=3) were stimulated with zoledronate, 
left to expand for 14 days, and re-stimulated with E.coli overnight on day 14. γδT cell 
intracellular IFN-γ, TNF-α and cell surface CD69 as well as CD107a were assessed via FACS 
analysis. Parameter MFI in response to E.coli stimulation were compared between freshly-
isolated and 14 day zoledronate-expanded γδT cells. Bar graphs indicate the mean ± standard 
deviation. 
 
47-Fig. 6.11. γδT cell loss 
of early Th1 and 
reduction of cytotoxic 
phenotype occurs in 
response to expansion 
with zoledronate. 
Fig. 5.8. Expanded γδT cells lose IFN-γ and TNF-α production capacity, but retain cytotoxicity, 
upon re-stimulation with E.coli. Freshly-isolated PBMC (n=5) were stimulated with E.coli and 
analyzed after overnight (16-18h) culture or left to expand for 14 days, and re-stimulated with 
E.coli or mock-stimulated (media only) overnight on day 14. γδT cell accumulation of 
intracellular IFN-γ, TNF-α, granulysin and cell surface CD69, as well as CD107a were assessed 
via FACS analysis. (A) γδT cell MFI in response to E.coli or mock stimulation were compared 
between freshly-isolated and 14 day E.coli-expanded γδT cells. (B) Shown are overlaid five 
donor sample stains of overnight mock or E.coli-stimulated γδT cell CD107a in fresh versus 
E.coli-expanded PBMC (marker in black, unshaded; isotype control in gray, shaded). Bar 
graphs indicate the mean ± standard deviation. 
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The decrease in cytokine production by E.coli-expanded compared to freshly-isolated γδT 




Fig. 5.10. Expansion in response to PBMC stimulation with E.coli does not lead to a 
significant change in γδT cell memory phenotype or PD1 expression. (A) γδT cell memory 
phenotype, as determined by cell surface expression of CD27 and CD45RA, was compared 




 γδT cells (n=7). (B) 
Representative donor stains are shown comparing PD-1 expression on fresh (D0) and 
expanded (D14) γδT cells with PD-1 in black, unshaded, overlaid with isotype control in 
gray, shaded. (C) Cell surface PD-1 MFI on γδT cell surface was tracked throughout PBMC 
expansion with E.coli (n=7).  
48-Fig. 6.12. Expansion in response to PBMC stimulation with E.coli does not lead to a significant change in γδT 
cell memory phenotype or PD1 expression. 
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In order to establish whether the failure of E.coli re-stimulation to induce Th1-type 
cytokine production in expanded γδT cells is due to a lack of non-T cell ‘helper’ cells, I 
set up an autologous expanded + freshly-isolated PBMC culture system (described in the 
materials and methods chapter). Briefly, E.coli-expanded γδT cells were mixed with 
autologous, freshly-isolated PBMC at a γδT cell:PBMC ratio of 1:10 prior to the addition 
of E.coli. Therefore, if γδT cell production of IFN-γ requires, for example, the presence 
of freshly-isolated monocytes, the presence of such ‘helper’ cells would be provided by 
autologous PBMC. This addition of autologous PBMC did not rescue the lost expanded 
γδT cell Th1-like phenotype (Fig.5.11). I, thus, concluded that the altered cytokine profile 
of expanded versus freshly isolated γδT cells represents a true phenotypic shift. 
 
Having established that expanded γδT cells do maintain some CD107a-mediated cytotoxic 
degranulation in response to E.coli re-stimulation, I evaluated direct expanded γδT cell 
cytotoxicity against E.coli. FACS-sorted E.coli-expanded γδT cells were exposed to live 
Fig. 5.11. γδT cell primary response effector phenotype is not rescued by the addition of 
fresh PBMC to expanded γδT cell culture. 14 day E.coli-expanded γδT cell culture (n=5) was 
stained for cell surface markers and supplemented with freshly-isolated, autologous, γδT 
cell-depleted PBMC at a ratio of 1:10 prior to overnight co-culture with E.coli at MOI 10. 
γδT cell responses were compared in terms of cell surface CD69, CD107a, as well as 
intracellular IFN-γ and TNF-α between i) freshly-isolated PBMC, ii) 14 day expanded PBMC, 
and iii) 14 day expanded PBMC supplemented with freshly-isolated PBMC. 
49-Fig. 6.13. γδT cell primary response effector phenotype is not rescued by the addition of fresh PBMC to 
expanded γδT cell culture. 
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bacteria for specified time intervals; cytotoxicity was inferred from residual colony 
numbers on agar plates. Remarkably, E.coli colony forming unit (CFU) count declined by 
>90% within 30 minutes (Fig.5.12). The high efficiency of bactericidal activity was 




Fig. 5.12. Expanded γδT cells kill E.coli rapidly and effectively. Freshly-isolated PBMC (n=4) 
were stimulated with E.coli or zoledronate and left to expand for 14 days. γδT cells were 
then purified by twice-repeated positive magnetic selection and rested overnight. Rested 
γδT cells were co-cultured with live E.coli at MOI 10. At designated time points the co-
culture was lysed in H
2
O, and plated on agar for overnight growth; resulting E.coli CFU 
were counted. 
50-Fig. 6.14. Expanded γδT cells kill E.coli rapidly and effectively. 
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5.4. Discussion 
The data laid out in this chapter explores the pAPC capacity of expanded Vδ2 cells, and 
attempts to correlate it to more commonly-described γδT cell functions, such as Th1-type 
cytokine production and cytotoxicity. Findings included:  
i) Expanding Vδ2 cells display classic T cell morphological features in terms of 
clustering and a single, round, regularly sized nucleus. 
ii) Expanding Vδ2 cells also display morphological features characteristic of 
myeloid phagocytes, such as an irregular cell shape with numerous membrane 
protrusions, and probing behaviour via guided membrane ruffling and motility.  
iii) Expanded Vδ2 cells, co-cultured with IgG-opsonized E.coli (but not medium 
alone), induce IFN-γ production in naïve, autologous αβT cells.  
iv) E.coli-pulsed Vδ2 cell-induced IFN-γ production is specific for CD4 αβT cells. 
v) IFN-γ production by αβT cells is not seen when E.coli is added to whole 
freshly-isolated PBMC. This indicates that expanded (phagocytic, HLA-DRpos 
CD86pos) Vδ2 cells are necessary for the triggering of an αβT cells IFN-γ 
response. 
vi) Freshly-isolated PBMC stimulation with irradiated E.coli induces potent γδT 
cell Th1-like cytokine (IFN-γ and TNF-α) production that is consistent among 
all donors examined.  
vii) Freshly-isolated γδT cells within PBMC are highly positive for granulysin at 
baseline. While stimulation with E.coli induces potent CD107a-meditaed 
cytotoxic degranulation, intracellular granulysin levels are not significantly 
altered.  
viii) These responses within PBMC are seen in freshly-isolated γδT cells, but not 
αβT cells.  
ix) γδT cell response to E.coli is subset-specific. Vδ2 cells are significantly more 
activated and are the predominant producers of Th1-type cytokines, while Vδ1 
cells display the most potent cytotoxicity.  
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x) The potent Th1-type, cytotoxic response to E.coli is seen in freshly-isolated 
γδT cells, but not expanded Vδ2 cells. This loss of phenotype does not appear 
to be due to exhaustion, memory phenotype shift, nor absence of myeloid 
‘helper’ cells (e.g. monocytes) within expanded PBMC. 
xi) The loss of a Th1-type phenotype to E.coli challenge results from γδT cell 
expansion with E.coli as well as zoledronate.  
xii) An effector function that is preserved, albeit at lower level than when freshly-
isolated, is Vδ2 cell CD107a-mediated cytotoxic degranulation.  
xiii) γδT cells expanded with E.coli and zoledronate display remarkably effective 
and rapid anti-E.coli bactericidal capacity.   
Establishing that HLA-DRpos CD86pos phagocytic Vδ2 cells display myeloid-like 
morphology and probing behaviour, combined with the observation that E.coli-pulsed Vδ2 
cells are capable of inducing IFN-γ production in naïve, autologous αβT cells in a CD4-
dependent manner provides a strong case for the pAPC capacity of peripheral human γδT 
cells. I concede, however, that the antigen presentation assay described in this chapter is 
non-standard and far from exhaustive. While there are indeed published statistics on the 
frequency of E.coli-reactive αβT cell clones in the periphery, they are significantly lower 
than the proportion of IFN-γpos CD4 αβT cells I observed in our antigen presentation assay 
(14-24% of all αβT cells). This casts doubt on the reliability of the findings described. I 
stipulate that the high proportion of activated αβT cells observed is likely a consequence 
of the purification method employed: αβT cells were isolated from PBMC using positive 
magnetic selection, a method known to cross-link the αβTCR. A longer ‘resting’ period 
sans stimulation (e.g. two days instead of one) may be necessary to fully mute this initial 
stimulus. Alternatively, other cell purification methods may be employed, such as FACS 
sorting for e.g. CD3pos γδTCRneg PBMC. It is interesting to note, however, that αβT cells 
co-cultured with non-pulsed Vδ2 cells failed to show any IFN-γ production. It is unclear 
as to why that is. It is conceivable that the high proportion of IFN-γpos CD4 αβT cells post 
stimulation with E.coli-plused Vδ2 cells was the consequence of a necessary double 
stimulus from anti-αβTCR-coated magnetic beads, followed by TCR stimulation via 
HLA-DR-presented E.coli antigen and co-stimulation from γδT cells. The data obtained 
 146 
in these experiments further requires a significant enlargement of the panel of target 
antigens used. E.coli on its own is insufficient as a model to test the pAPC capacity of γδT 
cells. The use of whole bacteria complicates the investigation in a number of manners, 
including the possibility that the observed αβT cell activation is due, in some part, to 
triggering of TLRs or other PRRs by E.coli that have been carried over from the γδT cell 
pulsing co-culture. Such issues may be overcome by the use of protein targets that still 
require pAPC processing for presentation on MHC class II, as was the case with previous 
work in my laboratory by Himoudi et al. (49). A peptide target stimulus does, however, 
require αβT cell responder cells with a known TCR specificity and, therefore, transduction 
or the use of a cell line. Microfluidic platforms for the examination of single cell pair Ca2+ 
flux as the result of TCR triggering (as described by Dura, et al. (204)) would doubtless 
provide fascinating insight into Vδ2 cell activation of naïve αβT cells. A further matter to 
be considered in a protein-stimulus experimental setup is the necessity for IgG 
opsonisation.  
Perhaps, most striking of all the findings is the total loss of freshly-isolated Vδ2 cell Th1-
type cytokine production during expansion, concurrent with the acquisition of a 
phagocytic HLA-DRpos CD86pos phenotype. This observation, in combination with IgG-
opsonisation as a pre-requisite of phagocytosis (and other pAPC functions), suggests 
careful regulation of Vδ2 T cell effector function. It is tempting to speculate that, 
whenever an early immune response is sufficient to neutralize infection, Vδ2 cells are 
prevented from posing an unnecessary inflammatory threat by amplifying responses 
further through downregulation of their early cytokine responsiveness. Noteworthy was 
the finding that, despite the loss of Th1-type cytokine production, Vδ2 cells retained 
highly efficient bactericidal capacity. It is unusual to consider that T cells are capable of 
such potent and direct bacterial killing. While significant further study is warranted to 
establish the exact mechanisms, the data presented in this chapter highlights the plethora 
of information yet to be learned. Vδ2 cell CD107a-mediated degranulation was decreased 
with expansion, but not entirely. It is conceivable that the residual CD107a-mediated 
degranulation was sufficient to kill E.coli in culture. It is also possible that the bactericidal 
functions of expanded Vδ2 cells are not limited to CD107a-mediated cytotoxicity. Mass 
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spectrometry of E.coli-stimulated Vδ2 cell supernatants would provide fascinating insight 
into the efficient killing of bacteria observed.   
γδT cell direct killing of cellular and/or microbial targets combined with inflammatory 
cytokine production followed by uptake of the target into acidifying antigen processing 
compartments raises a novel paradigm. It is tantalizing to hypothesize that the combination 
of innate-like recognition and killing followed by myeloid cell-like phagocytosis by a 
lymphocyte-like cell may evolutionarily have preceded the full development of T 
lymphocyte-mediated adaptive immunity. Such a hypothesis is supported by previous 
studies showing that γδTCR chain genes may have preceded the development of αβTCR 
chain genes (205). In addition, the existence in jawless fish of three lymphocyte-like cells 
expressing variable lymphocyte receptors instead of TCR or BCR chain genes also 
supports this contention, as they otherwise resemble γδT, αβT and B cells by the 




Data examined in this chapter revealed that Vδ2 cell acquisition of a pAPC phenotype 
during expansion with E.coli or zoledronate is accompanied by a loss of a Th1-type pro-
inflammatory phenotype, whilst maintaining potent cytotoxicity.  
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6. Vδ2 γδT CELL EFFECTOR FUNCTION DEPENDENCE 
ON THE TCR 
6.1. Aims 
Having documented the evolution of peripheral γδT cell effector function in response to 
stimulation by both, E.coli and zoledronate, I ventured to explore a mechanistic basis for 
this transition. The data presented in this chapter addresses the above-described range of 
effector functions in the context of the γδTCR. Blocking with monoclonal antibody was 
employed to determine γδT cell functional dependence on the TCR.  
 
6.2. Phagocytosis by expanded γδT cells is TCR-dependent 
As described in Chapter III, E.coli and zoledronate-expanded γδT cells phagocytosed 
opsonized bacteria with similar dynamics – with a similar level of uptake of beads, and 
uptake as well as acidification of bacteria. Chapter V, meanwhile, described that E.coli 
and zoledronate-expanded γδT cells express highly homologous TCR repertoires. I, thus, 
hypothesized that both stimuli may lead to γδT cell engagement of effector functions in a 
similar manner in the context of the TCR. To examine the importance of the TCR in γδT 
cell phagocytosis, E.coli or zoledronate-expanded γδT cells were cultured with anti-
γδTCR mAb (clone: B1), isotype-matched control mAb of known non-E.coli specificity 
(clone: MG1-45) or media alone, prior to co-culture. Both uptake and acidification of 
opsonized bacteria by E.coli-expanded γδT cells were highly sensitive to TCR inhibition 
(Fig.6.1).  Zoledronate-expanded γδT cells too displayed TCR-dependence for both 
measures of phagocytosis, although the sensitivity to inhibition was less marked than that 
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seen with E.coli-expanded cells (Fig.6.1). It remains unclear as to whether this difference 
between the expansion conditions is a real one or caused by technical discrepancy, e.g. 
better viability of zoledronate- versus E.coli-expanded γδT cells. I note that all the 
phagocytosis data presented herein is only that of expanded PBMC culture, as I was unable 
to detect substantial, and therefore quantifiable, phagocytosis by freshly-isolated γδT 
cells. Measurements of expanded γδT cell TCR dependence for phagocytosis are, thus, 




Fig. 6.1. E.coli and zoledronate-expanded γδT cells phagocytose E.coli in a TCR-dependent 
manner. Freshly-isolated PBMC (n=5) were expanded with UV-irradiated E.coli or 
zoledronate for 14 days, and examined for E.coli phagocytosis on day 14. To determine 
uptake, PBMC were incubated with IgG-opsonized E.coli for 60min. PBMC were pre-
cultured with normal media (control), anti-γδTCR mAb (clone: B1) or isotype-matched 
control. The effect of pre-culture with anti-γδTCR mAb on phagocytosis was examined; 
data is shown for E.coli-expanded (left) or zoledronate-expanded (right) γδT cells, 
incubated with FITC-E.coli or pHrodo-E.coli. Bar graphs indicate the mean ± standard 
deviation. 
51-Fig. 7.2. E.coli and zoledronate-expanded γδT cells phagocytose E.coli in a TCR-dependent manner. 
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To further investigate the role of the TCR in Vγ9Vδ2 cell phagocytosis, expanded PBMC 
were incubated with IgG-opsonized green fluorescent beads for 60 minutes, and analyzed 
via Trypan Blue quenching and flow cytometry, with or without γδTCR blocking 
(Fig.6.2A). Uptake of opsonized beads by expanded γδT cells was significantly inhibited 
in the presence of anti-γδTCR mAb (Fig.6.2B). Bead adherence, as measured in non-




Fig. 6.2. Expanded γδT cells take up 1.0μm beads in a TCR-dependent manner. Freshly-
isolated PBMC (n=5) were expanded with UV-irradiated E.coli for 14 days, and examined 
for uptake of fluorescent green beads on day 14. (A) PBMC were incubated with opsonized 
green fluorescent beads and quenched post-culture with Trypan Blue. Shown are 
representative stains, gated on γδT cells: i) non-quenched co-culture indicating total bead 
fluorescence (black, solid, unshaded), ii) quenched co-culture indicating intracellular bead 
fluorescence (red, dotted, unshaded), iii) cells alone (gray, shaded). (B) The effect of anti-
γδTCR mAb was examined on γδT cell uptake of opsonized beads in quenched and non-
quenched samples (n=3). Bar graphs indicate the mean ± standard deviation. 
 
52-Fig. 7.3. Expanded γδT cells take up 1.0μm beads in a TCR-dependent manner. 
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6.3. γδT cell cytokine production and proliferation in response to E.coli are 
TCR-dependent, whereas TCR dependence of cytotoxicity appears only 
partial 
To assess the TCR dependence of freshly-isolated γδT cell cytokine and cytotoxic effector 
function in response to stimulation with UV-irradiated E.coli, freshly-isolated PBMC 
were stimulated with UV-irradiated E.coli at MOI 10 and analyzed after overnight (16-
18h) co-culture. Exposure to anti-γδTCR mAb prior to co-culture led to abrogation of 
CD69 upregulation and cytokine production (Fig.6.3)  
  
Fig. 6.3. Fresh γδT cell cytokine response to E.coli are TCR-dependent. Prior to stimulation 
with E.coli, freshly-isolated PBMC (n=5) were cultured for 2h with blocking anti-γδTCR mAb 
or isotype-matched control. PBMC were then stimulated with E.coli and analyzed after 
overnight (16-18h) culture. γδT cell accumulation of intracellular IFN-γ, TNF-α and cell 
surface CD69 were assessed via FACS analysis after overnight stimulation of freshly-
isolated PBMC. Shown left are representative stains from one donor (marker in black, 
unshaded; isotype control in gray, shaded); shown right are donor parameter compilation 
MFI. Bar graphs indicate the mean ± standard deviation. 
 
53-Fig. 7.4. Fresh γδT cell cytokine response to E.coli are TCR-dependent. 
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Pre-culture with anti-γδTCR mAb further lead to a decrease in the double positive IFN-
γpos CD107apos but not in single positive CD107apos γδT cell populations (Fig.6.4). The 
decrease in IFN-γposCD107apos γδT cells was subset specific, as only Vδ2 but not Vδ1 γδT 









γδT cells display different sensitivity to 
TCR inhibition. Prior to stimulation with E.coli, freshly-isolated PBMC (n=5) were cultured 
for 2h with blocking anti-γδTCR mAb or isotype-matched control. PBMC were then 
stimulated with E.coli and analyzed after overnight (16-18h). Two representative donor 
samples,  gated on γδT cells, are shown correlating intracellular IFN-γ and cell surface 




γδT cells display 
different sensitivity 
to TCR inhibition. 
Fig. 6.5. Vδ2 cell, but not Vδ1 cell, CD107a-mediated degranulation is partially TCR-
dependent. Prior to stimulation with E.coli, freshly-isolated PBMC (n=5) were cultured for 
2h with blocking anti-γδTCR mAb or isotype-matched control. PBMC were then stimulated 
with E.coli and analyzed after overnight (16-18h) culture. The effect of anti-γδTCR mAb on 
fresh γδT cell surface CD107a post-PBMC E.coli stimulation is shown for five representative 
donors, comparing Vδ1 and Vδ2 cells. Bar graphs indicate the mean ± standard deviation. 
 
55-Fig. 7.6. Vδ2 cell, but not 
Vδ1 cell, CD107a-mediated 
degranulation is partially 
TCR-dependent. 
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To evaluate the impact of TCR blocking on direct γδT cell cytotoxicity against E.coli, 
FACS-sorted E.coli-expanded γδT cells (predominantly with a Vδ2 TCR) were pre-treated 
with blocking anti-γδTCR mAb and exposed to live bacteria; cytotoxicity was inferred 
from residual colony numbers on agar plates. As described in the previous chapter, E.coli 
colony forming unit (CFU) count declined by >90% within 30 minutes of exposure to 
purified γδT cells. Interestingly, this effect was not dependent upon γδTCR engagement 
(Fig.6.6). Although γδTCR blocking showed no significant impact on bactericidal 
function, it completely blocked γδT cell proliferation in response to E.coli (Fig.6.7).  
Fig. 6.6. Expanded γδT cell killing of live E.coli is not significantly TCR-dependent. Freshly-
isolated PBMC (n=4) were stimulated with E.coli and left to expand for 14 days. γδT cells 
were then purified by twice-repeated positive magnetic selection and rested overnight. 
Prior to stimulation with live E.coli, γδT cells were cultured for 2h with blocking anti-γδTCR 
mAb or isotype-matched control. γδT cells were then co-cultured with live E.coli at MOI 
10. At designated time points the co-culture was lysed in H
2
O, and plated on agar for 
overnight growth; resulting E.coli CFU were counted. 
57-Fig. 7.7. Expanded γδT 
cell killing of live E.coli is 
not significantly TCR-
dependent. 
Fig. 6.7. γδT cell proliferation in response to E.coli is TCR-dependent. Prior to stimulation 
with E.coli, freshly-isolated PBMC (n=5) were cultured for 2h with blocking anti-γδTCR 
mAb or isotype-matched control. PBMC were then stimulated with E.coli and left to 
expand for 14 days. Proliferation in response to E.coli stimulation was assessed.  
56-Fig. 7.8. γδT cell proliferation in 
response to E.coli is TCR-dependent. 
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6.4. Discussion 
Data presented in this chapter documents freshly-isolated and expanded γδT cell effector 
function dependency on the TCR. Findings included:  
i) E.coli and zoledronate-expanded γδT cells take up and acidify IgG-opsonized 
E.coli in a TCR-dependent manner.  
ii) E.coli-expanded γδT cells take up IgG-opsonized 1.0μm beads in a TCR-
dependent manner.  
iii) Freshly-isolated γδT cell activation (as measured by CD69 upregulation), IFN-
γ and TNF-α production in response to E.coli is TCR-dependent.  
iv) Freshly-isolated γδT cell CD107a-mediated cytotoxic degranulation is 
partially TCR-dependent for Vδ2 cells, but not Vδ1 cells.  
v) The decrease in viable E.coli CFU number after exposure to expanded γδT 
cells was not affected by γδT cell pre-culture with anti-TCR mAb. 
 
Prior to engaging in discussions of the physiological implications of the TCR blocking 
data presented in this chapter, I note that all data herein presented hinges on the use of a 
particular anti-γδTCR mAb, clone B1. There exists some literature on the use of this 
antibody for the effective blocking of human γδT cell effector function , particularly in the 
context of recognizing tumour (and virus)-associated antigens (207). As in the present 
thesis, data indicated that anti-γδTCR mAb, clone B1, inhibited Vδ2 IFN-γ production. 
Other γδT cell subsets remained unexamined. The question arises, therefore, whether the 
B1 antibody can be used as a credible, broad blocker of all γδTCRs. There are several 
ways of assessing this question. Firstly, is fluorescent staining with the B1 mAb inclusive 
of non-Vδ2 cells? Indeed, a number of commercial suppliers provide pan anti-γδTCR B1 
mAb; numerous peer-reviewed publications cite the use of this antibody clone for 
fluorescent pan-γδT cell staining (49,208–210). Moreover, published protocols describe 
the use of anti-γδTCR B1 mAb for the non-biased expansion of Vδ1, Vδ2 and non- Vδ1/ 
Vδ2 γδT cells (211), or the induction of proliferation and IFN-γ of non-Vγ9Vδ2 γδT cells 
(212).  Crucially, the difference between using the anti-γδTCR B1 mAb as a pan-
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stimulator or pan-blocker of peripheral human γδT cells appears to lie in the way that the 
antibody is presented to the cells. Free-floating, monomeric IgG exerts a blocking effect, 
whereas IgG conjugated to beads or the well of a culture well-plate – a stimulatory one, 
as resultant from antibody binding to single TCRs or cross-linking multiple TCRs on the 
same cell, respectively.  
Having established the existence of a substantive body of peer-reviewed literature that 
cites the use of anti-γδTCR B1 mAb, it was fascinating to note that pre-incubation with 
this antibody substantially decreased E.coli as well as zoledronate-expanded γδT cell 
phagocytosis of opsonized E.coli. Previous chapters present my finding that expansion 
with either stimulus leads to highly homologous Vγ9Vδ2 TCR repertoires. Knowing that 
zoledronate activates Vγ9Vδ2 cells via accumulation of endogenous IPP, this observation, 
thus, alludes strongly to a scenario where E.coli is not being engaged by the γδTCR 
directly. It suggests instead that E.coli too is inducing accumulation of endogenous 
pyrophosphates, which is what then drives γδT cell effector function and proliferation – 
possibly via inducing conformational changes in BTN3A molecules, as laid out in 
previous chapters. If it is indeed stressed self that is engaged upon γδT cell exposure to 
E.coli and not E.coli directly, TCR dependence of E.coli phagocytosis suggests a 
‘licensing’-type reaction occurring. I stipulate that 14 day expanded PBMC exposure to 
E.coli – via HMBPP release, endogenous IPP stimulation or otherwise – induces markers 
of cell stress. It is conceivable, even, that expanded γδT cells are recognizing these stress 
markers on each other, given that they constitute the vast majority of live cells remaining 
in culture. A signal of self-stress may then ‘license’ HLA-DRpos CD86pos γδT cell 
phagocytic effector function, which is further regulated by the necessity for target 
opsonisation with IgG. 
To test whether phagocytosis of IgG opsonized targets is dependent on TCR engagement, 
I examined whether expanded γδT cell uptake of opsonized 1.0μm beads is affected by 
pre-culture with anti-γδTCR B1 mAb. It is conceivable, for example, that TCR blocking 
impedes E.coli adherence to γδT cells, but not phagocytosis directly. Upon examination 
of IgG-coated beads I found, however, that bead adherence to expanded γδT cells was not 
significantly affected, while phagocytosis was. As discussed in Chapter III, I maintain that 
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further investigation and experimental approaches are necessary to establish the fine 
details of γδT cell phagocytosis. For example, are receptors other than those for IgG 
opsonin or (possibly) BTN3A involved? Are γδT cell TLRs triggered by exposure to 
E.coli and do these interactions modulate the effector function observed? The observation, 
however, that E.coli and zoledronate-expanded γδT cell phagocytosis of IgG-opsonized 
beads or E.coli is inhibited by pre-incubation with anti-γδTCR B1 mAb lead us to 
postulate that expanded HLA-DRpos CD86pos Vγ9Vδ2 cell phagocytosis requires an 
interactive ‘licensing’-type event between the γδTCR and FcγR. It remains unclear 
whether the interaction between γδTCR and FcγR is direct or indirect.  
E.coli exposure led to potent TCR-dependent freshly-isolated γδT cell IFN-γ and TNF-α 
production, proliferation as well as substantial cytotoxic degranulation and bacterial 
killing. Interestingly, freshly-isolated Vγ9Vδ2 cell CD107a-mediated cytotoxicity was 
only partially TCR-dependent, while E.coli killing was entirely unaffected by pre-
blocking of the γδTCR. The observation that expanded, purified Vδ2 cells exhibited high 
bactericidal activity despite decreased CD107a-mediated cytotoxic degranulation and 
blocking of the TCR, may be attributable to the high efficiency of γδT cell CD107a-
mediated E.coli killing, whereupon low level degranulation is sufficient to significantly 
decrease bacterial viability, or may allude instead to CD107a-independent bactericidal 
mechanisms. These data suggest differential control for Vγ9Vδ2 cell Th1 responses, 
proliferation and pAPC function versus cytotoxicity. Such a difference is, perhaps, 
unsurprising in a physiological context. γδT cells reside largely at epithelial surfaces 
populated by billions of commensal and pathogenic microorganisms. Encountering non-
self via non-TCR PRRs (e.g. TLRs) may trigger an immediate, cytotoxic response. Once 
the target is killed, however, decisions about further inflammatory processes or even the 
initiation or regulation of an adaptive immune response are tightly regulated by additional 
layers of control, involving e.g. γδTCR and FcγR. I note that freshly-isolated Vδ1 cell 
CD107-mediated cytotoxic degranulation appeared entirely γδTCR independent. As 
discussed in the chapter introduction, similar TCR dependence differences have been 
observed among mouse γδT cell subsets. Significant further experimental probing is 
necessary to determine the nature and reasons for this difference between human 
peripheral Vδ1 and Vδ2 γδT cells. It would be interesting to examine further whether 
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intestinal Vδ1 IELs display a similar TCR-independence to PBMC Vδ1 cells with regard 
to cytotoxicity.  
To our knowledge, we are the first group to document direct bactericidal activity of human 
Vγ9Vδ2 cells. While I’ve also demonstrated simultaneous CD107a-mediated cytotoxic 
degranulation, it is unclear whether this is the mechanism by which the remarkably 
efficient killing took place. Significant further investigation of Vγ9Vδ2 cell direct 
bactericidal activity is necessary, spanning different microorganisms, strains, from Gram-
positive to Gram-negative and intracellular bacteria, plasmodia, fungi, etc. It would be 
interesting to determine, for example, whether γδT cells can distinguish, in the context of 
bacterial killing, commensal E.coli from enteropathogenic E.coli. In terms of mechanisms 
of killing, reproducible mass spectrometry of E.coli-Vγ9Vδ2 cell co-culture supernatants 
would doubtless provide fascinating insight into what are likely multiple modes of 
bactericidal attack that Vγ9Vδ2 cells engage in.  
TCR-engagement as a pre-requisite of Vγ9Vδ2 cell Th1 cytokine production, proliferation 
and pAPC function suggests careful regulation of the Vγ9Vδ2 T cell compartment. 
Whenever an early immune response is sufficient to neutralize infection, MHC class 
IIposCD86pos Vγ9Vδ2 cells expanded in response to encountering self-stress markers may 
be prevented from posing an unnecessary inflammatory threat by amplifying responses 
further. This then would be achieved by downregulation of their initial Th1 cytokine 
responsiveness, as well as imposing a necessity for TCR triggering by stressed-self to 
exert pAPC function. The requirement for opsonization of a target may be a further safety 
feature. This could be operative at two levels: i) as herein, when opsonizing with switched 
target-specific IgG, and ii) in a ‘naïve’ non-immune situation, where natural antibodies 
(NAb) of different isotype, including IgG, may be involved.  
Further study of the engagement of the Vγ9Vδ2 TCR, possibly with BTN3A targets, is 
likely to carry significant implications for γδT cell anti-tumor immunity by supporting the 
notion that stress recognition, particularly in combination with Ab-opsonisation, may be 
sufficient not only for killing of a tumor cell but also for uptake, processing and 
presentation of tumor-associated antigens (49). Documenting the significance of the TCR 
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for the engagement of γδT cell pAPC function, I set out to determine in the next chapter 
what relationship this bears to endogenous BTN3A targets. Indeed, is the observed 
Vγ9Vδ2 cell TCR dependence linked intimately to recognition of self-stress, even upon 
exposure to such a target-rich stimulus as E.coli? 
 
6.5. Summary 
Data laid out in this chapter documents that Th1-type cytokine production, proliferation 
and phagocytic capacity of Vγ9Vδ2 cells is dependent on the TCR. CD107a-mediated 
cytotoxic degranulation displayed only partial TCR dependency, while Vγ9Vδ2 cell 





7. Vγ9δ2 γδT CELL EFFECTOR FUNCTION DEPENDENCE 
ON BTN3A 
7.1. Aims 
Finding that freshly-isolated and expanded Vδ2 γδT cell activation, cytokine production 
and pAPC phenotype in response to stimulation with E.coli are TCR-dependent, the 
question arose of what the TCR may be recognizing. The following chapter explores 
whether the Vγ9Vδ2 TCR ligand in my model is indeed the BTN3A molecule. γδT cell 
responses in the presence or absence of TCR / BTN3A blocking were explored in the 
context of various ‘self’ and ‘non-self’ stimuli.  
 
 
7.2. BTN3A is ubiquitously expressed on PBMC 
In order to decipher the role of BTN3A (CD277) in γδT cell recognition of target cells, I 
first set out to determine the expression pattern of BTN3A in freshly-isolated and 
differentially expanded PBMC. FACS-staining revealed that nearly all live, freshly-
isolated PBMC were positive for BTN3A, with expressioin levels largely equivalent 
among CD3pos and CD3neg cells (Fig.7.1A). Overnight stimulation with irradiated E.coli 
lead to a modest downregulation of BTN3A on all PBMC, although predominant 
positivity was maintained, with expression levels recovering during expansion. PBMC re-
stimulation with E.coli on day 14 of the expansion resulted in a less marked 
downregulation of BTN3A.  
 160 
  
Fig. 7.1. PBMC express high levels of CD277 throughout expansion with E.coli. Freshly-isolated 
PBMC (n=5) were expanded with UV-irradiated E.coli for 14 days. Cell surface CD277 levels 
were monitored throughout. (A) Representative stains of one donor E.coli-stimulated PBMC 




 cells. Points of E.coli stimulation are 
indicated with black arrows. (B) Donor CD277 levels in response to E.coli were compiled and 
compared in γδT and αβT cells.  
58-Fig. 8.7. PBMC express high levels of CD277 throughout expansion with E.coli. 
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Interestingly, E.coli stimulation resulted in significantly higher BTN3A levels on αβT 
cells than γδT cells as the expansion progressed (Fig.7.1B). Similar results were obtained 
upon freshly-isolated PBMC stimulation with zoledronate (Fig.7.2.).  
 
 
Fig. 7.2. PBMC express high levels of CD277 throughout expansion with E.coli and zoledronate. 
Freshly-isolated PBMC (n=4) were expanded with zoledronate for 14 days. Cell surface CD277 
levels were monitored throughout. (A) Representative stains of one donor zoledronate-




 cells. Points of 
zoledronate stimulation are indicated with black arrows. (B) Donor CD277 levels in response 
to zoledronate were compiled and compared in γδT and αβT cells.  
59-Fig. 8.8. PBMC express high levels of CD277 throughout expansion with E.coli and zoledronate. 
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7.3. γδT cells are activated by autologous pAg-stimulated PBMC 
To determine the role of BTN3A in γδT cell antigen recognition, an autologous 
stimulation experimental system was set up (illustrated in the materials and methods 
section). Briefly, γδT cells were stimulated with autologous PBMC, which in turn had 
previously been co-cultured overnight with various pAg-inducing and/or –containing 
stimuli, e.g. zoledronate and irradiated E.coli. To test whether such a system may be a 
viable experimental probe for γδT cellactivation, γδT ‘responder’ cells were stained for 
various activation markers after overnight co-culture with differentially-stimulated 
‘stimulator’ PBMC.  
Indeed, overnight co-culture resulted in responder γδT cell upregulation of CD69 in 




Fig. 7.3. γδT cells are activated by autologous zoledronate or E.coli-stimulated PBMC. 
Freshly-isolated PBMC were co-cultured overnight with autologous, freshly-isolated, γδT 
cell-depleted and overnight E.coli or zoledronate-stimulated PBMC. γδT cell upregulation 
of cell surface CD69 in response to differentially-stimulated, autologous PBMC was 
recorded. PBMC were analyzed via FACS. γδT cell surface CD69 was compared post-PBMC 
O/N co-culture with mock-, E.coli- or zoledronate-exposed stimulator cells. Shown are 
representative stains from one donor (marker in black, unshaded; isotype control in gray, 
shaded). 
60-Fig. 8.9. γδT cells are activated by autologous zoledronate or E.coli-stimulated PBMC. 
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A potent IFN-γ response was observed after responder γδT cell stimulation with both, 
E.coli and zoledronate-exposed, stimulator cells (Fig.7.4A). As seen with direct PBMC 
stimulation with E.coli or zoledronate (discussed in Chapter V), the IFN-γ response was 




Fig. 7.4. Vδ2 γδT cells produce IFN-γ in response to autologous E.coli or zoledronate-stimulated 
PBMC. Freshly-isolated PBMC (n=4) were co-cultured overnight with autologous, freshly-
isolated, γδT cell-depleted and overnight E.coli or zoledronate-stimulated PBMC. γδT cell 
responses to differentially-stimulated, autologous PBMC were recorded. PBMC were analyzed 
via FACS; representative single donor stains are shown (marker in black, unshaded; staining 
isotype control in gray, shaded). (A) γδT cell intracellular IFN-γ was compared post-PBMC O/N 
co-culture with E.coli- or zoledronate-stimulated targets. (B) Intracellular IFN-γ was correlated 
to γδT cell expression of the Vδ2 TCR chain.  
61-Fig. 8.10. Vδ2 γδT cells produce IFN-γ in response to autologous E.coli or zoledronate-stimulated PBMC. 
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γδT cell stimulation with stimulator PBMC further elicited potent CD107a-mediated 
cytotoxic degranulation. Strikingly, the level of cytotoxicity elicited by direct γδT cell 
stimulation with E.coli within whole PBMC was statistically indistinguishable from that 




Fig. 7.5. γδT cells display equivalent CD107a-mediated cytotoxic degranulation in response to 
direct E.coli stimulation or stimulation with E.coli-exposed stimulator PBMC. E.coli-expanded 
PBMC (n=3) were co-cultured overnight with UV-irradiated E.coli at MOI 10 or autologous, 
γδT cell-depleted and overnight E.coli-stimulated PBMC, or mock-stimulated (media only). 
Cell surface CD107a was compared between the various stimulated groups. Donor MFI were 
compiled and compared. 
62-Fig. 8.11. γδT cells display equivalent CD107a-mediated cytotoxic degranulation in response to direct E.coli 
stimulation or stimulation with E.coli-exposed stimulator PBMC. 
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7.4. Vγ9Vδ2 cell effector responses to autologous stimulator PBMC are 
differentially sensitive to blocking of the γδTCR and BTN3A  
Having established that γδT cells are indeed responsive to differentially stimulated 
autologous PBMC, I proceeded to examine the sensitivity of this responsiveness to 
blocking of BTN3A on stimulator PBMC and blocking of the γδTCR on responder γδT 
cells (as illustrated in the materials and methods section). Given that BTN3A dependency 
has been ascribed to Vγ9Vδ2 cells specifically, I first examined Vγ9 chain expression 
within freshly-isolated peripheral Vδ2 cells. In all donors examined, all freshly isolated 
Vδ2 also expressed a Vγ9 TCR chain (Fig.7.6).  
 
  
Vγ9Vδ2 cell responses to various stimuli were then examined in the presence or absence 
of pre-culture with blocking antibody. Freshly-isolated stimulator PBMC were cultured 
with medium only (mock), irradiated E.coli, HMBPP, IPP or zoledronate. Such a panel 
was designed to include i) a complex, pAg-expressing non-self target that further includes 
non-TCR inflammatory stimuli for Vγ9Vδ2 cells, e.g. LPS via TLR-4 (E.coli), ii) 
exogenous non-self pAg (HMBPP), iii) exogenous self pAg (IPP) and iv) a 
pharmacological agent that induces accumulation endogenous pAg, including IPP 
(zoledronate).  
Fig. 7.6. Peripheral Vδ2 cells express a predominantly Vγ9Vδ2 TCR. Freshly-isolated PBMC 
were stained for CD3, αβTCR and the TCR chains Vδ2 and Vγ9. Shown are three representative 
donor samples, gated on live CD3pos αβTCRneg cells.  
63-Fig. 8.12. Peripheral Vδ2 cells express a predominantly Vγ9Vδ2 TCR. 
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Vγ9Vδ2 cell CD69 upregulation in response to overnight co-culture with these 
differentially stimulated autologous PBMC was examined (Fig.7.7). Significant CD69 
upregulation was seen in response to all stimulator conditions (Fig.7.7A). Donor responses 
to the various conditions were, however, heterogeneous in potency. Data on the effects of 
blocking antibodies were, therefore, standardized against each donor’s CD69 MFI in the 
absence of any blocking mAb (i.e. R(iso)+S(iso)), and expressed instead as a percentage 
change in marker MFI after the addition of blocking antibody (Fig.8.13B). Unexpectedly, 
it was apparent that responder pre-blocking with anti-γδTCR or stimulator pre-blocking 
with anti-BTN3A exerted no significant effect on Vγ9Vδ2 upregulation of CD69 
(Fig.7.7B).  
The same assay was repeated with five donors, and measured CD107a-mediated cytotoxic 
degranulation as well as accumulation of intracellular IFN-γ. Once again, whilst all stimuli 
elicited Vγ9Vδ2 cell cytotoxicity and IFN-γ production, significant donor-dependent 
variation could be observed (Fig.7.8A and Fig.7.9A). Standardisation against each 
condition’s cell surface CD107a in the absence of blocking mAb revealed that cytotoxic 
degranulation too was unaffected by responder or stimulator pre-culture with anti- γδTCR 
or anti-BTN3A mAb, respectively (Fig.7.9A and B). Vγ9Vδ2 intracellular IFN-γ levels, 
meanwhile, were sensitive to blocking γδTCR or anti-BTN3A mAb in response to every 
stimulus examined (Fig.7.9B). It must be noted that an exception was the IFN-γ response 
to IPP-stimulated PBMC in the presence of clone B1 mAb, which decreased upon addition 
of blocking antibody, but failed to acquire meaningful statistical significance at a p value 
of 0.08 (Fig.7.9B). It is possible that statistical significance could have been acquired with 
an increased donor number. A vast difference was, thus, observed between CD69 
upregulation and CD107a-mediated cytotoxic degranulation versus IFN-γ production in 




Fig. 7.7. Peripheral Vγ9Vδ2 responder cell CD69 upregulation in response to autologous  
stimulator cells is not sensitive to blocking of BTN3A or γδTCR. Freshly-isolated PBMC (n=3) 
responder cells were stimulated with autologous stimulator PBMC. Stimulator PBMC were 
prepared by culturing γδT cell-depleted, freshly-isolated PBMC overnight with irradiated 
E.coli, HMBPP, zoledronate or IPP. Stimulator PBMC were then pre-blocked with either 
antagonistic anti-BTN3A mAb (clone: 103.2) or isotype-matched control. Freshly-isolated 
responder PBMC were, meanwhile, rested overnight, and pre-blocked with anti-γδTCR 
mAb (clone: B1) or isotype-matched control. Responder Vγ9Vδ2 cell upregulation of CD69 
in response to co-culture with stimulator PBMC was recorded via FACS. “R(iso)” indicates 
responder cells pre-incubated with isotype control mAb; “R(B1)” indicates responder cells 
pre-incubated with B1 mAb; “S(iso)” indicates stimulator cells pre-incubated with isotype 
control mAb; “S(103.2)” indicates stimulator cells pre-incubated with 103.2 mAb. (A) 
Shown are donor Vγ9Vδ2 cell CD69 MFI after O/N co-culture in the presence of various 
blocking conditions. The upper panel shows individual donor points and the lower panel 
shows a mean and standard deviation of the data compiled. (B) Shown is the percentage 
change in response to blocking mAb for each donor data point. Each donor’s CD69 
upregulation in the presence of blocking mAb was compared to that seen with 
“R(iso)+S(iso)”, which represents 100%. Bar graphs indicate the mean ± standard 
deviation. 
 
64-Fig. 8.13. Peripheral 
Vγ9Vδ2 responder cell 
CD69 upregulation in 
response to autologous  
stimulator cells is not 
sensitive to blocking of 






Fig. 7.8. Peripheral Vγ9Vδ2 responder cell CD107a upregulation in response to autologous  
stimulator cells is not sensitive to blocking of BTN3A or γδTCR. Freshly-isolated PBMC (n=5) 
responder cells were stimulated with autologous stimulator PBMC. Stimulator PBMC were 
prepared by culturing γδT cell-depleted, freshly-isolated PBMC overnight with irradiated 
E.coli, HMBPP, zoledronate or IPP. Stimulator PBMC were then pre-blocked with either 
antagonistic anti-BTN3A mAb (clone: 103.2) or isotype-matched control. Freshly-isolated 
responder PBMC were, meanwhile, rested overnight, and pre-blocked with anti-γδTCR 
mAb (clone: B1) or isotype-matched control. Responder Vγ9Vδ2 cell upregulation of 
CD107a in response to co-culture with stimulator PBMC was recorded via FACS. “R(iso)” 
indicates responder cells pre-incubated with isotype control mAb; “R(B1)” indicates 
responder cells pre-incubated with B1 mAb; “S(iso)” indicates stimulator cells pre-
incubated with isotype control mAb; “S(103.2)” indicates stimulator cells pre-incubated 
with 103.2 mAb. (A) Shown are donor Vγ9Vδ2 cell CD107a MFI after O/N co-culture in the 
presence of various blocking conditions. The upper panel shows individual donor points 
and the lower panel shows a mean and standard deviation of the data compiled. (B) Shown 
is the percentage change in response to blocking mAb for each donor data point. Each 
donor’s CD107a upregulation in the presence of blocking mAb was compared to that seen 
with “R(iso)+S(iso)”, which represents 100%. Bar graphs indicate the mean ± standard 
deviation. 
 
65-Fig. 8.14. Peripheral 
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Fig. 7.9. Peripheral Vγ9Vδ2 responder cell IFN-γ production in response to autologous  
stimulator cells is sensitive to blocking of BTN3A as well as γδTCR. Freshly-isolated PBMC (n=5) 
responder cells were stimulated with autologous stimulator PBMC. Stimulator PBMC were 
prepared by culturing γδT cell-depleted, freshly-isolated PBMC overnight with irradiated 
E.coli, HMBPP, zoledronate or IPP. Stimulator PBMC were then pre-blocked with either 
antagonistic anti-BTN3A mAb (clone: 103.2) or isotype-matched control. Freshly-isolated 
responder PBMC were, meanwhile, rested overnight, and pre-blocked with anti-γδTCR mAb 
(clone: B1) or isotype-matched control. Responder Vγ9Vδ2 cell upregulation of IFN-γ in 
response to co-culture with stimulator PBMC was recorded via FACS. “R(iso)” indicates 
responder cells pre-incubated with isotype control mAb; “R(B1)” indicates responder cells 
pre-incubated with B1 mAb; “S(iso)” indicates stimulator cells pre-incubated with isotype 
control mAb; “S(103.2)” indicates stimulator cells pre-incubated with 103.2 mAb. (A) Shown 
are donor Vγ9Vδ2 cell intracellular IFN-γ MFI after O/N co-culture in the presence of various 
blocking conditions. The upper panel shows individual donor points and the lower panel 
shows a mean and standard deviation of the data compiled. (B) Shown is the percentage 
change in response to blocking mAb for each donor data point. Each donor’s intracellular IFN-
γ in the presence of blocking mAb was compared to that seen with “R(iso)+S(iso)”, which 
represents 100%. Bar graphs indicate the mean ± standard deviation. 
 
66-Fig. 8.15. Peripheral 
Vγ9Vδ2 responder cell 
IFN-γ production in 
response to autologous  
stimulator cells is sensitive 
to blocking of BTN3A as 
well as γδTCR. 
IFN-γ 
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The majority of published data addressing the interaction between Vγ9Vδ2 cells and 
BTN3A on target cells (numerous seminal papers included) has been generated using cell 
lines rather than autologous cells as stimulators (101,152,161,164,213). A likely 
contributing factor to these experimental setups is the practical difficulty of obtaining and 
working with large numbers of primary human cells, exacerbated particularly by the usual 
scarcity of γδT cells in human peripheral blood. An additional hurdle of working with 
primary cells is introduced by the inherent magnitude heterogeneity of γδT cell responses. 
It has been speculated, for example, that γδT cell constitution and responsiveness to 
various stimuli may be significantly impacted by infectious exposure in early life (7). The 
use of cell line stimulators is a way of standardizing immunogenic targets for all donors 
within a given study. A number of important γδT cell-BTN3A publications have relied on 
the use of THP-1 cells, specifically (101,164,214).  
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7.5. Vγ9Vδ2 cell effector responses to stimulator THP-1 cells are 
differentially sensitive to blocking of the γδTCR and BTN3A  
In a setup that differed from the autologous stimulator-responder system with the use of 
THP-1 cell line stimulator cells (illustrated in Fig.7.6), Vγ9Vδ2 cell responses were tested. 
In order to validate initial experimental reservations on my part regarding the use of 
allogeneic ‘non-self’, transformed stimulator cells, I tested Vγ9Vδ2 cell activation upon 
stimulation with THP-1 cells only in the absence of further pAg stimulus. Indeed, Vγ9Vδ2 
cells upregulated CD69, engaged in CD107a-mediated cytotoxic degranulation and 
produced IFN-γ in response to overnight co-culture with otherwise unmodified THP-1 
cells (Fig.7.10).  
  
  
Fig. 7.10. Vγ9δ2 cells are potently activated by co-culture with THP-1  cells. Freshly-isolated 
PBMC (n=3) responder cells were stimulated with THP-1 cells. Shown are compilations of 
donor Vγ9Vδ2 cell surface CD69, CD107a and intracellular IFN-γ MFI. The graphs indicate 
mean and range of the data data. Effector responses were compared between 
unstimulated Vγ9Vδ2 cells (unstimulated) and Vγ9Vδ2 cells that had undergone O/N co-
culture with THP-1 cells.  
67-Fig. 8.16. Vγ9δ2 cells are potently activated by co-culture with THP-1  cells. 
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Having documented a baseline reactivity of freshly-isolated Vγ9Vδ2 cells to unstimulated 
THP-1 cells, I set out to clarify whether this reactivity can be modified by exposing 
stimulator THP-1 cells to pAg in the form of E.coli, HMBPP, IPP or zoledronate. Vγ9Vδ2 
cell CD69 upregulation in response to overnight co-culture with differentially stimulated 
THP-1 cells was examined (Fig.7.11).  
Significant CD69 upregulation upon co-culture with pAg-exposed versus pAg-non-
exposed (mock) THP-1 cells could be seen with most donor Vγ9Vδ2 cells (Fig.7.11A). 
Notably, in one of the three examined donors, extremely high CD69 upregulation could 
be seen even with the addition of only mock-stimulated THP-1 cells. As was the case in 
the autologous donor PBMC stimulator system, significant donor variation could be 
observed, if to a lesser extent. As before, the effect of blocking antibodies was calculated 
as a percentage change set against each donor’s CD69 MFI in the absence of any blocking 
mAb (Fig.7.11B). In contrast to observations from the autologous PBMC system, 
stimulator pre-culture with anti-BTN3A mAb 103.2 significantly inhibited Vγ9Vδ2 cell 
CD69 upregulation. Borderline statistical significance, which may have been improved 
upon increased donor number, was observed for E.coli-stimulated (p=0.06) as well as 
mock-stimulated (p=0.08) THP-1 cell stimulators. Responder pre-culture with anti-
γδTCR mAb B1, meanwhile, appeared to exert little to no effect on most Vγ9Vδ2 cell 
THP-1 responses, save for, interestingly, in the case of IPP-stimulation.  
Similar results were obtained when examining CD107a-mediated cytotoxic degranulation 
(Fig.7.12). Vγ9Vδ2 cell degranulation was inhibited by stimulator pre-culture with anti-
BTN3A mAb for every pAg THP-1 stimulus examined, but not mock-stimulated THP-1. 
Borderline statistical significance could be obtained also for inhibition by responder pre-
culture with anti-γδTCR mAb (Fig.7.12B). Perhaps the most striking sensitivity to 
blocking mAbs was obtained upon examining the Vγ9Vδ2 cell IFN-γ response (Fig.7.13). 
As with cytotoxicity, all responses to pAg-exposed, but not mock, THP-1 stimulators were 
sensitive to anti-BTN3A mAb (Fig.7.13A). It appeared that anti-BTN3A mAb pre-culture 
abrogated Vγ9Vδ2 cell IFN-γ production entirely. Significant inhibition could also be 
achieved with anti-γδTCR mAb, when THP-1 stimulators were specifically HMBPP or 
IPP-exposed. Vγ9Vδ2 cell responses to pAg-stimulated THP-1 cells, thus, appeared 
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largely sensitive, in terms of activation, cytotoxicity and IFN-γ production, to blocking by 
the 103.2 and B1 mAbs. It must be noted, however, that the vast inter-donor differences 
necessitate repeated experiments with increased donor numbers. It is possible that greater 
statistical significance could be achieved for all pAg stimulation conditions, blocking of 




   
Fig. 7.11. Peripheral Vγ9Vδ2 responder cell surface CD69 in response to THP-1  stimulator cells is 
sensitive to blocking of BTN3A. Freshly-isolated PBMC (n=3) responder cells were stimulated with 
THP-1 stimulator cells. Stimulator THP-1 were prepared by culturing THP-1 cells overnight with 
irradiated E.coli, HMBPP, zoledronate or IPP. Stimulator THP-1 were then pre-blocked with either 
antagonistic anti-BTN3A mAb (clone: 103.2) or isotype-matched control. Freshly-isolated 
responder PBMC were, meanwhile, rested overnight, and pre-blocked with anti-γδTCR mAb 
(clone: B1) or isotype-matched control. Responder Vγ9Vδ2 cell upregulation of CD69 in response 
to co-culture with stimulator THP-1 was recorded via FACS. “R(iso)” indicates responder cells 
pre-incubated with isotype control mAb; “R(B1)” indicates responder cells pre-incubated with 
B1 mAb; “S(iso)” indicates stimulator cells pre-incubated with isotype control mAb; “S(103.2)” 
indicates stimulator cells pre-incubated with 103.2 mAb. (A) Shown are donor Vγ9Vδ2 cell 
surface CD69 after O/N co-culture in the presence of various blocking conditions. The upper 
panel shows individual donor points and the lower panel shows a mean and standard deviation 
of the data compiled. (B) Shown is the percentage change in response to blocking mAb for each 
donor data point. Each donor’s cell surface CD69 in the presence of blocking mAb was compared 
to that seen with “R(iso)+S(iso)”, which represents 100%. Bar graphs indicate the mean ± 
standard deviation. 
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Fig. 7.12. Peripheral Vγ9Vδ2 responder cell surface CD107a in response to THP-1  stimulator cells 
is sensitive to blocking of BTN3A. Freshly-isolated PBMC (n=3) responder cells were stimulated 
with THP-1 stimulator cells. Stimulator THP-1 were prepared by culturing THP-1 cells overnight 
with irradiated E.coli, HMBPP, zoledronate or IPP. Stimulator THP-1 were then pre-blocked with 
either antagonistic anti-BTN3A mAb (clone: 103.2) or isotype-matched control. Freshly-isolated 
responder PBMC were, meanwhile, rested overnight, and pre-blocked with anti-γδTCR mAb 
(clone: B1) or isotype-matched control. Responder Vγ9Vδ2 cell upregulation of cell surface 
CD107a in response to co-culture with stimulator THP-1 was recorded via FACS. “R(iso)” indicates 
responder cells pre-incubated with isotype control mAb; “R(B1)” indicates responder cells pre-
incubated with B1 mAb; “S(iso)” indicates stimulator cells pre-incubated with isotype control 
mAb; “S(103.2)” indicates stimulator cells pre-incubated with 103.2 mAb. (A) Shown are donor 
Vγ9Vδ2 cell surface CD107a after O/N co-culture in the presence of various blocking conditions. 
The upper panel shows individual donor points and the lower panel shows a mean and standard 
deviation of the data compiled. (B) Shown is the percentage change in response to blocking mAb 
for each donor data point. Each donor’s cell surface CD107a in the presence of blocking mAb was 
compared to that seen with “R(iso)+S(iso)”, which represents 100%. Bar graphs indicate the mean 
± standard deviation. 
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Fig. 7.13. Peripheral Vγ9Vδ2 responder IFN-γ production in response to THP-1 stimulator cells is 
sensitive to blocking of BTN3A. Freshly-isolated PBMC (n=3) responder cells were stimulated 
with THP-1 stimulator cells. Stimulator THP-1 were prepared by culturing THP-1 cells overnight 
with irradiated E.coli, HMBPP, zoledronate or IPP. Stimulator THP-1 were then pre-blocked with 
either antagonistic anti-BTN3A mAb (clone: 103.2) or isotype-matched control. Freshly-isolated 
responder PBMC were, meanwhile, rested overnight, and pre-blocked with anti-γδTCR mAb 
(clone: B1) or isotype-matched control. Responder Vγ9Vδ2 cell intracellular IFN-γ in response to 
co-culture with stimulator THP-1 was recorded via FACS. “R(iso)” indicates responder cells pre-
incubated with isotype control mAb; “R(B1)” indicates responder cells pre-incubated with B1 
mAb; “S(iso)” indicates stimulator cells pre-incubated with isotype control mAb; “S(103.2)” 
indicates stimulator cells pre-incubated with 103.2 mAb. (A) Shown are donor Vγ9Vδ2 
intracellular IFN-γ after O/N co-culture in the presence of various blocking conditions. The upper 
panel shows individual donor points and the lower panel shows a mean and standard deviation 
of the data compiled. (B) Shown is the percentage change in response to blocking mAb for each 
donor data point. Each donor’s intracellular IFN-γ in the presence of blocking mAb was 
compared to that seen with “R(iso)+S(iso)”, which represents 100%. Bar graphs indicate the 
mean ± standard deviation. 
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Data laid out in this chapter explores freshly-isolated Vγ9Vδ2 cell effector function 
dependency on the TCR and BTN3A in the context of an autologous and an allogeneic 
stimulation model. Findings included:  
i) Nearly all freshly-isolated PBMC express BTN3A. 
ii) E.coli and zoledronate stimulation of whole PBMC causes mild 
downregulation of BTN3A, but overall levels are restored throughout 
expansion with both stimuli.  
iii) Freshly-isolated Vγ9Vδ2 cells upregulate CD69, engage in CD107a-mediated 
cytotoxicity and produce IFN-γ in response to stimulation with E.coli, 
HMBPP, IPP or zoledronate-exposed autologous PBMC.  
iv) Vγ9Vδ2 cell IFN-γ production, but not CD69 upregulation and CD107a-
mediated cytotoxic degranulation, in this autologous stimulation model were 
sensitive to blocking by both anti-BTN3A mAb (clone: 103.2) and anti-γδTCR 
mAb (clone: B1).  
v) Freshly-isolated Vγ9Vδ2 cells upregulate CD69, engage in CD107a-mediated 
cytotoxicity and produce IFN-γ in response to stimulation with the otherwise 
unstimulated, allogeneic THP-1 cell-line, exhibiting baseline reactivity.  
vi) Baseline THP-1-reactivity of Vγ9Vδ2 cells is highly donor-dependent.  
vii) This baseline Vγ9Vδ2 cell activation by THP-1 cells is enhanced by THP-1 
cell pre-stimulation with E.coli, HMBPP, IPP or zoledronate.  
viii) Vγ9Vδ2 cell IFN-γ production as well as CD69 upregulation and CD107a-
mediated cytotoxic degranulation in response to THP-1 stimulators were 
sensitive to blocking by anti-BTN3A mAb (clone: 103.2). Sensitivity to anti-
γδTCR mAb (clone: B1) was effector function and stimulus-dependent. As 
with the autologous stimulator experimental system, IFN-γ production 
exhibited the highest sensitivity to blocking mAb.  
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Data laid out in this chapter indicates that freshly-isolated peripheral Vγ9Vδ2 cells 
respond to pAg-stimulated targets in a BTN3A (and, partially, TCR)-dependent manner. 
This finding expands and further develops data presented in previous chapters, which 
outlined that apparently similar factors govern γδT cell responses to zoledronate and 
E.coli-stimulated autologous cells. The findings of this chapter are further consistent with 
the role of BTN3A in Vγ9Vδ2 cell recognition of targets that is described in the literature 
(152,157,161,213,215). 
Despite continuity with previous chapters, I note that the effect of γδTCR blocking was 
far less pronounced in the autologous or THP-1 stimulator systems described in the present 
chapter than what was observed with direct addition of anti-γδTCR mAb to whole PBMC, 
as described in Chapter VII. The efficacy of blocking mAb pre-culture was, furthermore, 
dependent on the pAg in use (e.g. IPP versus HMBPP), the type of stimulator cell 
(autologous PBMC versus allogeneic THP-1) and the donor in consideration. Thus, while 
general trends could be observed, I emphasize that significant further work is necessary to 
enhance the reliability and reproducibility of the conclusions drawn.  
Foremost, noting the donor-dependence of observed Vγ9Vδ2 cell responses, the number 
of donors tested needs to be increased substantially. Given the differences between 
blocking potency in whole PBMC versus autologous PBMC stimulator versus allogeneic 
THP-1 stimulator systems, testing the blocking capacity of anti-BTN3A and anti-γδTCR 
mAbs needs to be examined in additional experimental setups. These experimental setups 
will require careful standardization for factors such as number of washes and culture times. 
It is possible, for example, that the lower impact of anti-γδTCR mAb in the stimulator 
systems compared to direct PBMC stimulation (as described in Chapter VI) is due to the 
higher number of washes and extended experimental protocol used in the BTN3A 
blocking experiments. It is not inconceivable that the anti-γδTCR mAb simply detaches 
from the TCR after a given period of time or is instead removed from the cell surface upon 
re-cycling of the TCR, as part of normal T cell physiology. A way to potentially mitigate 
these effects would be to leave the anti-γδTCR mAb in culture at a saturating 
concentration with responder and stimulator cells, so as to permit continuous binding of 
blocking antibody. A novel danger may be introduced, however, if anti-γδTCR mAb is 
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bound via its Fc portions to cells in culture (e.g. THP-1 stimulator cells) and therefore acts 
instead as an activatory signal by cross-linking the TCR. Anti-γδTCR clone B1 is a well-
established stimulator to γδT cells, if adhered to the surface of beads, well-plates or 
stimulator cells (211). A troubling recent report that needs to be considered in the context 
γδTCR blocking mAbs has been compiled by Dutta et al. (216). They speculate and 
present supporting data to the notion that decreased effector function (cytotoxicity in this 
instance) upon pre-culture with anti-γδTCR is not necessarily or solely the consequence 
of functional blocking of the TCR, but alternatively or additionally of mAb-induced cell 
apoptosis. Lowered functional capacity was, thus, merely a reflection of mAb-related 
dramatically reduced γδT cell viability. While a limited number of experimental setups 
and readouts were investigated, Dutta et al. make the recommendation that B1 and 11F2 
anti-γδTCR clones be avoided, and replaced instead with the less viability-damaging 
5A6.E9 clone. Reasons for the dramatic effect that mAb binding alone can exert on γδT 
cell viability and function remain unclear, but are critically important in evaluating the 
credibility of a vast number of earlier anti-γδTCR mAb-utilizing publications. In the 
context of the present thesis, I am confident that at a considerable degree of cell viability 
remained, as continued γδT cell proliferation could be observed even post clone B1 mAb 
treatment. In many cases, as seen in Figures 7.13 and 7.14, for example, anti-γδTCR mAb 
failed to exert any functional effect, even in the context of cytotoxicity. Nonetheless, these 
experiments need to be repeated with the anti-γδTCR clones 11F2 and 5A6.E9, with cell 
viability tracked closely and carefully.  
Similar allowances need to be given to the data presented using anti-BTN3A mAb clone 
103.2. As described in the chapter introduction, 103.2 is only one of a number of clones 
available for agonistic as well as antagonistic BTN3A assays. 103.2 is the only clone 
documented to act antagonistically on BTN3A, and is stipulated to exert its inhibitory 
function by ‘holding’ BTN3A in its inactive, closed conformation (157). Other anti-
BTN3A mAb are agonistic and instead hold BTN3A in its active, open conformation, 
including the clones 19.5, 20.1 and 232.5. Despite a similar effect on BTN3A 
extracellularly, the functional effect of these clones are vastly different, ranging from 
strongly activatory to T cells, inducing proliferation, cytokine production and enhancing 
survival with clone 20.1 and T cell inhibition with clone 232.5. The specific reasons for 
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the different effects of these mAbs on T cell activation are unclear, but appear to result 
from epitope location on the extracellular portion of BTN3A, antibody binding affinity, 
avidity and valency (155–158). In addition to uncertainty of the specific mechanisms of 
action and physiological relevance of blocking mAbs, also binding of FACS staining 
mAbs warrants investigation. BTN3A.1 is known to change conformation upon exposure 
to pAg. It is possible that the decreased positivity of BTN3A seen after PBMC stimulation 
with E.coli and zoledronate (Figures 7.1 and 7.2) was simply reflective of impaired 
binding of the staining mAb (clone BT3.1) to a conformationally-altered BTN. 
Another important yet ambiguous avenue of the data presented in this chapter is the 
activatory potency of the various target stimuli used, i.e. E.coli, HMBPP, IPP and 
zoledronate. While some trends emerged, overall, all differentially-stimulated stimulator 
cells (autologous or THP-1) appeared to induce similar Vγ9Vδ2 cell activation, albeit in 
a strongly donor-dependent manner. It didn’t appear to be the case, for example, that 
E.coli-stimulated target cells elicited vastly more CD69 upregulation, cytotoxicity or IFN-
γ in Vγ9Vδ2 cells than IPP-stimulated target cells. Such an observation is surprising given 
that – in contrast to IPP - E.coli contain a multitude of immunogenic signals, far in excess 
of pAg content. Moreover, HMBPP (also found in E.coli) has been reported to be a ~10 
000 more potent Vγ9Vδ2 cell activator than IPP – a phenoment that is likely due to its 
binding affinity to the intracellular B30.2 domain of BTN3A.1 (162). Such an observation 
appears logical in a physiological context, whereupon endogenous stress-induced IPP has 
a higher threshold towards activating Vγ9Vδ2 cells than de facto non-self HMBPP, which 
is of obligate microbial origin. Nonetheless, my findings of roughly similar activation 
levels would be consistent with the supposition that, given saturation of pAg stimulus, the 
central (if not only) activatory signal Vγ9Vδ2 cells perceive is BTN3A conformational 
changes. It may be the case that, upon direct exposure to E.coli, Vγ9Vδ2 cell activation is 
further modulated by e.g. TLR engagement, but it is clearly not necessary for induction of 
effector function. Indeed, work by De Libero et al. suggests that even HMBPP-expressing 
E.coli-induced activation of Vγ9Vδ2 cells is, in fact, mediated by E.coli induction of 
endogenous stress markers and pyrophosphates (including IPP) (101). Examining such 
questions in the experimental setups described in this chapter, once again, requires an 
increased donor number, and, importantly, a titration of pAg stimulus applied to target 
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cells. An interesting experiment would be autologous (or THP-1) target cell stimulation 
with a pAg-negative bacterium, e.g. S.aureus, and observing how that response compares 
to that of pAg-positive bacteria, such as E.coli, and those, in turn, to the addition of IPP.  
Interesting differences in response could be observed between THP-1 versus autologous 
PBMC-stimulated Vγ9Vδ2 cells. Unexpectedly, CD69 upregulation, CD107a-mediated 
degranulation and IFN-γ were far more sensitive to anti-BTN3A and anti-γδTCR blocking 
in the context of THP-1 cells. THP-1 cells are allogeneic and, therefore, inevitably contain 
immunogenic signals other than just BTN3A; signals, which include NK cell receptor 
incompatibilities that are likely to be fortuitously different between donors. Vγ9Vδ2 cells 
are known to express a number of NK cell receptors, which one would expect to be 
triggered by allogeneic cells – particularly transformed allogeneic cells, as is the case with 
THP-1 cells (44,211). It is possible, however, that the standardization of stimulus cell type 
(i.e. all donor γδT cells being treated with the same THP-1 cells and not with 
corresponding autologous PBMC) improved reproducibility of data and, thus, improved 
the statistical significance of inhibitor effects observed. It is difficult to compare results 
from the two experimental systems, howerver, due to the earlier mentioned protocol 
differences and technical considerations of working with blocking antibodies. For 
example, it may be the case that BTN3A cycles from the cell surface more readily in 
freshly-isolated PBMC than THP-1 cells, therefore, making it appear that anti-BTN3A 
mAb exerts a greater effect on THP-1 cell recognition than recognition of autologous 
PBMC. As mentioned earlier, extensive standardization of various experimental setups 
with titration of antibody as well as pAg is imperative to determine whether such 
conclusions can indeed be drawn.  
It was interesting to note, nevertheless, that the effector function consistently sensitive to 
blocking mAb across stimulator systems was production of IFN-γ. Unlike CD69 
upregulation, induction of IFN-γ production requires overcoming a relatively high 
activation threshold (217). It may be the case, for example, that cell surface receptor 
cycling has removed a portion of the blocking anti-BTN3A or anti-γδTCR mAbs exposing 
sufficient ‘active’ BTN3A and ‘free’ γδTCR for the induction of CD69 but not IFN-γ. Cell 
surface CD107a, meanwhile, presents a more perplexing case. Even in previous chapters 
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that described a near total loss of Vδ2 cell IFN-γ production upon whole PBMC pre-
culture with B1 mAb, these same cells maintained a degree of CD107a-mediated cytotoxic 
degranulation. The factors that regulate Vγ9Vδ2 cell cytotoxicity appear to include the 
TCR, FcR and NK-like receptors (e.g. killer-immunoglobulin-like receptors and NKG2D) 
as well as TLRs (44,211,218), but remain to be elucidated completely. Determinants of 
non-Vδ2 γδT cell cytotoxicity and activation remain even more poorly understood.  
One Vγ9Vδ2 cell effector function that would be interesting to explore in the context of 
BTN3A-dependency is phagocytosis and pAPC function. In Chapter VII, I documented 
that expanded Vδ2 cell phagocytosis of IgG opsonized E.coli is TCR-dependent. Such 
TCR and IgG-dependence was observed for both E.coli and zoledronate-expanded Vδ2 
cells, which were subsequently found to express almost identical Vγ9Vδ2 TCR 
repertoires. The conclusion drawn from this data was that the Vγ9Vδ2 TCR is unlikely to 
engage E.coli directly, but recognize instead a self-molecule that is present also on 
zoledronate-stimulated PBMC. Most likely this molecule is BTN3A and its 
conformational changes. I speculate, therefore, that Vγ9Vδ2 cell phagocytosis is regulated 
by a ‘licensing’-type interaction between the TCR and BTN3A, as well as FcγR. It cannot 
be ruled out that further undetected interactions between Vγ9Vδ2 cells and neighboring 
PBMC are taking place, required for the successful engagement of phagocytic effector 
function. If indeed phagocytosis of target material is TCR and BTN3A-dependent, 
Vγ9Vδ2 cell pAPC function is likely to be as well.  
Significant insight could be gained from a repeat of the above-mentioned E.coli 
phagocytosis assays in the presence of BTN3A blocking mAb, clone 103.2. To address 
specific mechanistic questions, however, perhaps the most valuable source of data may be 
bead-uptake experiments. Does Vγ9Vδ2 cell pre-culture with mAb 103.2-coated 
stimulator cells prevent the uptake of IgG-opsonized beads? Is this uptake in the presence 
of 103.2-blocked cells restored if the beads further contain stimulatory anti-γδTCR mAb? 
Does pre-culture with the BTN3A agonistic mAb clone 20.1 enhance Vγ9Vδ2 cell 
phagocytosis of beads? Such a reductionist experimental setup may have questionable 
direct in vivo relevance, but may provide insight into some of the basic questions regarding 
the mode of action BTN3A, and its role in Vγ9Vδ2 cell. As laid out in the chapter 
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introduction and Figure 7.3, it is unclear, as of yet, how exactly BTN3A enhances Vγ9Vδ2 
cell activation. Is it engaged directly by the TCR? Does it act more as a B7 molecule 
instead, and bind a homotypic, unknown CTLA-4-like or CD28-like molecule on Vγ9Vδ2 
cells? Is ‘active’ BTN3A instead a crucial adhesion molecule, which is not directly 
engaged by the TCR, but is necessary to stablizie TCR engagement with another target? 
Simplistic bead experiments in the presence of stimulator cells, anti-γδTCR mAb and 
agonistic, as well as antagonistic BTN3A mAbs may shead some light on these questions.  
 
7.7. Summary 
Data compiled in this chapter documents that Vγ9Vδ2 cell activation, cytokine production 
and cytotoxicity in response to pAg-exposed stimulator cells is BTN3A-dependent, in a 
manner that appears to be linked to TCR-dependency. Such dependency is, however, 






The primary driver of scientific interest in human γδT cells derives from their potential as 
effectors in cancer and infectious disease immunotherapy (7,9,10,219,220). As the 
literature suggests, and indeed my data supports, peripheral γδT cells are highly effective 
cytotoxic killers and producers of pro-inflammatory cytokines, yet exhibit high, 
lymphoid-like specificity for targets, and appear tightly regulated by the need for detection 
of cellular stress and IgG opsonisation. Moreover, γδT cells appear capable of significant 
immune regulation and perhaps even initiation of αβT cell responses in a manner 
reminiscent of DCs. Unlike DCs, however, Vγ9Vδ2 cells can be accessed in the human 
periphery with relative ease, and amplified exponentially in vitro in an antigen-specific 
context. Strikingly, infiltrating γδT cells have been identified as the single most positive 
predictive factor in human cancer survival in both pan-cancer and solid-tumour analysis 
(221).  
As approach to the clinic of γδT cell-based therapies for cancer and infectious disease 
gathers momentum, crucial basic biology questions about the nature of these enigmatic 
lymphocytes remain. How do γδT cells recognize self- and non-self antigen en masse in 
an apparently similar manner? How, if at all, do γδT cells differentiate between self- and 
non-self targets? How are γδT cell responses generated so rapidly? How exactly do γδT 
cells kill virally infected and transformed self-cells, and how does this compare to their 
direct killing of microorganisms? Are γδT cells truly capable of DC-like professional 
antigen presentation? Is their pAPC function important in the initiation of an immune 
response, or, rather, in the regulation of an existing response? How is γδT cell 
phagocytosis carried out? What are the molecular interactions that govern γδT cell effector 
function and proliferation in response to stimulation? Do the same γδT cells engage in 
cytotoxicity and pro-inflammatory cytokine production, as well as antigen presentation 
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and immune regulation? How do these disparate functional phenotypes relate to one 
another during acute immune activation events, such as sepsis?   
The examination of these questions is hugely complicated by the physiological differences 
between human and rodent γδT cells. A lack of cheap and easily modifiable animal models 
has presented a significant hurdle to the dissection of γδT cell function and clinical 
potential. Given the near-necessity for work with human γδT cells when attempting to 
decipher γδT cell clinical potential, an important consideration emerges: Are in vitro 
observations regarding γδT cell functionality, including pAPC function, relevant in vivo?  
While this question remains acutely present in my evaluation of data output from the γδT 
cell field, an increasing body of clinical data is adding credibility to the notion that 
conclusions from in vitro study of human γδT cells bear resemblance to what is happening 
in vivo during the early stages of infection. Significant increases in systemic (and mucosal) 
γδT cell numbers are seen during acute infection with a wide variety of viral, parasitic and 
bacterial infections, ranging from HCMV and Escherichia to Plasmodium and 
Mycobacterium  (19,62–64,102,134,208,222,223). Data indicates that these γδT cells 
display an activated phenotype (as evidenced by cell surface CD69), are positive for MHC 
class II and CD86, and correlate negatively with mortality during sepsis and acute 
systemic inflammatory response syndrome (21,22,24–26,28). Furthermore, natural or 
experimental elevation of γδT cell numbers in human, non-human primate and murine 
models has correlated with improved prognosis or even protection from a range of 
infections, including M. tuberculosis, HCMV, T. gondii and L. monocytogenes (28–36). 
The present thesis describes an attempt at ex vivo modelling of peripheral human γδT cell 
behavior during acute in vivo microbial exposure as is seen during e.g. sepsis. Cell 
responses were examined and tracked after whole freshly isolated PBMC stimulation with 
irradiated E. coli. While the data describes γδT cell phenotypic and functional shift in 
response to in vitro stimulation with E. coli, ultimately, the themes and findings of the 
work extended beyond a description of γδT cell interaction with E.coli. At its core, the 
experimental setup is an exploration of the factors that govern peripheral γδT cell 
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(Vγ9Vδ2 cell, specifically) recognition of target, behaviour after encounter with target and 
subsequent functional evolution – whether the inflammatory context is of non-self (e.g. 
E.coli) or self (e.g. IPP) origin. The main experimental findings of the present thesis were 
as follows:  
i. E.coli as well as zoledronate-expanded γδT cells are capable of effective 
phagocytosis of IgG-opsonized targets, including E.coli, while freshly-isolated 
γδT cells are not. 
ii. E.coli and zoledronate-expanded γδT cells bear a close resemblance to one another 
in terms of functional cell surface marker expression, with both populations 
presenting with a predominantly Vγ9Vδ2 TCRpos HLA-DRpos CD86pos CCR7neg 
CD62Llow CD4neg CD8neg CD16pos CD56pos phenotype.  
iii. Further homology in the differentially expanded cells is seen with TCR CDR3 
sequences, which are similar to one another, but different to freshly-isolated TCR 
CDR3s. This suggests that PBMC stimulation with E.coli and zoledronate leads to 
Vγ9Vδ2 CDR3 focusing on a similar set of ligands.  
iv. Vγ9Vδ2 cell acquisition of a pAPC phenotype during expansion with E.coli or 
zoledronate is accompanied by a loss of a Th1-type pro-inflammatory phenotype, 
whilst maintaining potent cytotoxicity. 
v. Expansion does not alter γδT cell memory phenotype, which remains effector 
memory (CD27neg CD45RAneg) prior to, during and after 14 day expansion. 
Almost no naïve Vγ9Vδ2 cell can be detected at any time.  
vi. Th1-type cytokine production, proliferation and phagocytic capacity of Vγ9Vδ2 
cells are all dependent on the TCR. CD107a-mediated cytotoxic degranulation 
appears only partially TCR dependent, while bactericidal activity appears 
unaffected by blocking of the γδTCR. 
vii. Vγ9Vδ2 cell activation, cytokine production and cytotoxicity in response to pAg-
exposed stimulator cells are BTN3A-dependent, in a manner that appears linked 
to TCR-dependency. Whether this dependency is indeed consistent among various 
pAg stimuli and donors remains to be determined.  
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Altogether, the data permit development of an intriguing hypothesis as to the unique role 
of γδT cells (with a Vγ9Vδ2 TCR, specifically) in inflammation related to acute peripheral 
infection and/or cellular stress. I form the following narrative with published γδT cell 
literature in mind, expanded by the laboratory findings described in this thesis. A summary 
of my hypothesis of Vγ9Vδ2 cell functional evolution after exposure to antigen can be 
viewed in figure 8.1.  
I postulate that circulating Vγ9Vδ2 cells, of an effector memory phenotype, surveil 
peripheral blood (and possibly mucosal epithelial sites) for evidence of cellular stress. This 
stress, manifesting itself as BTN3A conformational changes, can be induced by a wide 
variety of stimuli, all of which result in the rapid intracellular accumulation of pAg. Such 
stimuli include abnormally rapid cell proliferation, mutagenic transformation, infection 
with virus, intracellular bacteria, extracellular bacteria or parasites 
(64,135,164,165,179,195,224). While it may be the case that some microorganisms, such 
as M. tuberculosis, P. falciparum and E.coli, express pAgs that are exclusively microbial 
in origin (e.g. HMBPP), it remains unclear whether these induce BTN3A conformational 
changes directly or act instead by inducing accumulation of endogenous pAg, or both 
(64,101).  Upon encounter with BTN3A in its ‘active’ conformation, effector memory 
Vγ9Vδ2 cells are activated in a TCR-dependent manner, and respond with production of 
Th1-type cytokines (e.g. IFN-γ, TNF-α) as well as potent cytotoxicity. Given the apparent 
broad specificity of the Vγ9Vδ2 TCR for BTN3A (or cells that express ‘active’ BTN3A, 
rather), γδT cells are activated en masse, thus, mounting a rapid and vigorous pro-




Fig. 8.1. A model of peripheral Vγ9Vδ2 T cell functional evolution following antigenic challenge. 
Informed by the laboratory data gathered throughout the progression of this thesis, and placed 
within a context of existing literature on γδT cell physiology, I postulate that, during acute 
infection-driven cellular stress, Vγ9Vδ2 cell effector phenotype is plastic, and transitions from a 
Th1-type to a pAPC phenotype following exposure to target antigen.  
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Through direct, en masse target lysis, as well as activation of downstream immune 
effectors, Vγ9Vδ2 cells form a widely-acting bulwark against a variety of environmental, 
infectious or mutagenic threats. Upon neutralizing the immediate threat, activated Vγ9Vδ2 
cells proliferate, and undergo a profound functional evolution. Shedding their initial Th1-
type pro-inflammatory phenotype, expanding Vγ9Vδ2 cells acquire in its stead a 
regulatory pAPC phenotype. The loss of canonical T cell capacities, such as IFN-γ 
production, is paralleled by acquisition of phagocytic capacity, expression of MHC class 
II and co-stimulatory molecules, necessary for the initiation and/or regulation of the 
developing adaptive immune response. While my data and data published by others 
indicates that Vγ9Vδ2 cells can act as pAPCs to αβT cells (60,178,225), γδT cells have 
also been implicated in regulation of humoral immunity (225). Such a narrative places 
peripheral Vγ9Vδ2 cells squarely at the interface between the innate and adaptive immune 
systems. An almost PRR-like TCR with apparently limited specificity, rapid, en masse 
reactivity, phagocytic capacity and antigen presenting properties allude to the many 
myeloid-like characteristics of these cells. The maintenance, nonetheless, of an 
oligoclonal TCR repertoire, expansion and early Th1-like reactivity place Vγ9Vδ2 cells 
in the lymphoid branch of the immune system.  
One functional hallmark that my data indicates as sustained throughout γδT cell functional 
transition is potent cytotoxicity. While the rapid and efficient killing of E. coli by 
expanded MHC class IIpos CD86pos Vγ9Vδ2 cells I report is atypical of most classic 
pAPCs, such as DCs, it may allude to the unique effector phenotype of activated γδT cells. 
It appears that even Vγ9Vδ2 cell pAPCs retain a highly cytotoxic phenotype. Such potent 
cytotoxic capacity is well beyond what is required for the killing of a phagocytosis or 
antigen presentation target. It is known, for example, that DCs can effectively present 
antigens of internalized cell debris, revealing that killing of targets is not a pre-requisite 
for professional antigen presentation (226). It is unlikely, therefore, that activated, 
expanding Vγ9Vδ2 cells retain cytotoxicity in service of pAPC function. The purpose of 
γδT pAPC cytotoxicity remains to be determined. It is, moreover, an important 
consideration in the design of γδT cell-based immunotherapies. Almost all current 
immunotherapeutic strategies involve ex vivo expansion of Vγ9Vδ2 cells, and is, thus, 
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likely to induce the above-described functional shift, which is accompanied throughout by 
potent cytotoxic capacity. 
Given the plethora of effector functions at the disposal of peripheral Vγ9Vδ2 cells and 
their plasticity in employing these functions, careful control of the γδT cell compartment 
appears necessary. TCR-engagement as a pre-requisite for activation, proliferation, 
cytokine production, phagocytosis (and other pAPC functions) paired with a dependence 
on stress-induced BTN3A conformational changes suggests an elegant mode of 
regulation. Potentially dangerous pro-inflammatory effector functions of Vγ9Vδ2 cells are 
prevented from occurring in the absence of cellular stress through the dependence on 
‘active’ BTN3A. Moreover, whenever an early immune response is sufficient to neutralize 
infection, MHC class IIpos CD86pos Vγ9Vδ2 cells may be prevented from posing an 
unnecessary inflammatory threat through downregulation of their early cytokine (e.g. 
IFN-γ, TNF-α) responsiveness. Even in the event that the infectious (‘stressful’) threat is 
sustained throughout Vγ9Vδ2 cell functional transit after encounter with antigen, IgG 
opsonisation of target is required for such effector functions as phagocytosis and 
consequent antigen presentation. This could be operative at two levels: i) as herein, when 
opsonizing with isotype-switched target-specific IgG, ii) in a ‘naïve’ non-immune 
situation, where natural antibodies (NAb) of different isotype, including IgG, may be 
involved. It has previously been demonstrated that NAb can enhance DC uptake and 
antigen presentation of viruses (227). Numerous, inter-connected layers of regulation, 
thus, exist to guide Vγ9Vδ2 cell activity. In addition, while dependence on stress-induced 
BTN3A conformational changes and IgG opsonin restricts their functionality, it permits 
broad and rapid en masse activation of Vγ9Vδ2 cells if the appropriate conditions are met.   
A curious issue with this narrative, nonetheless, persists. Namely, if Vγ9Vδ2 cells do 
indeed specialize in the recognition of stress-induced BTN3A conformational changes, 
then why is an oligoclonal (or even polyclonal) Vγ9Vδ2 TCR repertoire maintained? Data 
presented in this thesis suggests that expansion in response to E. coli or zoledronate lead 
to a focusing of Vγ9Vδ2 CDR3 sequences. Even though the freshly-isolated Vγ9Vδ2 
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repertoire was dominated by several, highly numerous clones, almost no overlap could be 
seen between the freshly-isolated versus E.coli or zoledronate-expanded repertoire delta 
chain CDR3 (Fig.4.17). The suggestion is, therefore, that Vγ9Vδ2 cells do indeed have a 
baseline oligoclonal repertoire, but that it is not, in fact, finely-tuned to recognize E.coli 
or zoledronate-induced antigens, which are, presumably, BTN3A conformational 
changes. Perhaps an even more obvious question emerges upon considering why Vγ9Vδ2 
cells need have a varied TCR repertoire at all. If Vγ9Vδ2 cells act primarily as surveyors 
of cellular stress that manifests itself via pre-determined BTN3A conformational changes, 
then why maintain such TCR CDR3 diversity? While an argument could be made for 
physiological redundancy, TCR re-arrangements are, nevertheless, a life-long energy 
expenditure. Moreover, if γδT cells are indeed as evolutionarily ancient as has been 
suggested by the study of lampreys (206), then their maintenance of a resource-intensive 
but unnecessary feature over millions of generations seems unlikely. It is known, for 
example, that mouse dendritic epidermal γδT cells bind a murine B7-homologue on 
keratynocytes, SKINT1, that is crucial for their organ-specificity and survival, in a manner 
that may parallel human Vγ9Vδ2 cell-BTN3A interactions (141,228,229). These mouse 
dendritic epidermal γδT cells do, however, express an almost entirely homogeneous, 
invariant TCR repertoire, consistent with their TCR-dependent recognition of a totally 
restricted set of target antigens focused on the SKINT1 molecule (69,141,229,230). As 
the literature and my own data indicates, such baseline TCR focus is not seen with 
peripheral human Vγ9Vδ2 cells (6,32,210). 
I note that none of the data presented in this thesis sheds light on whether the Vγ9Vδ2 
TCR engages BTN3A directly or whether BTN3A leads to TCR-mediated activation via 
other means, e.g. by binding to a co-stimulatory molecule on Vγ9Vδ2 cells. Perhaps, the 
maintenance of an oligoclonal (or even polyclonal) Vγ9Vδ2 repertoire indicates that the 
TCR binds a diverse set of target antigens that are not merely BTN3A conformational 
changes, even if it is done so in a BTN3A-dependent manner. Significant ambiguity and 
controversy on the details of Vγ9Vδ2 cell antigen recognition persists. A recent 
publication by Starick et al. suggests that Vγ9Vδ2 cells exhibit differential pAg versus 
agonistic anti-BTN3A mAb reactivity depending on fine CDR3 differences, implicating 
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the TCR in direct recognition of the conformational changes therein (231). They further 
postulate that Vγ9Vδ2 cells may also recognize pAg in a BTN3A-independent manner, 
given particular TCR specificity. These postulates were, however, formed using 
reductionist animal transductant models, inter-species hybrid cell lines and anti-BTN3A 
mAbs. The in vivo relevance of these findings is yet to be confirmed experimentally. In 
this respect, for now, Vγ9Vδ2 cells remain a quandary.  
Despite a lack of clarity regarding the exact mode of antigen recognition and engagement, 
clues as to the physiological role of peripheral Vγ9Vδ2 cells can be drawn from their 
species specificity. Absent in rodents, Vγ9Vδ2 cells are present in such animals as humans 
and non-human primates. They have been ascribed a particularly important role in the life 
of young animals, with a disproportionate reactivity to infectious challenge by pAg-
expressing pathogens, M. tuberculosis and P. falciparum, that are further pathogens of 
high significance in humans as well as non-human primates, but not rodents (7). Indeed, 
animal models and clinical human data have implicated Vγ9Vδ2 cells in anti-malarial and 
tuberculosis responses (19,31,34,62,134,223,224,232). Both M. tuberculosis and P. 
falciparum are a frequent cause of serious and chronic infection in humans that is often 
exacerbated by inappropriate immune responses. It is, perhaps, the ever-present threat of 
M. tuberculosis and P. falciparum infection that has shaped the human peripheral γδT cell 
compartment. It is, perhaps, a co-evolutionary context in which Vγ9Vδ2 cells developed 
a plastic and transitory effector phenotype. Potent, Th1-type pro-inflammatory reactions 
upon encounter with M. tuberculosis and P. falciparum may be mounted in an attempt to 
prevent productive infection. These are then followed by the development of a regulatory 
phenotype upon triggering of the adaptive response, and when the disease enters its 
chronic stages. Importantly, such a physiological role would account for the highly potent 
cytotoxicity that Vγ9Vδ2 cells retain even upon acquiring an apparently regulatory 
phenotype. Cytotoxic killing of M. tuberculosis or P. falciparum-infected cells by immune 
effectors is likely crucial during the acute as well as chronic stages of disease.  
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Further study of the engagement of the Vγ9Vδ2 TCR, possibly with BTN3A targets or co-
receptors, will carry significant implications for γδT cell anti-tumor immunity. Data is 
increasingly supportive of the notion that stress recognition, particularly in combination 
with Ab-opsonisation, may be sufficient not only for killing of a tumor cell but also for 
uptake, processing and presentation of tumor-associated antigens (49). γδT cell direct 
killing of cellular and/or microbial targets combined with inflammatory cytokine 
production followed by uptake of the target into acidifying antigen processing 
compartments raises a novel paradigm. It is tempting to hypothesize that the combination 
of innate-like recognition and killing followed with myeloid-like phagocytosis by a 
lymphocyte-like cell may evolutionarily have preceded the full development of T 
lymphocyte-mediated adaptive immunity. Interestingly, the raised hypothesis is supported 
by previous studies showing that γδTCR chain genes may have preceded the development 
of αβTCR chain genes (205). In addition, the existence in jawless fish of three 
lymphocyte-like cells expressing variable lymphocyte receptors instead of TCR or BCR 
chain genes also supports this contention, since they otherwise resemble αβT, γδT and B 
cells by the expression of other orthologous genes (206).  
Detailed further study of γδT cell antigen recognition, engagement and responses in 
human and humanized animal models is key to unlocking the vast immunotherapeutic 
potential of these enigmatic lymphocytes. If current suppositions on the physiology of 
human γδT cells are confirmed and clarified in the laboratory, their clinical application is 
likely to extend well beyond treatment for malignancy, and expand into therapy 
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SUPLLEMENTARY MEDIA MATERIAL 
Fig. 5.4. Vδ2 cell expansion leads to their acquisition of a phagocyte-like 
morphology and probing behaviour.  
Panel (C). Day 14 E.coli-expanded PBMC were stained with Vδ2-PE mAb and examined 
via confocal microscopy. Shown is a representative field of vision, with PBMC in light 
phase contrast. Light phase contrast images from the same field of vision as shown in 
Fig.5.4 panel (A) were collected every 2 seconds for 5 minutes. Shown is a video sequence 
of the collected images. Vδ2 PBMC are indicated with white arrows.   
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APPENDIX  
E.coli promotes human Vγ9δ2 T cell transition from cytokine-producing 
bactericidal effectors to professional phagocytic killers in a TCR-dependent 
manner 
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